WO1995014012A1 - 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents - Google Patents

5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents Download PDF

Info

Publication number
WO1995014012A1
WO1995014012A1 PCT/US1994/012269 US9412269W WO9514012A1 WO 1995014012 A1 WO1995014012 A1 WO 1995014012A1 US 9412269 W US9412269 W US 9412269W WO 9514012 A1 WO9514012 A1 WO 9514012A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyran
dihydro
hydroxy
phenyl
mmol
Prior art date
Application number
PCT/US1994/012269
Other languages
French (fr)
Inventor
Edmund Lee Ellsworth
Elizabeth Lunney
Bradley Dean Tait
Original Assignee
Parke, Davis & Company
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/319,820 external-priority patent/US5840751A/en
Application filed by Parke, Davis & Company, Warner-Lambert Company filed Critical Parke, Davis & Company
Priority to RU96113098/04A priority Critical patent/RU2140917C1/en
Priority to NZ275961A priority patent/NZ275961A/en
Priority to JP51445895A priority patent/JP3684426B2/en
Priority to AU81256/94A priority patent/AU689158B2/en
Priority to EP95900429A priority patent/EP0729464A1/en
Publication of WO1995014012A1 publication Critical patent/WO1995014012A1/en
Priority to FI962022A priority patent/FI962022A/en
Priority to NO19962017A priority patent/NO316172B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to novel 5,6-dihydropyrone derivatives and related structures which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The 5,6-dihydropyrone derivatives are useful in the development of therapies for the treatment of bacterial and viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of multifunctionalized 5,6-dihydropyrones and of related structures.

Description

5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND
ANTIVIRAL AGENTS
1. FIELD OF THE INVENTION
The present invention relates to 5,6-dihydropyrone derivatives that are inhibitors of aspartyl proteases, in particular the aspartyl proteases found in retroviruses including Human Immunodeficiency Virus (HIV). The 5,6-dihydropyrones are expected to have utility as antiviral agents, for the treatment of infection caused by HIV or other retroviruses employing aspartyl proteases, and to be useful in the treatment of diseases caused by the retroviruses,
including AIDS. 2. BACKGROUND OF THE INVENTION
Acquired Immunodeficiency Syndrome (AIDS) was coined in 1982 to describe the clinical manifestations of
immunodeficiency. The etiological agent of AIDS was later associated with a retrovirus. Human Immunodeficiency Virus (HIV), from the lentivirus subfamily. At least two infectious strains of HIV have been identified, HIV-1 and HIV-2. Here, HIV will be used as a general term describing all strains and mutants of the Human Immunodeficiency Virus. The detailed study of HIV has given rise to many approaches to antiviral drug development including inhibition of the viral aspartyl protease (D. Richman, Control of Virus Diseases , 45th
Symposium of the Society for General Microbiology, 261-313 (1990)).
Aspartyl proteases have been found in many retroviruses including the Feline Immunodeficiency Virus (FIV), the
Myeloblastosis Associated Virus (MAV), HIV, and the Rous
Sarcoma Virus (RSV) [H. Ton et al . Nature , 315: 691 (1985); J. Kay, B. M. Dunn, Biochim . Biophys . Acta , 1: 1048 (1990); C. Cameron, J. Biological Chem . , 168: 11711-720 (1993)]. Since there are structural similarities among the known retroviral proteases, compounds which inhibit the HIV protease may well inhibit other retroviral proteases. HIV aspartyl protease is responsible for post-translational processing of viral precursor polyproteins such as pol and gag. (M. Graves, Structure and Function of the Aspartic Proteases, 395-405 (1991)). Cleavage of these polyproteins is essential for maturation of the virus, since the proteolytic activity necessary for polyprotein processing cannot be provided by host cellular enzymes. An important finding has been that viruses which lack this protease, or contain a mutant which is a defective protease, lack
infectivity [C. Ping et al . , J. Virol , 63: 2550-556 (1989) and N. Kohl et al . , Proc. Nati . Acad. Sci . USA, 85: 4686-90
(1987)]. Thus, a selective HIV protease inhibitor has been shown to inhibit viral spread and the production of cytopathic effects in cultures of acutely infected cells (J. C. Craig, Antiviral Research, 16: 295-305 (1991)). For this reason, inhibitiori of HIV protease is believed to be a viable approach to antiviral therapy.
HIV protease inhibitors have been extensively reviewed (see for example A. Tomasselli et al . , Chimica Oggi , 6-27 (1991) and T. Meek, J. Enzyme Inhibition 6: 65-98 (19.92)). However, the majority of these inhibitors are peptides and thus unsuitable as drugs, due to the well known
pharmacological deficiencies exhibited by most peptide drugs (biliary excretion, low bioavailability and stability in physiological milieu, etc.) Nonpeptidic inhibitors of HIV protease are thus very important, since these may lead to useful therapeutic agents.
Hei 3-227923 claimed coumarins with anti-HIV activity. However, only 4-hydroxycoumarin was specifically described without discussion of mechanism of action.
World Patent 89/07939 claimed eight coumarin derivatives as HIV reverse transcriptase inhibitors with potential
antiviral activity. These derivatives are hexachlorocoumarin, 7-acetoxycoumarin, and the structures shown below.
Figure imgf000005_0002
Warfarin (3-(α-acetonylbenzyl)-4-hydroxycoumarin), shown below, was reported by R. Nagorny et al . in AIDS 7: 129-130 (1993) as inhibiting cell-free and cell-mediated HIV
infection. However, Warfarin was the only analog pyrone studied and its mechanism of action in HIV inhibition was not specified.
Figure imgf000005_0001
Selected flavones, structurally different from the 5,6-dihydropyrones of the present invention, were reported by Fairli et al . , (Biochem . Biophys . Res . Comm . , 188: 631-637, (1992)) to be inhibitors of HIV-1 protease. These compounds are shown below.
Figure imgf000006_0002
United States Patent Number 3,206,476 describes several pyrones, specifically 3-substituted-4-hydroxy-6-aryl-2-pyrones, as antihypertensive agents. However, the range of substituents at the 3-position of these heterocycles is limited to halo and amino groups and alkanoylamino
derivatives.
United States Patent Number 3,818,046 describes several pyrone derivatives, specifically 4-hydroxypyrones with sulfur-containing carbon chains at the 3-position, as growth stunters and antimicrobial agents. These pyrones are substituted as follows: R = Me; M = H or alkali metal; and R' = H, alkyl, phenyl, halophenyl, nitrophenyl, lower alkylphenyl, benzyl, phenethyl, naphthylmethyl, halobenzyl, lower alkylbenzyl, nitrobenzyl, propargyl, allyl, cyclohexyl, lower alkyl, lower thioalkyl, or adamantyl; and n = 0 to 2.
Figure imgf000006_0001
A process for preparing the pyrones shown above is claimed in United States Patent No. 3,931,235.
EP 278742 describes several cyclic 2-benzoyl-1,3-diones with herbicidal activity. All of these compounds possess 3-benzoyl substituents. Their structures, in the keto
tautomeric forms, are shown below:
Figure imgf000007_0001
3. SUMMARY OF THE INVENTION
The present invention is based in great part on the extraordinary discovery of the inventors that novel 5,6-dihydropyrone derivatives and related compounds, selected from a broad spectrum of tailored molecular structures, potently inhibit the HIV aspartyl protease blocking infection by HIV. The present invention is also based on the insights of the applicants regarding the mechanism of action of antiviral drugs, especially as revealed by their studies on structure-activity relationships characteristic of anti-HIV compounds that include 5,6-dihydropyrone derivatives.
The invented 5,6-dihydropyrones are expected to be extremely useful in the development of treatments for
infections caused by viruses, especially by retroviruses that rely on aspartyl protease activities for replication and infectivity. One such retrovirus is HIV. For this reason, the antiviral 5,6-dihydropyrones are also expected to be very useful in the treatment of diseases and syndromes associated with viral pathogens. One such syndrome is AIDS.
Efficient syntheses of the biologically active 5,6-dihydropyrones involving either de novo assemblies of the 5,6-dihydropyrone nucleus or modifications of suitably functionalized 5,6-dihydropyrones, are disclosed.
Furthermore, many working examples outlining the preparation of specific 5,6-dihydropyrones whose structures contain the desired functional groups in proper geometric arrangements are given.
The testing of specific 5,6-dihydropyrones as inhibitors of the HIV aspartyl protease, based on the study of the hydrolysis of an undecapeptide enzyme substrate, and the testing of the 5,6-dihydropyrones as inhibitors of viral growth and infectivity, based on the study of infection of H9 cell lines by the HIV-liiib strain, are also disclosed.
Striking enzyme inhibitions, at nanomolar levels, with
corresponding anti-HIV activities were observed.
The present inventors contemplate the preparation of pharmaceutically useful antiviral compositions comprising one or more of the invented 5,6-dihydropyrones and related
compounds and a pharmaceutically acceptable carrier. They also contemplate the use of these compositions, alone or in combination with other antiviral treatments, in the treatment of infections and diseases caused by retroviruses, including AIDS.
The present inventors contemplate the preparation of pharmaceutically useful antibacterial compositions cmprising one or more of the invented 5,6 dihydropyrones and related compounds and a pharmaceutically acceptable carrier.
The present invention relates to compounds or the
pharmaceutically acceptable salts thereof of formula 1, shown below,
Figure imgf000008_0001
wherein
X is OR5, NHR5, CH2OR5, CO2R6, or SR5 wherein R5 is R6 or
COR6 wherein R6 is independently H, a straight chain alkyl group containing 1 to 6 carbon atoms, a branched or cyclic alkyl group containing 3 to 7 carbon atoms, an
alkylcycloalkyl of 5-9 carbon atoms, benzyl, phenyl or a heterocycle;
Z is O or S;
Y is O, S, C(R6)2, NF, or NR6;
R1 and R1' are each independently [CH2]nl-[W1]n2-[Ar]n2- [CH2]n3- [W2]n4-R7;
R2 is independently selected from the group of
structures from which R1 is selected with the proviso that if W1 is a heteroatom n1 is an integer of from 1 to 4;
R3 is independently selected from the group of
structures from which R1 is selected with the proviso that if W1 is a heteroatom nl is an integer of from 1 to 4;
R2 and R3 may be taken together to form an unsubstituted or substituted 3-, 4-, 5-, 6-, or 7-membered ring, wherein the substituents are one or more of the R7 groups listed below;
R4 is [CH2] n1- [W3 ] n2- [ CH2 ] n3- [W4 ] n4- [Ar]n2- [CH2]n3- [W2 ] n4-R7 ;
n1, n2, n3, n4, and n5 are independently integers of
from 0 to 4, 0 to 1, 0 to 4, 0 to 1, and 0 to 2,
respectively;
W1, W2, and W4 are independently O, OCONR7, S(O)n5, CO,
C(=NR7)NR7, CR7=CR7, C≡C, NR7, CS, C=N-R7, C=NOR7, NR7SO2, SO2NR7, C=C(R7)2, CR7N(R7)2, CR7OR7, C(R7)2, NCO2R7, NR7CO2, CO2, NCON(R7)2, NR7CONR7, NCOR7, NR7CO, or CONR7;
W3 is independently selected from the group of structures from which W1 is selected, with the further limitation that if n1 in R4 is zero, that W3 is selected from the group of structures consisting of -CO, -CR7=CR7, -C≡C, -CS, -C=N-R7, -C=N-R7, -C=NOR7, -CR7N(R7)2, -C=C(R7)2, -CR7OR7, -C(R7)2, - CO2, and -CONR7, with the left hyphen denoting the point of attachment to the hydropyrone ring;
R7 is independently H, Ar, a straight or branched alkyl or alkenyl group containing from 1 to 6 carbon atoms, or two R7's can be taken together to form a ring of 3-7 atoms, or a substituted derivative thereof wherein the
substituents are one or more of CO2R6, COR6, CON(R6)2,
NR6CON(R6)2, NR6COR6, OR6, S(O)n5R6, N(R6)2, Cl, Br, F, CF3, Ar, OAr, or S(O)n5Ar;
Ar is independently phenyl, naphthyl, a 5- or 6- membered
heterocycle containing 1 to 4 heteroatoms, a cycloalkyl containing 3 to 6 atoms, a fused ring system containing 8- 10 atoms, or a substituted derivative thereof wherein the substituents are of F, Cl, Br, CN, NO2, (CH2)n6R6,
(CH2)n6C(Me)=CH2, (CH2)neN(R6)2, (CH2)n6NR6CON(R6)2,
(CH2)n6NR6COR6, (CH2)n6OR6, (CH2)n6OCOR6, (CH2)n6OCON(R6)2,
(CH2)n6CO2R6, (CH2)n6CON(R6)2, (CH2)n6COR6, CF3, (CH2)n6S(O)n5R6, OCH2O, or O(CH2)2O; and
n6 is independently an integer of from 0 to 3.
More preferred compounds of the present invention are those of formula 1 wherein
X is OR5 wherein R5 is H or COR6 wherein R6 is as
defined above;
Z is O;
Y is O, S, or CH2;
R1 and R1' are independently H, F, (CH2)n1CO2R6, (CH2)n1OR6, or
(CH2)n1CON(R6)2;
R2 is [CH2]n1-[W1]n2-[Ar]n2-[CH2]n3-[W2]n4-R7 with the
proviso that if W1 is a heteroatom nl is an integer of from 1 to 4;
R3 is independently selected from the group of
structures from which R2 is selected;
R2 and R3 can be part of a 5-, 6-, or 7-membered ring
optionally substituted by groups selected from the group of structures from which R7 is selected;
R4 is [CH2]n1-[W3]n2-[CH2]n3-[W4]n4-[Ar]n2-[CH2]n3-[W2]n4-R7;
n1, n2, n3, n4, and n5 are as defined above;
W. and W4 are independently O, S(O)n5, CO, CR7=CR7, NR7, CR7OR7, C(R7)2, NR7CO2, CO2, NR7CONR7, CONR7 or NR7CO; W, is as defined above;
W3 is CR7OR7, C(R7)a, or CONR7;
R7 is as defined above;
Ar is as defined above; and
n6 is as defined above.
Even more preferred compounds of the present invention are those of formula 1 wherein
X is OH;
Z is O;
Y is O or CH2;
R1 and R1' are H;
R3 is [CH3]n1-[W1]n2- [Ar]n2-rCH2]n3- [W2]n4-R7 with the proviso
that if W1 is a heteroatom n1 is an integer of from 1 to R3 is [CHa]n1-[Ar]n2-[CHa]n3- [W2]n4-R7;
R2 and R3 can be part of a 5-, 6-, or 7-member ed ring
structure optionally substituted by groups selected from the group from which R7 is selected;
R4 is [CHa]n1-[W3]n2-[CH3] n3- [W4]n4-[Ar]n2-[CH2]n3- [W2]n4-R7;
n1 , n2 , n3 , n4 , and n5 are as defined above;
w1 is O, S (O) n5, NR7 , CONR7 or C (R7)2;
w2 is as defined above;
w3 is C(R7)a;
W4 is independently CR7=CR7, NR7CONR7, C(R7)2,
NR7CO, CO, or CO2;
R6 is as defined above;
R7 is as defined above;
Ar is as defined above; and
n6 is as defined above.
Still wore preferred are compounds of formula 1 wherein X is OH;
Z is O;
Y is O;
R1 and R1' are H;
R2 is CH2-Ar-(CH2)n3-[W2]n4-R7, CH2-CH2-Ar-(CH2)n3-[W2]n6-R7, CH2OAr- (CH2)n3-[W2]n4-R7, cyclopentylmethyl, -(CH2)4-C(=O) -N(R7)2, cyclohexyImethyl, 2-(2- or 3-tetrahydrofuranyl)ethyl, 2-(2- or 3-furanyl)ethyl, propyl, butyl, iso-butyl, pentyl, iso- pentyl, 2-(cyclopropyl)ethyl, (CH2)2C(CH3)=CH2, Ar-(CH2)n3- [W2]n4-R7, phenyl, or 2-, 3-, or 4-pyridyl;
R3 is Ar-(CH2)n3-[W2]n4-R7, phenyl, cyclopentyl, cyclohexyl, 2- or 3-furanyl, 2- or 3-thienyl, 2-, 3- or 4-pyridyl, isobutyl, pentyl, CH2-CH2-Ar, or isopentyl;
R2 and R3 can be part of an unsubstituted or
substituted 5-, 6-, or to 7-membered ring structure where the substituents are independently one or more of those listed for R7 above;
R4 is as defined above for the even more preferreed
compounds of Formula 1;
n1, n2, n3, n4, and n5 are as defined above;
W2, W3 and W4 are as defined for the even more preferred compounds of the invention above;
R6 is as defined above;
R7 is as defined above;
Ar is as defined above; and
n6 is as defined above.
Some of the most preferred compounds of the present invention are included in the following:
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(phenyImethyl)thio-2H]-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(3-phenylpropyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(2-phenoxyethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(2-methylpropyl)-6-phenyl-3-[(phenyImethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(2-methylpropyl)-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
5-(3-Chlorophenyl)-2-[(2-phenylethyl)thio]-1,3-cyclohexanedione; 5,6-Dihydro-4-hydroxy-6-(4-methoxyphenyl)-3-[(phenyImethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(4-methylthiophenyl)-3-[(phenyImethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(4-methylphenyl)-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[4-(1,1-dimethylethyl)phenyl]-3-[(phenylmethyl)thio]-2H-pyran-2-one;
6-(4-Chlorophenyl)-5,6-dihydro-4-hydroxy-3-[(phenylmethyl)thio]-2H-pyran-2-one;
6-(3-Chlorophenyl)-5,6-dihydro-4-hydroxy-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-3-[(2-phenylethyl)thio]-6-[4-(phenylmethoxy)phenyl]-2H-pyran-2-one;
5,6-Dihydro-6-(4-methoxyphenyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-6-(4-methylthiophenyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
5, 6-Dihydro-6-(4-methylphenyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
6-[1,1'-Biphenyl]-4-yl-5,6-dihydro-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-6-[4-(1,1-dimethylethyl)phenyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
6-(3-Chlorophenyl)-5,6-dihydro-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
6-[([1,1'-Biphenyl]-4-yloxy)methyl]-5,6-dihydro-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
6-[1,1'-Biphenyl]-4-yl-6-butyl-5,6-dihydro-4-hydroxy-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
4-[2,3-Dihydro-4-hydroxy-6-oxo-5-[(phenylmethyl)thio]-2H-pyran-2-yl]benzonitrile;
6-(4-Trifluoromethylphenyl)-5,6-dihydro-4-hydroxy-3-[(phenylmethyl)thio]-2H-pyran-2-one;
6-(3,5-Dichlorophenyl)-5,6-dihydro-4-hydroxy-3-[(phenylmethyl)thio]-2H-pyran-2-one; 6-(Pentafluorophenyl)-5,6-dihydro-4-hydroxy-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(3-methylphenyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
6-(2-Chlorophenyl)-5,6-dihydro-4-hydroxy-3-[(phenylmethyl)thio]-2H-pyran-2-one;
6-Butyl-5,6-dihydro-4-hydroxy-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
6-[1,1'-Biphenyl]-4-yl-6-butyl-5,6-dihydro-4-hydroxy-3- [(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(phenylmethyl)thio]-6-propyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-6-propyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-pentyl-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-pentyl-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6,6-diphenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6,6-diphenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-(2-phenylethyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
1-[4-[3,6-Dihydro-4-hydroxy-6-oxo-5-[(2-phenylethyl)thio]-2H-pyran-2-yl]phenyl]-5-phenyl-1H-pyrrole-2-propanoic acid; 5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-3-[[2-(1-methylethyl)phenyl]thio]-6-phenyl-2H-pyran-2-one;
5, 6-Dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-3-[[3-(phenylmethoxy)phenyl]methyl]-2H-pyran-2-one;
5, 6-Dihydro-4-hydroxy-3-[5-methyl-2-(1-methylethyl)phenoxy]-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one;
N-(1,1-Dimethylethyl)-1-[[3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(2-phenylethyl)thio]-2H-pyran-2-yl]methyl]-cyclohexanecarboxamide;
6-Butyl-3-[(l-ethyl-1H-indol-3-yl)thio]-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(4-hydroxyphenyl)-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(4-hydroxyphenyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
[4-[5,6-Dihydro-4-hydroxy-2-oxo-3-[(phenylmethyl)thio]-2H-pyran-6-yl]phenoxy]acetic acid;
[4-[5,6-Dihydro-4-hydroxy-2-oxo-3-[(2-phenylethyl)thio]-2H-pyran-6-yl]phenoxy]acetic acid;
[4-[5,6-Dihydro-4-hydroxy-2-oxo-3-[(phenylmethyl)thio]-2H-pyran-6-yl]phenoxy]acetic acid ethyl ester;
[4-[5,6-Dihydro-4-hydroxy-2-oxo-3-[(2-phenylethyl)thio]-2H-pyran-6-yl]phenoxy]acetic acid ethyl ester
5,6-Dihydro-4-hydroxy-6-[4-(2-hydroxyethoxy)phenyl]-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[4-(2-hydroxyethoxy)phenyl]-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-[4-[2-(4-thiomorpholinyl)ethoxy]phenyl]-2H-pyran-2-one-S,S-dioxide;
5,6-Dihydro-4-hydroxy-3-[(2-phenylethyl)thio]-6-[4-[2-(4-thiomorpholinyl)ethoxy]phenyl]-2H-pyran-2-one-S,S-dioxide;
4-[5,6-Dihydro-4-hydroxy-2-oxo-3-[(phenylmethyl)thio]-2H-pyran-6-yl]benzoic acid;
4-[5,6-Dihydro-4-hydroxy-2-oxo-3-[(2-phenylmethyl)thio]-2H-pyran-6-yl]benzoic acid; 5,6-Dihydro-4-hydroxy-6-[4-(hydroxymethyl)phenyl]-3- [(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[4-(hydroxymethyl)phenyl]-3-[(2-phenylethyl)thio]-2H-pyran-2-one;
5, 6-Dihydro-4-hydroxy-6-(3-methylbutyl)-3-[5-methyl-1- (phenylmethyl)hexyl]-6-phenyl-2H-pyran-2-one;
3-[1-(Cyclohexylthio)-5-methylhexyl]-5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one;
3-[2-Cyclohexyl-1-[(3-methylbutyl)amino]ethyl]-5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-3-[(4-methylpentyl)(phenylmethyl)amino]-6-phenyl-2H-pyran-2-one;
5, 6-Dihydro-4-hydroxy-6-phenyl-3-[(phenylmethyl)thio]-6- [(tetrahydro-3-furanyl)methyl]-2H-pyran-2-one;
2,3-Dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(phenylmethyl)thio]-2H-pyran-3-acetamide;
2,3-Dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(phenyImethyl)thio]-2H-pyran-3-butanamide;
5-(4-Hydroxybutyl)-5,6-dihydro-4-hydroxy-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-2(1H)-pyridinone;
5,6-Dihydro-4-hydroxy-1-methyl-6-phenyl-3-[(2-phenylethyl)thio]-2(1H)-pyridinone;
Phenylmethyl 2-(1-methylethyl)-2-[[3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(2-phenylethyl)thio]-2H-pyran-2-yl]methyl]hydrazinecarboxylate;
N-[1-[[3,6-Dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(2-phenylethyl)thio]-2H-pyran-2-yl]methyl]cyclopentyl]urea;
N-[1-[[3,6-Dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(2-phenylethyl)thio]-2H-pyran-2-yl]methyl]cyclopentyl]-N'-(phenylmethyl) urea;
Phenylmethyl [1-[[3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(2-phenylethyl)thio]-2H-pyran-2-yl]methyl]cyclopentyl]carbamate;
6-[(2,3-Dimethyl-1H-pyrrol-1-yl)methyl]-5,6-dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one; 5,6-Dihydro-4-hydroxy-6-[2-(1-piperazinyl)ethyl]-6-phenyl-3-[(2-phenylethyl)thio]2H-pyran-2-one;
5, 6-Dihydro-4-hydroxy-6-[2-(4-morpholinyl)ethyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[3-(4-morpholinyl)propyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[4-(4-morpholinyl)butyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[2-(4-thiomorpholinyl)ethyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[3-(4-thiomorpholinyl)propyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5, 6-Dihydro-4-hydroxy-6-[4-(4-thiomorpholinyl)butyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[2-(1-piperazinyl)ethyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[3-(1-piperazinyl)propyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[4-(1-piperazinyl)butyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[2-(4-methyl-1-piperazinyl)ethyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2one;
5,6-Dihydro-4-hydroxy-6-[3-(4-methyl-1-piperazmyl)propyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[4-(4-methyl-1-piperazinyl)butyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2one;
5,6-Dihydro-4-hydroxy-6-[2-(4-morpholinyl)ethyl]-6-phenyl-3-[(2-isopropyIphenyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[3-(4-morpholinyl)propyl]-6-phenyl-3-[(2-isopropyIphenyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[4-(4-morpholinyl)butyl]-6-phenyl-3-[(2-isopropylphenyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[2-(4-thiomorpholinyl)ethyl]-6-phenyl-3-[(2-isopropylphenyl)thio]-2H-pyran-2-one; 5,6-Dihydro-4-hydroxy-6-[3-(4-thiomorpholinyl)propyl]-6-phenyl-3-[(2-isopropylphenyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[4-(4-thiomorpholinyl)butyl]-6-phenyl-3-[(2-isopropylphenyl)thio]-2H-pyran-2-one;
5, 6-Dihydro-4-hydroxy-6-[2-(1-piperazmyl)ethyl]-6-phenyl-3-[(2-isopropylphenyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[3-(l-piperazinyl)propyl]-6-phenyl-3-[(2-isopropylphenyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[4-(1-piperazinyl)butyl]-6-phenyl-3-[(2-isopropylphenyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[2-(4-methyl-1-piperazinyl)ethyl]-6-phenyl-3-[(2-isopropylphenyl)thio]-2H-pyran-2-one;
5, 6-Dihydro-4-hydroxy-6-[3-(4-methyl-1-piperazmyl)propyl]-6-phenyl-3-[(2-isopropylphenyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[4-(4-methyl-1-piperazinyl)butyl]-6-phenyl-3-[(2-isopropylphenyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy3-[(2-isopropylphenyl)thio]-6-(3-morpholin-4-yl-3-oxopropyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)thio]-6-(4-morpholin-4-yl-4-oxobutyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)thio]-6-(5-morpholin-4-yl-5-oxopentyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)thio]-6-(3-thiomorpholin-4-yl-3-oxopropyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)thio]-6-(4-thiomorpholin-4-yl-4-oxobutyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)thio]-6-(5-thiomorpholin-4-yl-5-oxopentyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropyIphenyl)thio]-6-(3-piperazin-1-yl-3-oxopropyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)thio]-6-(4-piperazin-1-yl-4-oxobutyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)thio]-6-(5-piperazin-1-yl-5-oxopentyl)-6-phenyl-2H-pyran-2-one; 5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)thio]-6-[3- (4-methylpiperazin-1-yl)-3-oxopropyl]-6-phenyl-2H-pyran-2-one
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)thio]-6-[4- (4-methylpiperazin-1-yl)-4-oxobutyl]-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)thio]-6-[5- (4-methylpiperazin-1-yl)-5-oxopentyl]-6-phenyl-2H-pyran-2-one
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-(3-morpholin-4-yl-3-oxopropyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-(4-morpholin-4-yl-4-oxobutyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-(5-morpholin-4-yl-5-oxopentyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-(3-thiomorpholin-4-yl-3-oxopropyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-(4-thiomorpholin-4-yl-4-oxobutyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-(5-thiomorpholin-4-yl-5-oxopentyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-(3-piperazin-1-yl-3-oxopropyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-(4-piperazin-1-yl-4-oxobutyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-(5-piperazin-1-yl-5-oxopentyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-[3-(4-methypiperazin-1-yl)-3-oxopropyl]-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-[4-(4-methylpiperazin-1-yl)-4-oxobutyl]-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(phenylmethyl)thio]-6-[5-(4-methylpiperazin-1-yl)-5-oxopentyl]-6-phenyl-2H-pyran-2-one;
Methyl 2-t-butyl-3-[[5,6-dihydro-4-hydroxy-2-oxo-6-phenyl-6-(2-phenylethyl)-2H-pyran-3-yl]thio]benzoate;
5-[3,6-Dihydro-4-hydroxy-5-[[5-methyl-3-(3-pyridinylmethoxy)-2-isopropylphenyl]thio]-6-oxo-2-phenyl-2H-pyran-2-yl]pentanoic acid;
3-[[5-Ethyl-2-(1-methyl-2-hydroxyethyl)phenyl]thio]-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one; 5-[5-[(2-Cyclopentyl-5-isopropylphenyl)thio]-3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl]pentanoic acid;
5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-3-[[2- [2-(3-pyridinyl)ethyl]phenyl]thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[[5-(2-hydroxyethyl)-3-(2-phenylethyl)-2-isopropylphenyl]thio]-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one;
4-[[5,6-Dihydro-4-hydroxy-2-oxo-6,6-diphenyl-2H-pyran-3-yl]thio]-2-hydroxyindane;
3-[[4,5-Diethyl-2-(1-hydroxyethyl)phenyl]thio]-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropyl-5-methylphenyl)methyl]-6-(2-phenylethyl)-6-phenyl-2H-pyrany-one;
5,6-Dihydro-4-hydroxy-3-[(3-hydroxymethyl-2-isopropyl-5-methylphenyl)methyl]-6,6-diphenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[[4- (hydroxymethyl)phenyl]methyl]-6-pentyl-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(3-hydroxyphenyl)methyl]-6-(2-phenylethyl)-6-phenyl-2H-pyran-2-one;
5, 6-Dihydro-4-hydroxy-6-pentyl-6-phenyl-3-[[4-(pyridin-3-ylmethoxy)phenyl]methyl]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[[2-isopropyl-3-[2-(morpholin-4-yl)ethoxy]phenyl]methyl]-6-(2-phenylethyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-(3-methyl-1-phenyl-but-2-enyl)-6,6-diphenyl-2H-pyran-2-one;
3-[(1,4-Di-tert-butyl-1H-imidazol-2-yl)thio]-5,6-dihydro-4-hydroxy-6-(2-phenylethyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-3-(3-methyl-1-propyl-but-2-enyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[[2-(hydroxymethyl)phenyl]methyl]-6-(2-phenylethyl)-6-phenyl-2H-pyran-2-one;
3-Diisobutylamino-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one; 5 ,6-Dihydro-4-hydroxy-6-(2-phenylethyl)-6-phenyl-3-(N-phenyl-N-propylamino)-2H-pyran-2-one;
3-(3,4-Dihydro-2H-guinolin-1-yl)-6-hexyl-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropyl-5-methylphenyl)amino]-6,6-diphenyl-2H-pyran-2-one;
6-Butyl-3-[(1,4-di-tert-butyl-1H-imidazol-2-yl)amino]-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one;
6-Butyl-3-(3,5-dimethylphenyl)-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one;
3-[4-[(Phenylmethoxy)methyl]-1-tert-butyl-1H-imidazol-2-yl]-5,6-dihydro-4-hydroxy-6-(2-phenylethyl)-6-phenyl-2H-pyran2-one;
3-(1-tert-Butyl-4-methyl-1H-pyrrol-2-yl)-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one;
6-[2-[4-(5,5-Dimethyl-4,5-dihydro-oxazol-2-yl)phenyl]ethyl]-5,6-dihydro-4-hydroxy-3-[(2-isopropyl-5-methylphenyl)thio]-6-phenyl-2H-pyran-2-one;
6-[2-[4-(4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)phenyl]ethyl]-5,6-dihydro-4-hydroxy-3-[(2-isopropyl-5-methylphenyl)thio]-6-phenyl-2H-pyran-2-one;
6-[2-[4-(1,1-Dioxothiomorpholin-4-yl)phenyl]ethyl]-5,6-dihydro-4-hydroxy-3-[(2-isopropyl-5-methylphenyl)thio]-6-phenyl-2H-pyran-2-one;
1-Hydroxy-4-[2-[4-hydroxy-5-[(2-isopropyl-5-methylphenyl)thio]-6-oxo-2-phenyl-3,6-dihydro-2H-pyran-2-yl]ethyl]-1H-pyridin-2-one;
5,6-Dihydro-4-hydroxy-6-[2-(1H-indol-5-yl)ethyl]-3-[(2-isopropyl-5-methylphenyl)thio]-6-phenyl-2H-pyran-2-one;
5 ,6-Dihydro-4-hydroxy-6-(2-phenylethyl)-6-phenyl-3-(2-phenyl-[1,3]dithiolan-2-yl)-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropyl-5-methylphenyl)thio]-6-(2-phenylethyl)-6-[4-[(pyridin-3-yl)methoxy]phenyl]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)thio]-6-phenyl-6-[5-(phenylmethyl)amino-2,2-dimethyl-pentyl]-2H-pyran-2-one; 5-[4-Hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl-3,6-dihydro-2H-pyran-2-yl]-4,4-dimethyl-pentanoic acidbenzylamide;
1-[2-[4-Hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl-3,6-dihydro-2H-pyran-2-yl]-1-phenylethyl]-3-pyridin-2-yImethylurea;
5,6-Dihydro-4-hydroxy-6-(5-hydroxypentyl)-3-[(2-isopropylphenyl)thio]-6-phenyl-2H-pyran-2-one;
5-[4-Hydroxy-5-[(2-isopropyl-5-methylphenyl)thio]-6-oxo-2-phenyl-3,6-dihydro-2H-pyran-2-yl]pentanoic acid, tert-butyl ester;
6-[4-(4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)butyl]-5,6-dihydro-4-hydroxy-3-[(2-isopropylphenyl)thio]-6-phenyl-2H-pyran-2-one;
1-[[3,5-Dihydro-4-hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl-2H-pyran-2-yl]methyl]cyclohexyl]methyl carbamic acid phenylmethyl ester;
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(phenylmethyl)thio]-6-[2-(4-pyridyl)ethyl]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[2-(5-hydroxy-2-methylphenyl)ethyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[2-(3-(morpholin-4-yl)phenyl)ethyl]-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-[2-phenylethyl]-3-[(phenylmethyl)thio]-6-(4-pyridyl)-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(phenylmethyl)thio]-6-[2-(2-thienyl)ethyl]-2H-pyran-2-one;
6-[2-(2-Furyl)ethyl]-5,6-dihydro-4-hydroxy-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(phenylmethyl)thio]-6-[2-(lH-pyrrol-2-yl)ethyl]-2H-pyran-2-one;
5-[4-Hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl-3,6-dihydro-2H-pyran-2-yl]pentanoic acid methyl ester;
5-[4-Hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl-3,6-dihydro-2H-pyran-2-yl]pentanoic acid ethyl ester; 5-[4-Hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl3,6-dihydro-2H-pyran-2-yl]pentanoic acid propyl ester;
5-[4-Hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl3,6-dihydro-2H-pyran-2-yl]pentanoic acid isopropyl ester;
5-[4-Hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl3,6-dihydro-2H-pyran-2-yl]pentanoic acid tert-butyl ester;
5-[4-Hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl3,6-dihydro-2H-pyran-2-yl]pentanoic acid benzyl ester;
[3-[4-Hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-pheny3,6-dihydro-2H-pyran-2-yl]propyl]-carbamic acid tert-butyl ester;
[3-[4-Hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-pheny3,6-dihydro-2H-pyran-2-yl]-propyl]-carbamic acid benzyl este
1-Benzyl-3-{3-[4-hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl-3,6-dihydro-2H-pyran-2-yl]-propyl}-urea;
4-[4-Hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl3,6-dihydro-2H-pyran-2-yl]-butane-1-sulfonic acid benzylamid
4-[4-Hydroxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl3,6-dihydro-2H-pyran-2-yl]-butane-1-sulfonic acid amide;
4-Hydroxy-3-[(2-isopropyl-5-methylphenyl)thio]-6.-phenyl5,6-dihydro-1H-pyridin-2-one;
4-Hydroxy-3-[(2-isopropyl-5-methylphenyl)thio]-6-phenyl6-(2-phenylethyl)-5,6-dihydro-1H-pyridin-2-one;
3-Hydroxy-2-[(2-isopropyl-5-methylphenyl)thio]-5-phenyl5-(2-phenylethyl)-cyclohex-2-enone;
3-Hydroxy-2-[(2-isopropyl-5-methylphenyl)thio]-5-phenylcyclohex-2-enone;
4-Hydroxy-3-[(2-isopropyl-5-methylphenyl)sulfonyl]-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
4-Hydroxy-3-(2-isopropylbenzoyl)-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
4-Hydroxy-3-[methoxyimino(phenyl)methyl]-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
4-Hydroxy-3-[methylimino(phenyl)methyl]-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
2,3-Dihydro-4'-hydroxy-3,3-dimethyl-5'-[(2-isopropyIphenyl) thio]-spiro[4H-1-benzopyran-4,2'-[2H]pyran]-6'(3,H)-one;
2 ,3-Dihydro-4'-hydroxy-2,2-dimethyl-5'-[(5-methyl-2-isopropylphenyl)thio]-spiro[1H-indene-1,2'-[2H]pyran]-6'(3'H)one;
2,3-Dihydro-4'-hydroxy-5,-[(5-methyl-2-isopropylphenyl)thio]-spiro[1H-indene-1,2,-[2H]pyran]-6'(3'H)one;
4"-Hydroxy-5"-[(5-methyl-2-isopropylphenyl)thio]-dispiro[cyclopropane-1,2'(3'H)-[1H]indene-1',2"-[2H]pyran]-6"(3"H)-one;
3,4-Dihydro-4'-hydroxy-5'-[(5-methyl-2-isopropylphenyl)thio]-spiro[naphthalene-1(2H),2'-[2H]pyran]-6'(3'H)-one;
3,4-Dihydro-4'-hydroxy-2,2-dimethyl-5'-[(5-methyl-2-isopropylphenyl)thio]-spiro[naphthalene-1,2'-[2H]pyran]-6'(3'H)-one;
3,,4,-Dihydro-4"-hydroxy-5"-[(5-methyl-2-isopropylphenyl)thio]-dispiro[cyclopropane-1, 2 '(1'H)-naphthalene-1',2"[2H]pyran]-6"(3"H)-one;
4-Hydroxy-3-(2-isopropylphenoxy)-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
4-Hydroxy-3-(2-isopropyl-5-methylphenoxy)-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
3-(2-tert-Butylphenoxy)-4-hydroxy-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
5-[5-(2-Cyclopentylphenoxy)-4-hydroxy-6-oxo-2-phenyl-3,6-dihydro-2H-pyran-2-yl]pentanoic acid;
4-Hydroxy-3-(2-isopropyl-5-methylphenoxy)-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-2-one;
6-Cyclopentylmethyl-4-hydroxy-3-(2-isopropylphenoxy)-6-phenyl-5,6-dihydro-2H-pyran-2-one;
3-(Cyclopropylphenylamino)-4-hydroxy-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
N-[3-[Cyclopropyl[4-hydroxy-2-oxo-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-3-yl]amino]phenyl]benzenesulfonamide; [3-[Cyclopropyl[4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]amino]phenyl]amide quinoline-8-sulfonic acid;
3-(CyclopropyIphenylamino)-4-hydroxy-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-2-one;
4-Hydroxy-6-isobutyl-6-(2-phenylethyl)-3-(phenylpropylamino)-5,6-dihydro-2H-pyran-2-one;
N-[4-Hydroxy-2-oxo-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-3-yl]-N-phenyl-methanesulfonamide;
N-[6-(2-Benzo[1,3]dioxol-5-yl-ethyl)-4-hydroxy-2-oxo-6-phenyl-5,6-dihydro-2H-pyran-3-yl]-N-(3-methylbutyl)benzenesulfonamide;
3-[Cyclopentyl(cyclopentylmethyl)amino]-4-hydroxy-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
4-Hydroxy-3-[methoxy(phenyl)methyl]-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
3-[Cyclopentyl(cyclopentyloxy)methyl]-4-hydroxy-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-2-one;
3-(1-Cyclopentyloxy-3-methylbutyl)-4-hydroxy-6-(3-methylbutyl)-6-phenyl-5,6-dihydro-2H-pyran-2-one;
6-Cyclopentyl-3-[cyclopentyl(isopropoxy)methyl]-4-hydroxy-6-(3-methylbutyl)-5,6-dihydro-2H-pyran-2-one;
4-Hydroxy-3-[(2-isopropylphenyl)thio]-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-2-one;
4-Hydroxy-6-isobutyl-3-[(2-isopropyl-5-methylphenyl)thio]-6-(2-phenylethyl)-5,6-dihydro-2H-pyrany-one;
3-[(2-tert-Butyl-furan-3-yl)thio]-4-hydroxy-6-phenyl-6- (2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
4-Hydroxy-3-[(3-isopropyl-pyridin-4-yl)thio]-6-phenyl-6- (2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
3-[(2-Cyclopentyl-pyridin-3-yl)thio]-4-hydroxy-6-pentyl-6-phenyl-5,6-dihydro-2H-pyran-2-one;
4-Hydroxy-6-isobutyl-3-[(3-isopropyl-isoxazol-4-yl)thio]-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one;
5-[(2-Isopropyl-5-methylphenyl)thio]-6-oxo-2-phenyl-2-(2-phenylethyl)-3,6-dihydro-2H-pyran-4-yl acetic acid ester; 2-[2-(Benzo[1,3]dioxol-5-yl)ethyl]-5-[(2-isopropyl-5-methylphenyl)thio]-6-oxo-2-phenyl-3,6-dihydro-2H-pyran-4-yl propionic acid ester;
5-[4-Isobutyryloxy-5-[(2-isopropylphenyl)thio]-6-oxo-2-phenyl-3,6-dihydro-2H-pyran-2-yl]-pentanoic acid;
N-[3-[Cyclopropyl[4-(acetyloxy)-5,6-dihydro-2-oxo-6-phenyl-(2-phenylethyl)-2H-pyran-3-yl]methyl]phenyl]-benzenesulfonamide;
Propanoic acid 5-[cyclopropyl[3- [(phenylsulfonyl)amino]phenyl]methyl]-3,6-dihydro-6-oxo-2,2-diphenyl-2H-pyran-4-yl ester;
2,2-Dimethylbutanoic acid 3,5-dihydro-6-oxo-2-(2-phenylethyl)-5-(1-phenylpropyl)-2-propyl-2H-pyran-4-yl ester and
Benzenacetic acid 5-[cyclopropyl[3- [(ethylsulfonyl)amino]phenyl]methyl]-3,6-dihydro-6-oxo-2-(2-phenylethyl)-2-propyl-2H-pyran-4-yl ester.
4. DETAILED DESCRIPTION OF THE INVENTION Here, the term "alkyl" means a straight or branched hydrocarbon radical having from 1 to 12 carbon atoms unless otherwise specified and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, undecyl, and dodecyl. The alkyl groups may contain one or more sites of unsaturation such as double or triple carbon-carbon bonds. The alkyl group is unsubstituted or substituted by from 1 to 3 substituents selected from alkyl, alkoxy, thioalkoxy all as defined herein, hydroxy, thiol, nitro, halogen, amino, formyl, carboxyl, nitrile, -NH-CO-R, -CO-NH-, -CO2R, -COR, aryl, or heteroaryl wherein alkyl (R), aryl, and heteroaryl are defined as herein.
The term "cycloalkyl" means a hydrocarbon ring which contains from 3 to 12 carbon atoms unless otherwise specified, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and adamantyl. Where possible, the cycloalkyl group may contain double bonds. The cycloalkyl ring may be
unsubstituted or substituted by from 1 to 3 substituents selected alkyl, alkoxy, thioalkoxy all as defined herein, hydroxy, thiol, nitro, halogen, amino, formyl, carboxyl, nitrile, -NH-CO-R, -CO-NHR-, -CO2R, -COR, aryl, or heteroaryl wherein alkyl (R), aryl, and heteroaryl are defined as herein.
The term alkylcycloalkyl means a cycloalkyl group as defined above attached directly to an alkyl group as defined above.
The terms "alkoxy" and "thioalkoxy" are O-alkyl or S-alkyl as defined above for alkyl.
The term spirocycle refers to a carbocyclic or
heterocyclic ring whose ends meet at a single carbon in a chain or another ring.
The term "aryl" means an aromatic radical which is a phenyl group, a benzyl group, a naphthyl group, a biphenyl group, a pyrenyl group, an anthracenyl group, a fluarenyl group or a fused ring resulting from any two of phenyl, naphthyl, and a 5- or 6- membered ring containing from 0 to 3 heteroatoms selected from guinolones, isoquinolones, indoles, indanes, benzofurans, benzothiophenes, benzoxazoles,
benzothiazoles, benzisoxazoles, coumarins, benzimidazoles and the like, unsubstituted or substituted by 1 to 3 substituents selected from alkyl as defined above, alkoxy as defined above, thioalkoxy as defined above, hydroxy, thiol, nitro, halogen, amino, formyl, carboxy, nitrile, -NHCOR, -CONHR, -CO2R, -COR, aryl, or heteroaryl wherein alkyl (R), aryl, and heteroaryl are defined as above.
The terms "heteroaryl" and "heterocycle", represented by an "Ar", mean a heterocyclic radical which is 2- or 3-thienyl,
2- or 3-furanyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isaxazolyl,
3- or 5- 1,2,4-triazolyl, 4- or 5- 1,2,3-triazolyl,
tetrazolyl, 2-, 3-, or 4-pyridinyl, 3-, 4-, or 5-pyridazinyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5- , 6-, or 7-benzimidazolyl, 2-, 4-, 5-, 6-, or 7-benzothiazolyl, 1- or 2-piperazmyl, 2-, 3-, or 4-morpholinyl, 2-, 3-, or 4-thiomorpholinyl, 1-, 2-, or 3-pyrrolidinyl, 2- or 3-tetrahydrofuranyl, 2-, 3-, or 4-tetrahydropyranyl, 2- 3-, or 4-piperidinyl, 1-, 2-, 4-, 5-, or 6-tetrahydropyrimidinyl, 2-dioxolinyl, 2-, 4-, or 5-imidazolidinyl, 1-, 2-, 3-, 4-, 5-, 6-, or 7-indolinyl, unsubstituted or substituted by 1 to 2 substituents selected from alkyl as defined above, aryl as defined above, alkoxy as defined above, thioalkoxy as defined above, hydroxy, thiol, nitro, halogen, formyl, amino,
carboxyl, nitrile, -NHCOR, -CO2R, -COR, wherein alkyl in as defined above or phenyl.
"Halogen" is fluorine, chlorine, bromine or iodine.
Some of the compounds of Formula 1 are capable of further forming pharmaceutically acceptable acid-addition and/or base salts. All of these forms are within the scope of the present invention.
Pharmaceutically acceptable acid addition salts of the compounds of Formula 1 include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate,
pyrosulfate, bisulfate, sulfite, bisulfite, nitrate,
phosphate, monohydrogenphosphate, dihydrogenphosphate,
metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinates suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzensoulfonate,
toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge, S.M., et al., "Pharmaceutical Salts," Journal of Pharmaceutical
Science , 66: 1-19 (1977).
The acid addition salt of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the
conventional manner.
Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline,
diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge, S.M., et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science , 66: 1-19 (1977).
The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the
conventional manner.
Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S(L) configuration. The present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof.
The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously,
intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula 1 or a corresponding pharmaceutically acceptable salt of a compound of Formula 1.
For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically
acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.
In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyIcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding
suitable colorants, flavors, stabilizing and thickening agents as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or, synthetic gums, resins, methyIcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These
preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is divided into unit doses containing appropriate quantities of the active
component. The unit dosage form can be a packaged
preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsules, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
The quantity of active component in a unit dose
preparation may be varied or adjusted from 0.1 mg to 100 mg preferably 0.5 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.
In therapeutic use as antagonists of a retroviral protease, as agents for the treatment of infections caused by a retrovirus including HIV, or as agents for the treatment of diseases due to AIDS, the compounds utilized in the
pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily. A daily dose range of about 0.01 mg to about 10 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
4.1 General Synthetic Approaches
to 5,6-Dihydropyrone Derivatives
Scheme I, shown below, illustrates the preparation of substituted dihydropyrones III.
Figure imgf000033_0001
Methyl acetoacetate (I) is treated sequentially with a metal hydride, preferably sodium hydride, in THF or ether at -20 °C to +10 °C, and with a stronger base, usually n-BuLi, in a solvent such as THF or ether at -20 °C to +10 °C, producing the dianion. The reaction mixture is quenched with an
appropriately substituted aldehyde or ketone, allowed to react for an additional 15 minutes to 24 hours, and finally worked up, furnishing the β-keto lactone (dihydropyrone) II.
Compound II is elaborated into target pyrones III via
treatment with a suitable electrophile, such as a
thiotosylate, an alkyl halide or the like, in ethanol or DMF solution containing an inert base such as triethylamine and/or sodium bicarbonate at 25 °C to 80 °C.
For purposes of the above and other syntheses of the compounds of the present invention, reactive functional group present in starting materials, reaction intermediaters, or reaction products may be protected during chemical reactions using protecting groups which render the reactive functional groups substantially inert to the reaction conditions. (See for example, Protective Groups in Organic Synthesis, 2 ed., T. W. Green and P. G. Wuts, John Wiley & Sons, New York, NY
1991). Thus, for example, protecting groups such as the following may be utilized to protect suitable amino, hydroxyl, and other groups of related reactivity: carboxylic acyl groups, such as formyl, acetyl, trifluoroacetyl;
alkoxycarbonyl groups, such as ethoxycarbonyl, t-butoxycarbonyl (BOC), β,β,β-trichloroethoxycarbonyl (TCEC), β-iodoethoxycarbonyl; aryloxycarbonyl groups, such as
benzyloxycarbonyl, p-methoxybenzyloxycarbonyl,
phenoxycarbonyl; trialkyl silyl groups, such as trimethyIsilyl and t-butyldimethylsilyl (TBDMS); and groups such as trotyl, tetrahydropyranyl, vinyloxycarbonyl, o-nitrophenylsulfenyl, diphenylphosphinyl, p-toluenesulfonyl, and benzyl, may all be utilized. The protecting group may be removed, after
completion of the synthetic reaction of interest, by
procedures known to those skilled in the art. For example, the BOC group may be removed by acidolysis, the trityl group by hydrogenolysis, TBDMS by treatment with fluoride ions, and TCEC by treatment with zinc.
Scheme II describes an alternate synthesis of
dihydropyrones which are substituted at C-3.
Figure imgf000035_0001
The acetoacetate I is treated with a base, such as sodium hydride or sodium ethoxide, in a suitable solvent such as THF, ether, or alcohol at -20 °C to 10 °C, and the resulting anion is quenched with an appropriately substituted alkyl or benzyl halide, usually the bromide or iodide, to give ketoester V (Y = CH2). Alternatively, chloroacetoacetate IV is reacted with a thiol, preferably in the presence of a suitable base such as triethylamine, piperidine, or pyridine, in a suitable solvent such as dichloromethane, at -10 °C to +25 °C, affording ketoester V (Y = S) (see Z. Yoshida et al . , Tetrahedron 26: 2987 (1970)). The requisite thiols can be prepared from the corresponding phenol via the Newman-Kwart rearrangement (see, for example, H. Kwart and H. Omura, J. Amer. Chem. Soc . 93: 7250 (1971); M. S. Newman and F. W. Hetzel, Org. Syn . Coll . Vol . VT: 824 (1988); M. S. Newman and H. A. Karnes, J. Org. Chem . 31: 3980 (1966)) or from the corresponding iodobenzene via a nucleophilic displacement with thiourea in the presence of a nickel catalyst (K. Takagi, Chem . Letters , 1307 (1985)). Similarly, reaction of IV with an alkoxide in a suitable solvent such as benzene, DMF, or mixtures of THF and HMPA, at -10 °C to 25 °C, yields acetoacetate V (Y = O) (see T. Sasaki et al . , Tetrahedron 38: 85 (1982)). Intermediate V is
subsequently elaborated into dihydropyrones VI using the general procedure outlined in Scheme I above.
Analogs possessing amino substituents at the 3-position can be prepared as shown in Scheme III.
Figure imgf000037_0001
Ester VII is treated with a suitable base, such as lithium diisopropylamide, in a suitable solvent such as THF or ether, at -78 °C to 0 °C, and the resulting anion is reacted with an appropriately substituted acylating agent such as ester VIII, producing ketoester IX. Cyclization of IX by e.g. treatment with a suitable base such as sodium hydroxide or sodium alkoxide yields desired dihydropyrones X.
Any of the 4-hydroxy-2H-pyran-2-ones such as III, VI, or X can be constructed to contain an appropriate leaving group (such as halogen, acetate, tosylate, etc.) in one of the R1 or R2 substituents. Such leaving groups can be displaced by primary or secondary amines to further embellish the R1 or R2 substituents. Such displacement would be carried out in alcohol or DMF or DMSO at -10° to 125°C. Likewise, if R1 or R2 contain a carboxylic acid related group, then further chemistry on that group would further embellish the R1 or R2 substituents. Such reactions would include esterification or amide formation using methods well known in the art.
Furthermore, 4-hydroxy-2(1H)-pyridinones such as XI, shown below, are known in the art (e.g. see M.J. Ashton et al . , Heterocycles 28: (2) 1015 (1989)), and can be converted to desired protease inhibitors and antiviral agents analogous to the 5,6-dihydropyrones by using reactions similar to that used for conversion of II→ III shown in Scheme I above.
Figure imgf000038_0001
Substituted 1,3-cyclohexandiones can be prepared as described by Werbel (see J. Med. Chem . 35: 3429-47 (1992) and references cited therein). The 1,3-cyclohexandiones can be converted to substituted analogues using reactions similar to those used for conversions II→ III.
Tetrahydro(thio)pyran-2,4-dione derivatives can be prepared as described in United States Patent 4,842,638 and references cited therein. The tetrahydro(thio)pyran-2,4-diones can be converted to various substituted analogues using reactions similar to those used for conversions of II→ III.
Derivatives containing a thio moiety at the 3-position can also be prepared as shown in Scheme IV:
Figure imgf000039_0001
Dihydropyrone II is treated with a suitable brominating agent, such as N-bromosuccinimide, in a suitable solvent, such as t-butanol, for 1 to 18 hours. The resulting bromo
intermediate XII is reacted with a thiol, usually in the presence of an appropriate base such as pyridine or
piperidine, in a suitable solvent such as dichloromethane at 0°C to +25°C to afford desired product XIII.
An alternate synthesis of derivatives containing a carbon substituent at the 3-position is shown in Scheme V.
Figure imgf000040_0001
The dihydropyrone II is reacted with a suitable acid chloride, and the product is rearranged to give intermediate XV according to procedures outlined in U.S. Patent 4,842,638 (1989). The keto group of XV is reduced to the methylene with an appropriate reducing agent, such as sodium cyanoborohydride or hydrogen in the presence of a catalyst, to afford compound XVI.
In Scheme VI, an optional method for preparing certain 4-hydroxy-2H-pyran-2-ones (such as III or VI) with complex amide containing side chains as R1 or R2 is shown.
Figure imgf000041_0001
The prerequisite acid XVII prepared by literature
conditions is cyclized to the lactone XVIII in DMF and
dichloromethane at temperatures of 0 to 75°C. The lactone is ring opened by the appropriately substituted amine either neat or in solvents such as toluene, at 75 - 110°C to produce ketone amide XIX. This amide XIX is treated with the dianion as described in Scheme I to produce the lactone XX which is identical to II where R1 is equal to the new amide containing chain. XX can be converted to the target compounds using conditions described in Scheme I.
The compounds of the present invention can exist in their tautomeric forms, i.e. the enol and keto forms shown in Scheme I. Both such forms as well as their mixtures are preferred aspects of the instant invention. The substituted phenylpropiophenones were prepared by hydrogenation of the corresponding chalcones in
tetrahydrofuran with 5% Pd on BaSO4 as catalyst.
The chalcones were prepared according to Kohler and
Chadwell Org. Synth. Coll. Vol. I, 78, 1941.
4.2 Procedures for the Preparation of
5,6-Dihydropyrone Derivatives
General Method 1.
Methyl acetoacetate was added dropwise to a slurry of hexane wasned sodium hydride in anhydrous tetrahydrofuran at 0 °C and the reaction stirred at 0 °C (15 minutes to 1 hour). n-Butyl lithium was then added at 0 °C and the reaction stirred at 0 °C (15 minutes to 1 hour). The aldehyde or ketone, in tetrahydrofuran, was added to the dianion and the reaction stirred at 0 °C (15 minutes to 24 hours) and allowed to warm to room temperature (15 minutes to 24 hours). To the reaction mixture was added water and the mixture allowed to stir 15 minutes to overnight. After extracting with diethyl ether, the aqueous layer at 0 °C was acidified with acid(2-6N HCl) to pH 1-2 and the aqueous layer extracted with ethyl acetate or CH2Cl2. The organic extracts of the acid solution were combined, dried over MgSO4 and concentrated.
Example A.
5,6-Dihydro-4-hydroxy-6-phenγl-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 1 using 13.67 g methyl acetoacetate, 8.5 g of NaH 60% dispersion in oil, 73.6 mL of 1.6 M n-butyl lithium in hexane, 10 g of benzaldehyde, and 300 mL of tetrahydrofuran. After addition of the aldehyde, the reaction was stirred 15 minutes at -78 °C then allowed to warm to room temperature overnight. A solid was filtered off after concentration (m.p. 145-146 °C). 1H NMR (CDCl3) δ 2.8-3.05 (m, 2 H), 3.5 (d, 1 H), 3.7 (d, 1 H), 5.7 (dd, 1 H), 7.3-7.5 (m, 5 H). Example B.
5,6-Dihydro-4-hydroxy-6-(2-methylpropyl)-6-phenyl-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 1 using 12 g methyl acetoacetate, 4.3 g of NaH 60% dispersion in oil, 64.5 mL of 1.6M n-butyl lithium in hexane, 10 g of iso-valerophenone, and 300 mL of tetrahydrofuran.
After addition of the phenone, the reaction was stirred 15 minutes at -78 °C and 2 hours at room temperature. The crude reaction was flash chromatographed using hexane/ethyl acetate 6/40-40/60 as eluent. The solid was triturated from diethyl ether (m.p. 123.5-125 °C). 1H NMR (CDCl3) δ 0.81 (d, 3 H), 0.89 (d, 3 H), 1.6-1.7 (M, 1 H), 1.91 (m, 2 H), 2.90 (d, 1 H), 2.95 (d, 1 H), 3.25 (d, 1 H), 3.35 (d, 1 H), 7.25-7.45 (m, 5 H).
Example C.
5,6-Dihydro-4-hydroxy-6-(4-methoxyphenyl)-2H-pyran-2-one, (±)
The title compound was prepared as described in General Method 1 using 5 mL of methyl acetoacetate, 2.0 g of NaH 60% dispersion in oil, 25 mL of 2.0 M n-butyl lithium in hexane, 7.0 mL of 4-methoxybenzaldehyde and 150 mL of tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 15 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p.159-162 °C (dec.)). 1H ΝMR
(CDCl3) 6 2.91 (dd, 2 H), 3.57 (dd, 2 H), 3.83 (s, 3 H), 5.66 (dd, 1 H), 6.93-6.97 (m, 2 H), 7.30-7.34 (m, 2 H). Example D.
5,6-Dihydro-4-hydroxy-6-[4-(methylthio)phenyl]-2H-pyran-2-one, (±)
The title compound was prepared as described in General Method 1 using 10 mL of methyl acetoacetate, 4.0 g of ΝaH 60% dispersion in oil, 60 mL of 1.6 M n-butyl lithium in hexane, 18.8 mL of 4-methylthiobenzaldehyde and 200 mL of
tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 15 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 139-141 °C). 1H NMR (CDCl3) δ 2.51 (s, 3 H), 2.92 (dd, 2 H), 3.58 (dd, 2 H), 5.68 (dd, 1 H), 7.27-7.31 (m, 4 H).
Example E
5,6-Dihydro-4-hydroxy-6-(4-methylphenyl)-2H-pyran-2-one, (±)
The title compound was prepared as described in General Method 1 using 10 mL of methyl acetoacetate, 3.7 g of NaH 60% dispersion in oil, 58 mL of 1.6 M n-butyl lithium in hexane, 10.9 mL of p-tolualdehyde and 250 mL of tetrahydrofuran.
After addition of the aldehyde, the reaction was stirred for 15 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 138-139 °C). 1H NMR (CDCl3) δ 2.39 (s, 3 H), 2.93 (dd, 2 H), 3.58 (dd, 2 H), 5.69 (dd, 1 H), 7.23-7.31 (m, 4 H). Example F.
6-[4-(1,1-Dimethylethyl)phenyl]-5,6-dihydro-4-hydroxy-2H-pyran-2-one, (±)
The title compound was prepared as described in General Method 1 using 5.0 mL of methyl acetoacetate, 2.0 g of NaH 60% dispersion in oil, 31.5 mL of 1.6 M n-butyl lithium in hexane, 9.0 g of 4-(1,1-dimethylethyl)benzaldehyde and 100 mL of tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 15 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 164-165 °C). 1H NMR (CDCI3) δ 1.33 (s, 9 H), 2.94 (dd, 2 H), 3.59 (dd, 2 H), 5.69 (dd, 1 H), 7.31-7.47 (m, 4 H).
Example G.
6-(4-Chlorophenyl)-5,6-dihydro-4-hydroxy-2H-pyran-2-one, (±)
The title compound was prepared as described in General Method 1 using 10 mL of methyl acetoacetate, 3.9 g of NaH 60% dispersion in oil, 58 mL of 1.6 M n-butyl lithium in hexane, 13.5 g of 4-chlorobenzaldehyde and 250 mL of tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 15 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 149-150 °C). 1H NMR (CDCl3) δ 2.83 (dd, 1 H), 2.95 (dd, 1 H), 3.60 (dd, 2 H), 5.67 (dd, 1 H), 7.33-7.44 (m, 4 H). Example H.
6-(3-Chlorophenyl)-5,6-dihydro-4-hydroxy-2H-pyran-2-one, (±)
The title compound was prepared as described in General Method 1 using 5.0 mL of methyl acetoacetate, 2.0 g of NaH 60 dispersion in oil, 25 mL of 2.0 M n-butyl lithium in hexane, 6.5 mL of 3-chlorobenzaldehyde and 150 mL of tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 15 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 122-124 ºC). 1H NMR (CDCl3) δ 2.83 (dd, 1 H), 2.96 (dd, 1 H), 3.60 (dd, 2 H), 5.68.(dd, 1 H), 7.25-7.42 (m, 4 H).
Example I
5,6-Dihydro-4-hydroxy-6-[4-(phenylmethoxy)phenyl]-2H-pyran-2-one, (±)
The title compound was prepared as described in General Method 1 using 5.0 mL of methyl acetoacetate, 2.0 g of NaH 60% dispersion in oil, 25 mL of 2.0 M n-butyl lithium in hexane, 12.0 g of 4-benzyloxybenzaldehyde and 150 mL of
tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 15 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 165-166 °C). 1H NMR (CDCl3) δ 2.91 (dd, 2 H), 3.56 (dd, 2 H), 5.09 (s, 2 H), 5.65 (dd, 1 H), 6.98-7.04 (m, 2 H), 7.30-7.44 (m, 7 H). Example J
6-[1,1'-Biphenyl]-4-yl-5,6-dihydro-4-hydroxy-2H-pyran-2-one,
(±)
The title compound was prepared as described in General Method 1 using 13.0 g of ethyl acetoacetate, 5.3 g of NaH 50% dispersion in oil, 60 mL of 1.6 M n-butyl lithium in hexane, 16.3 g of 4-biphenylcarboxaldehyde and 300 mL of
tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 15 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 150-152 °C). 1H NMR (CDCl3) δ 2.97 (dd, 2 H), 3.60 (dd, 2 H) 5.77 (dd, 1 H), 7.27-7.68 (m, 9 H). Example K
6-[[(1,1'-Biphenyl)-4-yloxy]methyl]-5,6-dihydro-4-hydroxy-2H-pyran-2-one, (±)
The title compound was prepared as described in General Method 1 using 4.76 g of methyl acetoacetate, 1.97 g of NaH 50% dispersion in oil, 19.5 mL of 2.1 M n-butyl lithium in hexane, 8.7 g of [[1,1'-biphenyl]-4-yloxy]-acetaldehyde and 200 mL of tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 60 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 152- 154 °C). 1H NMR (CDCl3) δ 2.83 (dd, 1 H), 2.95 (dd, 1 H) 3.61 (dd, 2 H), 4.23 (dd, 1 H), 4.38 (dd, 1 H), 5.03-5.07 (m, 1 H), 6.94-6.98 (m, 2 H), 7.30-7.57 (m, 7 H). Example L.
6-[1,1'-Biphenyl]-4-yl-6-butyl-5,6-dihydro-4-hydroxy-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 1 using 13 g ethyl acetoacetate, 5.3 g of NaH 60% dispersion in oil, 60 mL of 1.6M n-butyl lithium in hexane, 21 g of 1-[1,1'-biphenyl]-4-yl-1-pentanone and 300 mL of tetrahydrofuran. After addition of the ketone, the reaction was stirred 15 minutes at -78 °C and 2 hours at room
temperature. The crude reaction mixture afforded a solid which was washed with CH2Cl2 and two times with ethyl acetate (m.p. 165-170 °C). 1H NMR(d6-DMSO) δ 0.7-1.9 (m, 7 H), 2.0 (m, 2 H), 3.0 (s, 2 H), 4.9 (s, 1 H), 7.3-7.8 (m, 9 H), 11.3 (s, 1 H).
Example M.
4-[2,3-Dihydro-4-hydroxy-6-oxo-2H-pyran-2-yl]-benzonitrile, (±)
The title compound was prepared as described in General Method 1 using 5.0 mL of methyl acetoacetate, 2.0 g of NaH 60 dispersion in oil, 25 mL of 2.0 M n-butyl lithium in hexane, 7.6 g of 4-cyanobenzaldehyde and 150 mL of tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 10 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 149-152 °C). 1H NMR (CDCl3) δ 2.80 (dd, 1 H), 2.99 (dd, 1 H), 3.65 (dd, 2 H), 5.75 (dd, 1 H), 7.55 (d, 2 H), 7.75 (d, 2 H).
Example N.
6-(4-Trifluoromethylphenyl)-5,6-dihydro-4-hydroxy- 2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 1 using 10 mL of methyl acetoacetate, 3.7 g of NaH 60% dispersion in oil, 58 mL of 1.6 M n-butyl lithium in hexane, 11.5 g of 4-trifluoromethylbenzaldehyde and 250 mL of
tetrahydrofuran. After addition of the aldehyde, the reactio was stirred for 10 minutes at 0 °C then 30 minutes at room temperature. The crude product was triturated from diethyl ether to afford a solid (m.p. 155-156 °C). 1H NMR (CDCl3) δ 2.83 (dd, 1 H), 2.99 (dd, 1 H), 3.58 (dd, 2 H), 5.76 (dd, 1 H), 7.50-7.76 (m, 4 H). Example O.
6-(3,5-Dichlorophenyl)-5,6-dihydro-4-hydroxy- 2H-pyran-2-one,
(+/-)
The title compound was prepared as described in General Method 1 using 2.5 mL of methyl acetoacetate, 1.0 g of NaH 60% dispersion in oil, 12.5 mL of 2.0 M n-butyl lithium in hexane,
5.1 g of 3,5-dichlorobenzaldehyde and 75 mL of
tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 10 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 135-137 °C). 1H NMR (CDCl3) δ 2.78 (dd, 1 H), 2.97 (dd, 1 H), 3.63 (dd, 2 H), 5.64 (dd, 1 H), 7.31-7.40 (m, 3 H). Example P.
5,6-Dihydro-4-hydroxy-6-(pentafluorophenyl)-2H-pyran-2-one,
The title compound was prepared as described in General Method 1 using 2.5 mL of methyl acetoacetate, 1.0 g of NaH 60% dispersion in oil, 12.5 mL of 2.0 M n-butyl lithium in hexane, 3.4 mL of pentafluorobenzaldehyde and 75 mL of
tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 10 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 176-178 °C). 1H NMR (CDCl3) δ 2.89 (dd, 1 H), 3.15 (dd, 1 H), 3.70 (dd, 2 H),
6.02 (dd, 1 H).
Example Q.
5,6-Dihydro-4-hydroxy-6-(3-methylphenyl)- 2H-pyran-2-one,
(+/-)
The title compound was prepared as described in General Method 1 using 2.0 mL of methyl acetoacetate, 0.8 g of NaH 60% dispersion in oil, 10 mL of 2.0 M n-butyl lithium in hexane, 2.6 mL of 3-methylbenzaldehyde and 100 mL of tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 10 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 137-138 °C). 1H NMR (CDCl3) δ 2.38 (s, 3 H), 2.88 (dd, 1 H), 2.95 (dd, 1 H), 3.57 (dd, 2 H), 5.68 (dd, 1 H), 7.16-7.33 (m, 4 H).
Example R.
6-(2-Chlorophenyl)-5,6-dihydro-4-hydroxy- 2H-pyran-2-one,
(+/-)
The title compound was prepared as described in General Method 1 using 2.5 mL of methyl acetoacetate, 1.0 g of NaH 60% dispersion in oil, 12.5 mL of 2.0 M n-butyl lithium in hexane, 3.3 mL of 2- chlorobenzaldehyde and 75 mL of tetrahydrofuran. After addition of the aldehyde, the reaction was stirred for 10 minutes at 0 °C then stirred for 2 hours at room
temperature. The crude product was triturated from diethyl ether to afford a solid (m.p. 124-125 °C). 1H NMR (CDCl3) δ 2.63 (dd, 1 H), 3.10 (dd, 1 H), 3.68 (dd, 2 H), 6.07 (dd, 1 H), 7.3-7.65 (m, 4 H). Example S.
6-Butyl-5,6-dihydro-4-hydroxγ-6-phenyl-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 1 using 2.7 mL of methyl acetoacetate, 1.1 g of NaH 60% dispersion in oil, 12.5 mL of 2.0 M n-butyl lithium in hexane, 5.1 mL of valerophenone and 125 mL of tetrahydrofuran. After addition of the ketone, the reaction was stirred for 10 minutes at 0 °C then allowed to warm to room temperature overnight. The crude product was triturated from diethyl ether to afford a solid (m.p. 124-126 °C). 1H NMR (CDCl3) δ 0.85 (t, 3 H), 1.28 (m, 4 H), 1.97 (m, 2 H), 2.90 (dd, 2 H), 3.30 (dd, 2 H), 7.28-7.42 (m, 5 H).
Example T.
5,6-Dihydro-4-hydroxy-6-phenyl-6-propyl-2H-pyran-2-one, (+/-) The title compound was prepared as described in the
General Method 1 using 5 mmol of methyl acetoacetate, 5.5 mmol of NaH 60% dispersion in oil, 5.5 mmol of 1.6 M n-butyl lithium in hexane, 5.5 mmol of butyrophenone and 14 mL of tetrahydrofuran. After addition of the ketone, the reaction was stirred for 90 minutes at 0 °C. The reaction was poured into saturated NH4Cl solution and extracted with ethyl
acetate. The organic layer was dried over MgSO4,
concentrated, and the residue flash chromatographed using hexane/ethyl acetate 80/20 as eluent. The aldol product was stirred at room temperature in 100 mL of 0.1N NaOH for 3.5 hours. The reaction was worked up as in General Method 1 and the product triturated from diethyl ether to afford a solid (m.p. 131.5-132 °C). 1H NMR (CDCl3) δ 0.88 (t, 3 H), 1.1-1.4 (m, 2 H), 1.95 (m, 2 H), 2.90 (d, 1 H), 2.92 (d, 1 H),
3.25 (d, 1 H), 3.35 (d, 1 H), 7.2-7.4 (m, 5 H). Example U.
5,6-Dihydro-6-pentyl-6-phenyl-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 1 using 10 mmol of methyl acetoacetate, 11 mmol of NaH 60% dispersion in oil, 10.5 mmol of 1.6 M n-butyl lithium in hexane, 10 mmol of hexanophenone and 28 mL of tetrahydrofuran. Upon concentrating the reaction a solid precipitated out which was triturated with ether and filtered (m.p. 123-124 °C). 1H NMR (CDCl3) δ 0.83 (t, 3 H), 1.1-1.4 (m, 6 H), 1.9-2.0 (m, 2 H), 2.90 (d, 1 H), 2.92 (d, 1 H), 3.25 (d, 1 H), 3.35 (d, 1 H), 7.2-7.5 (m, 5 H).
Example V.
5,6-Dihydro-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 1 using 25 mmol of methyl acetoacetate, 27.5 mmol of NaH 60% dispersion in oil, 26.25 mmol of 1.6 M n-butyl lithium in hexane, 25 mmol of isohexanophenone and 70 mL of
tetrahydrofuran. Upon concentrating the reaction a solid precipitated out which was triturated with ether and filtered (m.p. 134-136 °C). 1H NMR (CDCl3) δ 0.83 (dd, 6 H), 1.1-1.3 (m, 2 H), 1.4-1.6 (m, 1 H), 1.9-2.1 (m, 2 H), 2.90 (d, 1 H), 2.92 (d, 1 H), 3.25 (d, 1 H), 3.35 (d, 1 H), 7.2-7.5 (m, 5 H). Example W.
5,6-Dihydro-6,6-diphenyl-2H-pyran-2-one
The title compound was prepared as described in General Method 1 using 20 mmol of methyl acetoacetate, 22 mmol of NaH 60% dispersion in oil, 21 mmol of 1.6 M n-butyl lithium in hexane, 20 mmol of benzophenone and 70 mL of tetrahydrofuran. Upon concentrating the reaction a solid precipitated out which was triturated with ether and filtered (m.p. 170.5-173 °C). 1H NMR (CDCl3) δ 3.18 (s, 2 H), 3.4 (s, 2 H), 7.3-7.5 (m, 10 H).
Example X.
5,6-Dihydro-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 1 using 25 mmol of methyl acetoacetate, 27.5 mmol of NaH 60% dispersion in oil, 26.25 mmol of 1.6 M n-butyl lithium in hexane, 25 mmol of 3-phenylpropiophenone and 70 mL of tetrahydrofuran. Upon concentrating the reaction a solid precipitated out which was triturated with ether and filtered (m.p. 130-130.55, °C). 1H NMR (CDCl3) δ 2.2-2.4 (m, 2 H), 2.4-2.6 (m, 1 H), 2.6-2.8 (m, 1 H), 2.9 (d, 1 H), 3.0 (d, 1 H), 3.3 (d, 1 H), 3.4 (d, 1 H), 7.0-7.5 (m, 15 H).
EXAMPLE Y.
5,6-Dihydro-4-hydroxy-6-phenyl-2(1H)-pyridinone (±)
The title compound was prepared by decarboxylation of methyl 6-phenyl-2-,4-dioxopiperidine-3-carboxylate (prepared as per Ashton et al., Heterocycles 28: (2) 1015 (1989)) by refluxing in acetonitrile (as per Toda et al., J. Antibiotics 23: (2) 173 (1980)). Removal of the solvent gave a solid
(m.p. 166-169 °C). 1H NMR (CDCl3) δ 2.77 (dd, 1 H), 2.90 (dd, 1 H), 3.38 (s, 2 H), 4.80 (dd, 1 H), 6.40 (s, 1 H), 7.32-7.46 (m, 5 H). Example Z
5,6-Dihydro-4-hydroxy-6-phenoxymethyl-6-phenyl-2H-pyran-2-one, (+/-) The title compound was prepared as described in General Method 1 using 0.85 mL of methyl acetoacetate, 350 mg of NaH 60% dispersion in oil, 5 mL of 1.6 M n-butyl lithium in hexane, 2.0 g of 2-phenoxy-1-phenyl ethanone and 60 mL of tetrahydrofuran. After addition of the ketone, the reaction was stirred for 15 minutes at 0°C then allowed to warm to room temperature and stirred for 1 hour. The crude product was triturated from diethyl ether to afford a solid (m.p. 133-135 °C). 1H NMR (DMSO-d6) δ 3.03 (d, 1 H), 3.35 (d, 1 H), 4.18 (dd, 2 H), 4.90 (s, 1 H), 6.92-6.95 (m, 3 H), 7.24-7.49 (m, 7 H), 11.56 (s, 1 H).
Example A1
6-(2-Benzo[l,3]dioxol-5-yl-ethyl)-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 1 using 0.22 mL of methyl acetoacetate, 90 mg of NaH 60% dispersion in oil, 1 mL of 2.1 M n-butyl lithium in hexane, 500 mg of 3-(3,4-methylenedioxyphenyl)propiophenone and 15 mL of tetrahydrofuran. After addition of the ketone, the reaction was stirred for 15 minutes at 0°C then allowed to warm to room temperature and stirred for 2 hours. The crude product was triturated from diethyl ether to afford a solid (m.p. 112-114 °C ). 1H NMR (CDCl3) δ 2.20-2.28 (m, 2 H), 2.37-2.44 (m, 1 H), 2.61-2.69 (m, 1 H), 2.95 (dd, 2 H), 3.32 (dd, 2 H), 5.90 (s, 2 H), 6.52-6.70 (m, 3 H), 7.33-7.44 (m, 5 H).
Example B1
6-[2-(3,4-Dichlorophenyl)-ethyl]-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 1 using 1.7 mL of methyl acetoacetate, 630 mg of NaH 60% dispersion in oil, 9.85 mL of 1.6 M n-butyl lithium in hexane, 4.0 g of 3-(3,4-dichlorophenyl)propiophenone and 150 mL of tetrahydrofuran. After addition of the ketone, the reaction was stirred for 15 minutes at 0°C then allowed to warm to room temperature and stirred for 4 hours. The crude product was triturated from diethyl ether to afford a solid (m.p. 145-147 °C ). 1H NMR (CDCl3) δ 2.18-2.35 (m, 2 H), 2.39-2.50 (m, 1 H), 2.68-2.80 (m, 1 H), 2.96 (dd, 2 H), 3.36 (dd, 2 H), 6.90-7.50 (m, 8 H).
Example C1
6-[2-(4-Fluorophenyl)-ethyl]-5,6-dihydro-4-hydroxy-6-phenyl- 2H-pyran-2-one (+/-)
The title compound was prepared as described in General Method 1 using 3.1 mL of methyl acetoacetate, 1.2 g of NaH 60% dispersion in oil, 18 mL of 1.6 M n-butyl lithium in hexane, 6.0 g of 3-(4-fluorophenyl)propiophenone and 200 mL of tetrahydrofuran. After addition of the ketone, the reaction was stirred for 15 minutes at 0°C then allowed to warm to room temperature and stirred for 4 hours. The crude product was triturated from diethyl ether to afford a solid (m.p. 155-157 °C ). 1H NMR (CDCl3) δ 2.23-2.29 (m, 2 H), 2.42-2.52 (m, 1 H), 2.67-2.78 (m, 1 H), 2.97 (dd, 2 H), 3.35 (dd, 2 H), 7.34-7.47 (m, 5 H), 6.91-7.07 (m, 4 H).
Example D1
5,6-Dihydro-6-hexyl-4-hydroxy-6-phenyl-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 1 using 25 mmol of methyl acetoacetate, 27.5 mmol of NaH 60% dispersion in oil, 26.25 mmol of 1.6 M n-butyl lithium in hexane, 25 mmol of heptanophenone and 70 mL of
tetrahydrofuran. Upon concentrating the reaction, a solid precipitated out which was triturated with ether and filtered (m.p. 119-120.5 °C). 1H NMR (CDCl3) δ 0.84 (t, 3 H), 1.1-1.4 (m, 8 H), 1.9-2.0 (m, 2 H), 2.89 (d, 1 H), 2.93 (d, 1 H), 3.24 (d, 1 H), 3.35 (d, 1 H), 7.2-7.5 (m, 5 H). Example E1
5,6-Dihydro-4-hydroxy-6-(4-methylpentyl)-6-phenyl-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 1 using 14.2 mmol of methyl acetoacetate, 15.6 mmol of NaH 60% dispersion in oil, 14.9 mmol of 1.6 M n-butyl lithium in hexane, 14.2 mmol of isoheptanophenone and 50 mL of
tetrahydrofuran. Isoheptanophenone was prepared by reacting the appropriate acid chloride with AlCl3 in benzene as
described by Vogel in Practical Organic Chemistry 1978, 770-775. Upon concentrating the reaction, a solid precipitated out which was recrystallized from ethyl acetate (m.p. 124-125 °C). 1H NMR (CDCl3) δ 0.80 (d,d, 6 H), 1.1-1.2 (m, 2 H), 1.15-1.40 (m, 2 H), 1.4-1.5 (m, 1 H), 1.9-2.0 (m, 2 H), 2.88 (d, 1 H), 2.9 (d, 1 H), 3.2 (d, 1 H), 3.3 (d, 1 H), 7.2-7.5 (m, 5 H).
Example F1
6-(Cyclopentylmethyl)-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 1 using 25 mmol of methyl acetoacetate, 27.5 mmol of NaH 60% dispersion in oil, 26.25 mmol of 1.6 M n-butyl lithium in hexane, 25 mmol of 2-cyclopentyl-1-phenyl-ethanone and 70 mL of tetrahydrofuran. 2-Cyclopentyl-1-phenyl-ethanone was prepared by reacting the appropriate acid chloride with AlCl3 in benzene as described by Vogel in Practical Organic
Chemistry 1978, 770-775. Upon concentrating the reaction, a solid precipitated out which was recrystallized from ethyl acetate (m.p. 158-160 °C). 1H NMR (DMSO-d6) δ 0.8-0.9 (m, 1 H), 1.0-1.1 (m, 1 H), 1.2-1.8 (m, 7 H), 1.9-2.1 (m, 2 H), 2.9 (ABq, 2 H), 4.8 (s, 1 H), 7.2-7.4 (m, 5 H), 11.3 (s, 1 H).
Example G1
3,4-Dihydro-4'-hydroxy-spiro[naphthalene-1(2H),2'-[2H]pyran]-6'(3'H)-one (±) The title compound was prepared as described in General Method 1 using 25 mmol of methyl acetoacetate, 27.5 mmol of NaH 60% dispersion in oil, 26.25 mmol of 1.6 M n-butyl lithium in hexane, 25 mmol of α-tetralone and 70 mL of
tetrahydrofuran. The product was recrystallized from ethyl acetate/diethyl ether (m.p. 117-119 °C). 1H NMR (CDCl3) δ 1.7-1.9 (m, 1 H), 1.9-2.1 (m, 2 H), 2.1-2.3 (m, 1 H), 2.7-3.0 (m, 2 H), 2.95 (d, 1 H), 3.1 (d, 1 H), 3.5 (s, 2 H), 7.1-7.2 (m, 1 H), 7.2-7.3 (m, 2 H), 7.4-7.5 (m, 1 H).
Example H1
3-(3,6-Dibydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl) propanoic acid (+)
The title compound was prepared as described in General Method 1 using 25 mmol of methyl acetoacetate, 27.5 mmol of NaH 60% dispersion in oil, 26.25 mmol of 1.6 M n-butyl lithium in hexane in 50 mL of tetrahydrofuran and 25 mmol of 3-benzoylpropionic acid sodium salt in 60 mL of tetrahydrofuran. 3-Benzoylpropionic acid sodium salt was prepared by reacting the acid (25 mmol) with hexane washed NaH (26.25 mmol) in tetrahydrofuran at 0°C for 30 minutes. The crude product was flash chromatographed using CH2Cl2/MeOH/CH3CO2H (90/10/0.2) to give a viscous gum. 1H NMR (CDCl3) δ 2.1-2.6 (m, 4 H), 2.9 (d, 1 H), 3.0 (d, 1 H), 3.3 (d, 1 H), 3.4 (d, 1 H), 7.2-7.5 (m, 5 H).
Example I1
4-(3,6-Dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl) butyric acid (±)
The title compound was prepared as described in General Method 1 using 25 mmol of methyl acetoacetate, 27.5 mmol of NaH 60% dispersion in oil, 26.25 mmol of 1.6 M n-butyl lithium in hexane in 50 mL of tetrahydrofuran and 25 mmol of 4-benzoylbutyric acid acid sodium salt in 100 mL of
tetrahydrofuran. 4-Benzoylbutyric acid sodium salt was prepared by reacting the acid (25 mmol) with hexane washed NaH (17.5 mmol) in tetrahydrofuran at 0°C for 25 minutes. The crude product was flash chromatographed using
CH2Cl2/MeOH/CH3CO2H (99/1/0.1-97.5/2.5/0.1) to give a solid which was recrystallized from ethyl acetate (m.p. 134-137 °C). 1H NMR (DMSO-d6) δ 1.1-1.2 (m, 1 H), 1.4-1.6 (m, 1 H), 1.8-2.0 (m, 2 H), 2.0-2.2 (m, 2 H), 2.9 (ABq, 2 H), 4.85 (s, 1 H), 7.2-7.4 (m, 5 H).
Example J1
5-(3,6-Dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)
pentanoic acid (±)
The title compound was prepared as described in General Method 1 using 25 mmol of methyl acetoacetate, 27.5 mmol of NaH 60% dispersion in oil, 26.25 mmol of 1.6 M n-butyl lithium in hexane in 50 mL of tetrahydrofuran and 25 mmol of 5-benzoylpentanoic acid sodium salt in 100 mL of
tetrahydrofuran. 5-Benzoylpentanoic acid sodium salt was prepared by reacting the acid (25 mmol) with hexane washed NaH (27.5 mmol) in tetrahydrofuran at 0°C for 25 minutes. The crude solid was recrystallized from ethyl acetate (m.p. 136-140 °C). 1H NMR (DMSO-d6) δ 0.8-1.0 (m, 1 H), 1.1-1.3 (m, 1 H), 1.3-1.5 (m, 2 H), 1.8-2.0 (m, 2 H), 2.1 (t, 2 H), 2.9 (ABq, 2 H), 4.85 (s, 1 H), 7.2-7.4 (m, 5 H), 11.4 (bs, 1 H), 12.0 (bs, 1 H). Example K1
5,6-Dihydro-4-hydroxy-6-phenyl-6-pyridin-4-yl-2H-pyran-2-one
(±)
The title compound was prepared as described in General Method 1 using 90 mmol of ethyl acetoacetate, 99 mmol of NaH 60% dispersion in oil, 95 mmol of 1.6 M n-butyl lithium in hexane and 90 mmol of 4-benzoylpyridine and 250 mL of
tetrahydrofuran. The reaction mixture was acidified with acetic acid and the crude solid was washed with ice water (m.p. 148-150 °C). Example L1
5,6-Dihydro-4-hydroxy-6-[(methyIphenylamino)methyl]-6-phenyl- 2H-pyran-2-one (±)
The 2-(methylphenylamino)-1-phenyl-ethanone was prepared by reacting N-methylaniline (50 mmol), α-bromoacetophenone (50 mmol), triethylamine (55 mmol) in diethyl ether at room temperature overnight. The diethyl ether was evaporated, replaced with p-dioxane, and the mixture refluxed for 15 hours. The solid triethylamine hydrochloride was filtered. The filtrate was concentrated and the solids were
recrystallized from ethyl acetate to afford the desired compound as a solid (m.p. 118-120 °C).
The title compound was prepared as described in General Method 1 using 6.7 mmol of methyl acetoacetate, 7.3 mmol of NaH 60% dispersion in oil, 7.0 mmol of 1.6 M n-butyl lithium in hexane, 6.7 mmol of 2-(methyIphenylamino)-1-phenylethanone and 40 mL of tetrahydrofuran. The reaction mixture was acidified to pH 7 with cone. HCl and then taken to pH 3 with acetic acid. The product was flash chromatographed using CH2Cl2/MeOH (99/1) to give a solid (m.p. 152-153 °C). 1H NMR (CDCl3) δ 2.9 (d, 1 H), 3.05 (s, 3 H), 3.1 (d, 1 H), 3.2 (d, 1 H), 3.3 (d, 1 H), 3.7 (ABq, 2 H), 6.7-6.8 (m, 3 H), 7.2-7.3 (m, 2 H), 7.3-7.5 (m, 5 H). Example M1
N-Benzyl-4-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)-N-methylbutyramide (±)
The 5-oxo-5-phenylpentanoic acid benzyl-methyl amide was prepared by refluxing N-methylbenzylamine (10.5 mmol) and 6-phenyl-3,4-dihydro-pyran-2-one (10.5 mmol) in toluene for one hour. The reaction was allowed to stir overnight at room temperature. It was poured into 100 mL of ethyl acetate and 100 mL of IN HCl. The organic extracts were washed with 100 mL of IN NaOH, 100 mL of water and dried over MgSO4. The crude product was flash chromatographed (CH2Cl2/MeOH 98/2) to afford a liquid. 1H NMR (CDCl3) δ 2.0-2.2 (m, 2 H), 2.5 (t, 2 H), 2.93/2.96 (s/s, 3 H), 3.0-3.2 (m, 2 H), 4.5/4.6 (s/s, 2 H),7.1-7.6 (m, 8 H), 7.8-8.0 (m, 2 H).
The title compound was prepared as described in General Method 1 using 5.6 mmol of methyl acetoacetate, 6.1 mmol of NaH 60% dispersion in oil, 5.9 mmol of 1.6 M n-butyl lithium in hexane, 5.6 mmol of 5-oxo-5-phenylpentanoic acid benzyl-methyl amide and 25 mL of tetrahydrofuran. The product was flash chromatographed using CH2Cl2/MeOH (98/2) to give a solid (m.p. 47-51 °C). 1H NMR (DMSO-d6) δ 1.1-1.3 (m, 1 H), 1.4-1.6 (m, 1 H), 1.8-2.0 (m, 2 H), 2.2-2.4 (m, 2 H), 2.75/2.81 (s/S 3 H), 2.85-3.1 (m, 2 H), 4.4/4.5 (s/s, 2 H), 4.85/4.9 (s/s 1 H), 7.1-7.4 (m, 10 H), 11.36/11.38 (s/s, 1 H).
General Method 2
The thiotosylate reagents were prepared by reacting equal molar quantities of alkyl halide and potassium thiotosylate in absolute ethanol and refluxing for 24 hours or in DMF and stirring at room temperature for 12 to 72 hours. The solvent was stripped off and the residue was taken up in ethyl acetate and washed with water. Alternatively, water was added and the aqueous layer was extracted with diethyl ether or ethyl acetate. The organic extracts were dried over MgSO4 and concentrated in vacuo.
Alternatively, the thiotosylate reagents were prepared as described by M. G. Ranasinghe and P. L. Fuchs in Syn . Comm . 18(3): 227 (1988).
Example AA. Benzyl-p-toluenethiosulfonate
The title compound was prepared as described in General Method 2 using 0.05 mol of benzyl chloride, 0.05 moles of potassium thiotosylate in 150 mL of ethanol. The residue was dissolved in hexane and seeded with a crystal of the product to afford 10.8 g (77%) of benzyl-p-toluenethiosulfonate (m.p. 52-56.5 °C). 1H NMR (CDCl3) δ 2.45 (s, 3 H), 4.26 (s, 2 H), 7.18-7.30 (m, 7 H), 7.74 (d, 2 H). Example BB. 2-Phenylethyl-p-toluenethiosulfonate
The title compound was prepared according to General Method 2 using phenethyl bromide (0.088 mmol), potassium thiotosylate (0.088 mol), and absolute ethanol (250 mL). A clear liquid was obtained which was used without purification. 1H NMR (CDCl3) δ 2.47 (s, 3 H), 2.92 (t, 2 H), 3.24 (t, 2 H), 7.1-7.4 (m, 7 H), 7.84 (d, 2 H).
Example CC. 3-Phenylpropyl-p-toluenethiosulfonate
The title compound was prepared as described in General Method 2 using l-bromo-3-phenyIpropane (0.044 mmol), potassium thiotosylate (0.044 mmol) and absolute ethanol (125 mL) to give an oil which was used without purification. 1H NMR
(CDCl3) δ 1.95 (quint., 2 H), 2.459 (s, 3 H), 2.63 (t, 2 H), 2.95 (t, 2 H), 7.0-7.4 (m, 8 H), 7.7 (d, 2 H).
Example DD. 2-Phenoxyethyl-p-toluenethiosulfonate
The title compound was prepared as described in General Method 2 using 2-phenoxyethyl bromide (0.025 mmol), potassium thiotosylate (0.025 mmol) and DMF (100 mL) to give a .solid. 1H NMR (CDCl3) δ 2.45 (s, 3 H), 3.34 (t, 2 H), 4.14 (t, 2 H), 6.80 (d, 2 H), 6.95 (t, 1 H), 7.26 (t, 2 H), 7.35 (d, 2 H), 7.82 (d, 2 H).
General Method 3
The 3-bromo-5,6-dihydro-4-hydroxy-2H-pyran-2-one intermediates were prepared by reacting equimolar amounts of the requisite 6-substituted 5,6-dihydro-4-hydroxy-2H-pyran-2-ones (prepared in General Method 1) with N-bromosuccinimide (1.0 equiv.) in dry t-butanol in the dark. The solvent was evaporated, and the residue was partitioned between chloroform and water. The organic layer was washed with brine, dried (MgSO4),, and concentrated.
Example AAA. 3-Bromo-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one
The title compound was prepared as described in General Method 3 using 4.0 mmol of 5,6-dihydro-4-hydroxy-6,6- diphenyl-2H-pyran-2-one (prepared in Example W) and 4.0 mmol of NBS. The product was obtained as a solid. 1H NMR (DMSO-d6) δ 3.68 (s, 2 H), 7.27-7.40 (m, 10 H). Example BBB. 3-Bromo-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 3 using 2.0 mmol of 5,6-dihydro-4-hydroxy-6-phenyl-6- (2-phenylethyl)-2H-pyran-2-one (prepared in Example X) and 2.0 mmol of NBS. 1H NMR (DMSO-d6) δ 2.16-2.58 (m, 4 H), 3.30 (m, 2 H), 7.04-7.60 (m, 10 H).
Example CCC. 3-Bromo-5,6-dihydro-4-hydroxy-(3-methylbutyl)-6-phenyl-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 3 using 2.0 mmol of 5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (prepared in Example V) and 2.0 mmol of NBS. 1H NMR (DMSO-d6) δ 0.80 (m, 6 H), 1.00 (m, 1 H), 1.14 (m, 1 H), 1.42 (m, 1 H), 1.95 (m, 2 H), 3.35 (m, 2 H), 7.25-7.52 (m, 5 H).
Example DDD. 5-[5-Bromo-4-hydroxy-6-oxo-2-phenyl-3,6-dihydro-2H-pyran-2-yl]pentanoic acid, (+/-)
The title compound was prepared as described in General Method 3 using 1.4 mmol of 5-[4-hydroxy-6-oxo-2-phenyl-3,6-dihydro-2H-pyran-2-yl]pentanoic acid (prepared in Example J1) and 1.4 mmol of NBS. 1H NMR (DMSO-d6) δ 0.94 (m, 1 H), 1.22-1.40 (m, 3 H), 1.92 (m, 2 H), 2.13 (t, 2 H), 3.28 (q, 2 H), 7.16-7.52 (m, 5 H).
General Method 4
The desired compounds were prepared by adding the 5,6-dihydro-2H-pyran-2-one, absolute ethanol, the p-toluenethiosulfonate reagent, and Et3N to a reaction vessel. The solution was stirred at room temperature to reflux for 4 hours to one week. The solvent was stripped off and the residue partitioned between 1N HCl and CH2Cl2 or ethyl acetate. The layers were separated and the aqueous layer was extracted with CH2Cl2 or ethyl acetate. The organic layers were combined and dried over MgSO4.
Example 1.
5, 6-Dihydro-4-hydroxy-6-phenyl-3- [ (phenylmethyl) thio] -2H-pyran-2-one (±) .
The title compound was prepared as described in General Method 4 using 2.1 mmol of 5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one, 10 mL of absolute EtOH, 2.3 mmol of benzyl-p-toluenethiosulfonate and 2.3 mmol of Et3N in 5 mL of absolute EtOH. The solution was stirred for 3 days at room
temperature. Concentration in vacuo gave a solid which was broken up and made into a slurry in diethyl ether and ethyl acetate. The solid was filtered off and the mother liquors were concentrated and flash chromatographed on silica gel using CH2Cl2/MeOH (99/1 to 97/3) as eluants. The combined crops gave 0.365 g (55%) of the desired product as a solid (m.p. 150-151.5 °C). 1H NMR (CDCl3) δ 2.65 (dd, 1 H),
2.78 (dd, 1 H), 3.85 (d, 1 H), 3.94 (d, 1 H), 5.29 (dd, 1 H), 7.2-7.4 (m, 11 H). Example 2.
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one (±).
The title compound was prepared as described in General Method 4 using 2.1 mmol of 5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one, 6 mL of absolute EtOH, 2.3 mmol) of 2-phenylethyl-p-toluenethiosulfonate in 6 mL of absolute EtOH and 2.3 mmol of triethylamine in 3 mL of absolute EtOH. The reaction was stirred at room temperature for 4 days. The product was purified by flash chromatography using
CH2Cl2/MeOH(99/1 to 97/3) as eluants. The viscous paste which was isolated was triturated from ether to yield a solid (m.p. 98-99 °C) . 1H NMR (CDCl3) δ 2 . 8-3 . 1 (m, 6 H), 5. 3 (dd , 1 H) , 7 . 1-7 . 7 (m, 11 H) .
Example 3.
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(3-phenylpropyl)thio]-2H-pyran-2-one (±).
The title compound was prepared as described in General Method 4 using 2.63 mmol of 5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one, 7 mL of absolute EtOH, 2.76 mmol of 3-phenylpropyl-p-toluenethiosulfonate in 6 mL of absolute EtOH and 2.89 mmol of triethylamine in 2 mL of absolute EtOH. The reaction was stirred at room temperature for 2 days. The product was triturated from ethyl acetate as a solid (m.p. 134-135 °C). 1H NMR (CDCl3) δ 1.8 (quint., 2 H), 2.6-2.8 (m, 4H), 2.87 (dd, 1 H), 3.01 (dd, 1 H), 5.43 (dd, 1 H), 7.1-7.5 (m, 10 H), 7.81 (bs, 1 H).
Example 4.
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(2-phenoxyethyl)thio]-2H-pyran-2-one (±).
The title compound was prepared as described in General Method 4 using 0.54 mmol of 5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one, 7 mL of absolute EtOH, 0.57 mmol of 2-phenoxyethyl-p-toluenethiosulfonate in 6 mL of absolute EtOH and 0.06 mmol of triethylamine in 2 mL of absolute EtOH. The reaction was stirred at room temperature for 2 days. The product was flash chromatographed and triturated from diethyl ether to give a solid (m.p. 107-108 °C). 1H NMR (DMSO-d6) δ 2.80(dd, 1 H), 2.9-3.0 (m, 2 H), 3.08 (dd, 1 H), 4.07 (t, 2 H), 5.47 (dd, 1 H), 6.9-7.0 (m, 3 H), 7.2-7.5 (m, 7 H).
Example 5.
5,6-Dihydro-4-hydroxy-6-(2-methylpropyl)-6-phenyl-3- [(phenylmethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 0.61 mmol of 5,6-dihydro-4-hydroxy-6-(2-methylpropyl)-6-phenyl-2H-pyran-2-one, 5 mL of absolute EtOH, 0.67 mmol of benzyl-p-toluenethiosulfonate in 3 mL of absolute EtOH and 0.67 mmol of triethylamine in 2 mL of absolute EtOH. The reaction was stirred at room temperature for 18 hours. The product was flash chromatographed (CH2Cl2/MeOH 99.5/0.5) to afford a viscous oil. 1H NMR (CDCl3) δ 0.72 (d, 3 H), 0.90 (d, 3 H), 1.5-1.7 (m, 1 H), 1.81 (dd, 1 H), 1.91 (dd, 1 H), 2.95 (ABq, 2 H), 3.53 (d, 1 H), 3.75 (d, 1 H), 6.8-6.9 (m, 2 H), 7.1-7.4 (m, 8 H). Example 6.
5,6-Dihydro-4-hydroxy-6-(2-methylpropyl)-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 0.61 mmol of 6-i-butyl-5,6-dihydro-4-hydroxy-6-(2-methylpropyl)-6-phenyl-2H-pyran-2-one, 5 mL of absolute EtOH, 0.67 mmol of 2-phenylethyl-p-toluenethiosulfonate in 3 mL of absolute EtOH and 0.67 mmol of triethylamine in 2 mL of absolute EtOH. The reaction was stirred at room temperature for 18 hours. The product was flash chromatographed
(CH2Cl2/MeOH 99.5/0.5) to afford a viscous oil. 1H NMR (CDCl3) δ 0.75 (d, 3 H), 0.89 (d, 3 H), 1.5-1.7 (m, 1 H), 1.87 (dd, 1 H), 1.95 (dd, 1 H), 2.2-2.3 (m, 1 H), 2.4-2.5 (m, 1 H), 2.6-2.8 (m, 1 H), 3.13 (ABq, 2 H), 6.90-6.95 (m, 2 H), 7.1-7.4 (m, 8 H).
Example 7.
5-(3-Chlorophenyl)-2-[(2-phenylethyl)thio-1,3-cyclohexanedione
5-(3-Chlorophenyl)-1,3-cyclohexanedione can be prepared as described in J. Med. Chem. 1992, 35, 19, 3429-3447.
To a 50 mL reaction flask was added 0.30 g (1.35 mmol) of 5-(3-chlorophenyl)-1,3-cyclohexanedione in 5 mL of absolute EtOH, 0.43 g (1.48 mmol) of 2-phenylethyl-p-toluenethiosulfonate in 3 mL of absolute EtOH and 0.16 g (1.62 mmol) of Et3N in 2 mL of absolute EtOH. The reaction was stirred at room temperature for 27 hours. The EtOH was removed in vacuo and the residue dissolved in 200 mL of diethyl ether and 100 mL of 1N HCl. The aqueous layer was extracted with 2×100 mL of diethyl ether. The organic extracts were combined, dried over MgSO4, and concentrated. The residue was flash chromatographed using CH2Cl2/MeOH 99/1 to give a solid (m.p.69-73 °C). 1H NMR(CDCl3) δ 2.5-3.1 (m, 8 H), 3.3 (m, 1 H), 7.1-7.4 (m, 9 H), 7.9 (bs, 1 H).
Example 8.
5,6-Dihydro-4-hydroxy-6-(4-methoxyphenyl)-3- [(phenylmethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 300 mg of 5,6-dihydro-4-hydroxy-6-(4-methoxyphenyl)-2H-pyran-2-one, 500 mg of benzyl-p-toluenethiosulfonate and 1.0 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using
CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid (m.p.168-170 °C). 1H NMR (CDCl3) δ 2.60 (dd, 1 H), 2.77 (dd, 1 H), 3.82 (s, 3 H), 3.89 (dd, 2 H), 5.23 (dd, 1 H), 6.89-7.33 (m, 10 H).
Example 9.
5,6-Dihydro-4-hydroxy-6-(4-methylthiophenyl)-3- [(phenylmethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 480 mg of 5,6-dihydro-4-hydroxy-6-(4-methylthiophenyl)-2H-pyran-2-one, 620 mg of benzyl-p-toluenethiosulfonate and 0.34 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred for 3 days at room temperature. Purification by flash chromatography using
CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid (m.p. 185-188 °C). 1H NMR (CDCl3) δ 2.49 (s, 3 H), 2.62 (dd, 1 H), 2.75 (dd, 1 H), 3.90 (dd, 2 H), 5.25 (dd, 1 H), 7.19-7.32 (m, 10 H).
Example 10. 5,6-Dihydro-4-hydroxy-6-(4-methylphenyl)-3- [(phenylmethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 123 mg of 5,6-dihydro-4-hydroxy-6-(4-methylphenyl)-2H-pyran-2-one, 170 mg of benzyl-p-toluenethiosulfonate and 0.90 mL of triethylamine in 3 mL of absolute ethanol. The solution was stirred for 18 hours at room temperature. The crude product was triturated with diethyl ether to afford a solid (m.p. 166-167 °C). 1H NMR (CDCl3) δ 2.36 (s, 3 H), 2.62 (dd, 1 H), 2.77 (dd, 1 H), 3.94 (dd, 2 H), 5.25 (dd, 1 H), 7.19-7.32 (m, 10 H).
Example 11.
5,6-Dihydro-4-hydroxy-6-[4-(1,1-dimethylethyl)phenyl]-3-[(phenylmethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 445 mg of 5,6-dihydro-4-hydroxy-6-[4-(1,1-dimethylethyl)phenyl]-2H-pyran-2-one, 550 mg of benzyl-p-toluenethiosulfonate and 0.3 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred for 3 days at room temperature. The crude product was triturated with diethyl ether to afford a solid (m.p. 140-142 °C). 1H NMR (CDCl3) δ 1.32 (s, 9 H), 2.65 (dd, 1 H), 2.79 (dd, 1 H), 3.89 (dd, 2 H), 5.27 (dd, 1 H), 7.18-7.43 (m, 10 H).
Example 12.
6-(4-Chlorophenyl)-5,6-dihydro-4-hydroxy-3- [(phenylmethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 250 mg of 6-(4-chlorophenyl)-5,6-dihydro-4-hydroxy-2H-pyran-2-one, 315 mg of benzyl-p-toluenethiosulfonate and 0.16 mL of triethylamine in 8 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using
CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid (m. p . 167-170 °C) . 1H NMR (CDCl3) δ 2 . 62 (dd , 1 H), 2 . 74 (dd , 1 H), 3 . 90 (dd , 2 H), 5. 21 (dd , 1 H), 7 . 23-7 .41 (m, 10 H) .
Example 13.
6-(3-Chlorophenyl)-5,6-dihydro-4-hydroxy-3- [(phenylmethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 300 mg of 6-(3-chlorophenyl)-5,6-dihydro-4-hydroxy-2H-pyran-2-one, 450 mg of benzyl-p-toluenethiosulfonate and 1.0 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid (m.p. 139-142 °C). 1H NMR (CDCl3) δ 2.64 (dd, 1 H), 2.73 (dd, 1 H), 3.89 (dd, 2 H), 5.25 (dd, 1 H), 7.18-7.41 (m, 10 H).
Example 14.
5,6-Dihydro-3-[(2-phenylethyl)thio]-6-[4- (phenylmethoxy)phenyl]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 109 mg of 5,6-dihydro-4-hydroxy-6-[4- (phenylmethoxy)phenyl]-2H-pyran-2-one, 114 mg of 2-phenylethyl-p-toluenethiosulfonate and 0.06 mL of
triethylamine in 3 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid (m.p. 99-101 °C). 1H NMR (CDCl3) δ 2.78 (dd, 1 H), 2.85 (dd, 1 H), 2.92-3.11 (m, 4 H), 5.07 (s, 2 H), 5.30 (dd, 1 H), 6.97-7.44 (m, 14 H), 7.62 (s, 1 H).
Example 15.
5,6-Dihydro-6-(4-methoxyphenyl)-3-[(2-phenylethyl)
thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 300 mg of 5,6-dihydro-4-hydroxy-6-(4- methoxyphenyl)-2H-pyran-2-one, 500 mg of 2-phenylethyl-p-toluenethiosulfonate and 1.0 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred overnight at room temperature. The crude product was triturated with diethyl ether to afford a solid (m.p. 112-115 °C). 1H NMR (CDCl3) δ 2.78 (dd, 1 H), 2.86 (dd, 1 H), 2.92-3.11 (m, 4 H), 3..81 (s, 3 H), 5.31 (dd, 1 H), 6.91-7.35 (m, 10 H).
Example 16.
5,6-Dihydro-6-(4-methylthiophenyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 430 mg of 5,6-dihydro-4-hydroxy-6-(4-methylthiophenyl)-2H-pyran-2-one, 585 mg of 2-phenylethyl-p-toluenethiosulfonate and 0.3 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred for 3 days at room temperature. The crude product was triturated with diethyl ether to afford a solid (m.p. 135-137 °C). 1H NMR (CDCl3) δ 2.48 (s, 3 H), 2.77-3.10 (m, 6 H), 5.32 (dd, 1 H), 7.16-7.33 (m, 9 H), 7.63 (s, 1 H).
Example 17.
5,6-Dihydro-6-(4-methylphenyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 500 mg of 5,6-dihydro-4-hydroxy-6-(4-methylphenyl)-2H-pyran-2-one, 720 mg of 2-phenylethyl-p-toluenethiosulfonate and 0.4 mL of triethylamine in 12 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using
CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid (m.p. 112-113 °C). 1H NMR (CDCl3) δ 2.36 (s, 3 H), 2.79 (dd, 1 H), 2.84 (dd, 1 H), 2.91-3.10 (m, 4 H), 5.33 (dd, 1 H), 7.16-7.33 (m, 9 H), 7.61 (s, 1 H). Example 18. 6-[1,1'-Biphenyl]-4-yl-5,6-dihydro-3-[(2-phenylethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 200 mg of 5,6-dihydro-4-hydroxy-6-[1,1'-biphenyl]-4-yl-2H-pyran-2-one, 300 mg of 2-phenylethyl-p-toluenethiosulfonate and 1.0 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid
(m.p. 130-133 °C). 1H NMR (CDCl3) δ 2.84-2.89 (m, 2 H), 2.96-3.12 (m, 4 H), 5.42 (dd, 1 H), 7.08-7.67 (m, 15 H).
Example 19.
5,6-Dihydro-6-[4-(l,l-dimethylethyl)phenyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 430 mg of 5,6-dihydro-4-hydroxy-6-[4-(1,1-dimethylethyl)phenyl]-2H-pyran-2-one, 560 mg of 2-phenylethyl-p-toluenethiosulfonate and 0.28 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred .for 3 days at room temperature. The crude product was triturated with diethyl ether to afford a solid (m.p. 130-131 °C). 1H NMR (CDCl3) δ 1.31 (s, 9 H), 2.79-2.88 (m, 2 H), 2.94-3.11 (m, 4 H), 5.34 (dd, 1 H), 7.16-7.43 (m, 9 H), 7.61 (s, 1 H).
Example 20.
6-(3-Chlorophenyl)-5,6-dihydro-3-[(2-phenylethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 300 mg of 6-(3-chlorophenyl)-5,6-dihydro-4-hydroxy-2H-pyran-2-one, 500 mg of 2-phenylethyl-p-toluenethiosulfonate and 1.0 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using
CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid (m.p. 99-100 °C). 1H NMR (CDCl3) 5.2.78-2.91 (m, 2 H), 2.97-3.13 (m, 4 H), 5.32 (dd, 1 H), 7.17-7.43 (m, 9 H), 7.62 (s, 1 H). Example 21.
6-[[(1,1'-Biphenyl)-4-yloxy]methyl]-5,6-dihydro-3-[(2-phenylethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 150 mg of 6-[[(1,1'-biphenyl)-4-yloxy]methyl]-5,6-dihydro-4-hydroxy-2H-pyran-2-one, 185 mg of 2-phenylethyl-p-toluenethiosulfonate and 1.0 mL of triethylamine in 5 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using
CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid
(m. p . 124-126 °C) . 1H NMR (CDCl3) δ 2 . 77 (dd, 1 H), 2 . 88 (dd, 1 H), 2 . 95-3 . 10 (m, 4 H), 4 . 19-4 .28 (m, 2 H), 4 . 71-4 . 76 (m,
1 H), 6. 96-7 . 56 (m, 14 H), 7 . 65 (s , 1 H) . Example 22.
6-[1,1'-Biphenyl]-4-yl-6-butyl-5,6-dihydro-4-hydroxy-3-[(2-phenylethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using (0.388 mmol) of 6-[1,1'-biphenyl]-4-yl-6-butyl-5,6-dihydro-4-hydroxy-2H-pyran-2-one, 5mL of absolute EtOH, (0.407 mmol) of 2-phenylethyl-p-toluenethiosulfonate in 3 mL of absolute EtOH and (0.426 mmol) of triethylamine in 2 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed(CH2Cl2/MeOH 99/1) to afford a solid which was recrystalized from ethyl acetate/diethyl ether. (m.p. 100-104 °C). 1H NMR (CDCl3) δ 0.86 (t, 3 H), 1.15-1.5 (m, 4 H), 1.9-2.1 (m, 2 H),2.2-2.5 (m,
2 H), 2.5-2.8 (m, 2 H), 3.2 (ABq, 2 H), 6.8-6.9 (m, 2 H),7.1-7.2 (m, 3 H),7.3-7.7 (m, 9 H). Example 23.
4-[2,3-Dihydro-4-hydroxy-6-oxo-5-[(phenylmethyl)thio]-2H-pyran-2-yl]benzonitrile, (+/-)
The title compound was prepared as described in General Method 4 using 250 mg of 4-[2,3-dihydro-4-hydroxy-6-oxo-2H-pyran-2-yl]benzonitrile, 385 mg of benzyl-p-toluenethiosulfonate and 1.0 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid (m.p. 148-151 °C). 1H NMR (CDCl3) δ 2.66-2.75 (m, 2 H), 3.91 (dd, 2 H), 5.33 (dd, 1 H), 7.20-7.72 (m, 10 H). Example 24.
6-(4-Trifluoromethylphenyl)-5,6-dihydro-4-hydroxy-3-[(phenylmethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 211 mg of 6-(4-trifluoromethylphenyl)-5,6-dihydro-4-hydroxy-2H-pyran-2-one, 273 mg of benzyl-p-toluenethiosulfonate and 1.0 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid
(m.p. 183-186 °C). 1H NMR (CDCl3) δ 2.65-2.77 (m, 2 H), 3.92 (dd, 2 H), 5.35 (dd, 1 H), 7.19-7.68 (m, 10 H).
Example 25.
6-(3,5-Dichlorophenyl)-5,6-dihydro-4-hydroxy-3-[(phenylmethyl) thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 250 mg of 6-(3,5-dichlorophenyl)-5,6-dihydro-4-hydroxy-2H-pyran-2-one, 320 mg of benzyl-p-toluenethiosulfonate and 1.0 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid (m.p. 147-149 °C). 1H NMR (CDCl3) δ 2.61-2.74 (m, 2 H), 3.90 (dd, 2 H), 5.21 (dd, 1 H), 7.18-7.36 (m, 9 H).
Example 26.
6-(Pentafluorophenyl)-5,6-dihydro-4-hydroxy- 3-[(phenylmethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 226 mg of 6-(pentafluorophenyl)-5,6-dihydro-4-hydroxy-2H-pyran-2-one, 269 mg of benzyl-p-toluenethiosulfonate and 1.0 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid (m.p. 113-115 °C). 1H NMR (CDCl3) δ 2.50 (dd, 1 H), 3.14 (dd, 1 H), 3.90 (dd, 2H), 5.57 (dd, 1 H), 7.19-7.365 (m, 6H). Example 27.
5,6-Dihydro-4-hydroxy-6-(3-methylphenyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 300 mg of 5,6-dihydro-4-hydroxy-6-(3-methyIphenyl)-2H-pyran-2-one, 515 mg of 2-phenylethyl-p-toluenethiosulfonate and 1.0 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid
(m.p. 81-83 °C). 1H NMR (CDCl3) δ 2.38 (s, 3H), 2.78-3.10 (m, 6 H), 5.35 (dd, 1 H), 7.17-7.34 (m, 9H), 7.61 (s, 1 H).
Example 28.
6-(2-Chlorophenyl)-5,6-dihydro-4-hydroxy-3-[(phenylmethyl)thio]-2H-pyran-2-one, (+/-) The title compound was prepared as described in General Method 4 using 200 mg of 6-(2-chlorophenyl)-5,6-dihydro-4-hydroxy-2H-pyran-2-one, 300 mg of benzyl-p-toluenethiosulfonate and 1.0 mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid (m.p. 89-91 °C). 1H NMR (CDCl3) δ 2.58 (dd, 1 H), 2.80 (dd, 1 H), 3.92 (dd, 2H), 5.64 (dd, 1 H), 7.20-7.67 (m, 10 H).
Example 29.
6-Butyl-5,6-dihydro-4-hydroxy-6-phenyl- 3-[(phenylmethyl)thio]-2H-pyran-2-one (+/-)
The title compound was prepared as described in General Method 4 using 400 mg of 6-butyl-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one, 540 mg of benzyl-p-toluenethiosulfonate and l.o mL of triethylamine in 10 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using
CH2Cl2/methanol (100/0 to 95/5) as eluent gave a viscous oil. 1H NMR (CDCl3) δ 0.82 (t, 3 H), 1.0-1.4 (m, 4 H), 1.83-1.99 (m, 2 H), 2.97 (dd, 2 H), 3.63 (dd, 2 H), 6.83-7.41 (m, 11 H).
Example 30.
6-[1,1'-Biphenyl]-4-yl-6-butyl-5,6-dihydro-4-hydroxy-3- [(phenylmethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using (0.388 mmol) of 6-[1,1'-biphenyl]-4-yl-6-butyl-5,6-dihydro-4-hydroxy-2H-pyran-2-one, 5 mL of absolute EtOH, (0.407 mmol) of benzyl-p-toluenethiosulfonate in 3 mL of absolute EtOH and (0.426mmol) of triethylamine in 2 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed (CH2Cl2/MeOH 99/1) to afford a solid (m.p. 45-52 °C). 1H NMR (CDCl3) δ 0.85 (t, 3 H), 1.15-1.7 (m, 5 H), 1.9-2.1 (m, 2 H), 3.0 (ABq, 2 H), 3 .5 (d , 1 H), 3 . 7 (d , 1 H), 6.8-6. 9 (m, 2 H), 7 . 0 7 . 7 (m, 12 H) .
Example 31.
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(phenylmethyl)thio]-6-propyl-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 1.08 mmol of 5,6-dihydro-4-hydroxy-6-phenyl-6-propyl-2H-pyran-2-one, 5 mL of absolute EtOH, 1.29 mmol of benzyl-p-toluenethiosulfonate in 10 mL of absolute EtOH and 1.51 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed (hexane/ethyl acetate 75/25) to afford a viscous oil. 1H NMR (CDCl3) δ 0.83 (t, 3 H), 1.0-1.2 (m, 1 H),1.3-1.5 (m, 1 H), 1.8-2.0 (m, 2 H),2.97 (ABq, 2 H), 3.5 (d, 1 H), 3.7 (d, 1 H), 6.8-6.9 (m, 2 H),7.0-7.5 (m, 9 H).
Example 32.
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-6-propyl-2H-pyran-2-one (+)
The title compound was prepared as described in General Method 4 using 1.08 mmol of 5,6-dihydro-4-hydroxy-6-phenyl-6-propyl-2H-pyran-2-one, 5 mL of absolute EtOH, 1.29 mmol of 2-phenylethyl-p-toluenethiosulfonate in 10 mL of absolute EtOH and 1.51 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed (hexane/ethyl acetate 60/40) to afford a viscous oil. 1H NMR (CDCl3) δ 0.85 (t, 3 H), 1.1-1.3 (m, 1 H), 1.3-1.5 (m, 1 H), 1.8-2.0(m, 2 H), 2.2-2.3 (m, 1 H), 2.3-2.5 (m, 1 H), 2.6-2.8 (m, 2 H), 3.1 (ABq, 2 H), 6.9 (d, 2 H), 7.1-7.5 (m, 9 H).
Example 33.
5,6-Dihydro-4-hydroxy-6-pentyl-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 0.96 mmol of 5,6-dihydro-6-pentyl-6-phenyl- 2H-pyran-2-one, 5 mL of absolute EtOH, 1.05 mmol of benzyl-p-toluenethiosulfonate in 10 mL of absolute EtOH and 1.05 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed (hexane/ethyl acetate 75/25) to afford a
Viscous oil. 1H NMR (CDCl3) δ 0.81(t, 3 H), 1.0-1.4 (m, 6 H), 1.8-2.0 (m, 2 H), 2.97 (ABq, 2 H), 3.5 (d, 1 H), 3.7 (d, 1 H), 6.8-6.9 (m, 2 H), 7.0-7.4 (m, 9 H). Example 34.
5,6-Dihydro-4-hydroxy-6-pentyl-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 0.96 mmol of 5,6-dihydro-6-pentyl-6-phenyl-2H-pyran-2-one, 5 mL of absolute EtOH, 1.05 mmol of 2-phenethyl-p-toluenethiosulfonate in 10 mL of absolute EtOH and 1.05 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed (hexane/ethyl acetate 70/30) to afford a viscous oil. 1H NMR (CDCl3) δ 0.82 (t, 3.H), 1.0- 1.4 (m, 6 H), 1.8-2.0(m, 2 H), 2.2-2.3 (m, 1 H), 2.3-2.5 (m,
1 H), 2.6-2.8 (m, 2 H) 3.13 (ABq, 2 H), 6.8-6.9 (m, 2 H), 7.1- 7.5 (m, 9 H). Example 35.
5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 0.96 mmol of 5,6-dihydro-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one, 5 mL of absolute EtOH, 1.05 mmol of benzyl-p-toluenethiosulfonate in 10 mL of absolute EtOH and 1.15 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed (hexane/ethyl acetate 80/20) to afford a viscous oil. 1H NMR (CDCl3) δ 0.80 (d,d, 6 H),
0.9-1.1 (m, 1 H), 1.2-1.3 (m, 1 H), 1.3-1.5 (m, 1 H), 1.8-2.0 (m, 2 H), 2 . 97 (ABq , 2 H), 3 . 5 (d, 1 H), 3 . 7 (d, 1 H), 6. 8-6. 9 (m, 2 H), 7 . 0-7 . 4 (m, 9 H) .
Example 36.
5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 0.96 mmol of 5,6-dihydro-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one, 5 mL of absolute EtOH, 1.05 mmol of 2-phenylethyl-p-toluenethiosulfonate in 10 mL of absolute EtO and 1.05 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed (hexane/ethyl acetate 80/20) to afford a viscous oil. 1H NMR (CDCl3) δ 0.80(d,d, 6H), 1.0-1.15 (m, 1 H), 1.2-1.3 (m, 1 H), 1.4-1.5 (m, 1 H), 1.9-2.0 (m, 2 H), 2.2-2.3 (m, 1 H), 2.3-2.5 (m, 1 H), 2.6-2.8 (m, 2 H), 3.15 (ABq, 2 H), 6.8-6.9 (m, 2 H), 7.1-7.5 (m, 9 H).
Example 37.
5,6-Dihydro-4-hydroxy-6,6-diphenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one
The title compound was prepared as described in General Method 4 using 0.94 mmol of 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one, 5 mL of absolute EtOH, 1.13 mmol of benzyl-p-toluenethiosulfonate in 10 mL of absolute EtOH and 1.31 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed (CH2Cl2/ MeOH 100/0-98/2) to afford a solid (m.p. 44-47.5 °C). 1H NMR (CDCl3) δ 3.34 (s, 2 H), 3.63 (s, 2 H), 6.8-6.9 (m, 2 H), 7.1-7.5 (m, 14 H).
Example 38.
5,6-Dihydro-4-hydroxy-6,6-diphenyl-3- [(2-phenylethyl)thio]-2H-pyran-2-one
The title compound was prepared as described in General Method 4 using 0.94 mmol of 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one, 5 mL of absolute EtOH, 1.13 mmol of 2-pheylnethyl-p-toluenethiosulfonate in 10 mL of absolute EtOH and 1.31 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The solid product was triturated from diethyl ether to afford a solid (m.p. 153-154.5 °C). 1H NMR (CDCl3) δ 2.3 (t, 2 H), 2.6 (t, 2 H), 3.49 (s, 2 H), 6.8-6.9 (m, 2 H), 7.1-7.6 (m, 14 H).
Example 39.
5,6-Dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-3-[(phenylmethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 0.85 mmol of 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one, 5 mL of absolute EtOH, 1.02 mmol of benzyl-p-toluenethiosulfonate in 10 mL of absolute EtOH and 1.19 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed (hexane/ethyl acetate 80/20) to afford a viscous oil. 1H NMR(CDCl3) δ 2.1-2.4 (m, 3 H), 2.7-2.8 (m, 1 H), 3.0(ABq, 2 H), 3.5 (d, 1 H), 3.8 (d, 1 H), 6.8-6.9 (m, 2 H), 7.0-7.5 (m, 14 H).
Example 40.
5,6-Dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-3-[(2-phenylethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 0.85 mmol of 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one, 5 mL of absolute EtOH, 1.02 mmol of 2-phenylethyl-p-toluenethiosulfonate in 10 mL of absolute EtOH and 1.19 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The solid product was triturated from ether to afford a solid (m.p. 56-58 °C). 1H NMR(CDCl3) 5 2.2-2.5 (m, 5 H), 2.6-2.8 (m, 3 H), 3.2 (ABq, 2 H), 6.8-6.9 (m, 2 H), 7.0-7.5 (m, 14 H). Example 41
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-2(1H)-pyridinone (±)
The title compound was prepared as described in General Metho 4 using 105 mg of 5,6-dihydro-4-hydroxy-6-phenyl-2(1H)-pyridinone, 175 mg of 2-phenylethyl-p-toluenethiosulfonate an 0.1 ML of triethylamine in 5 mL of absolute ethanol. The solution was stirred overnight at room temperature.
Purification by flash chromatography using CH2Cl2/methanol (100/0 to 97/3) as eluent gave a viscous oil which was triturated with diethyl ether to afford a solid (m.p. 111-113 °C). 1H NMR (CDCl3) δ 2.80-3.03 (m, 6 H), 4.70 (t, 1 H), 5.75 (s, 1 H), 7.16-7.40 (m, 11 H). Example 42
5,6-Dihydro-4-hydroxy-6-phenoxymethyl-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 200 mg of 5,6-dihydro-4-hydroxy-6-phenoxymethyl-6-phenyl-2H-pyran-2-one, 210 mg of benzyl-p-toluenethiosulfonate and 0.125 mL of triethylamine in 5 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using CH2Cl2/methanol (100/0 to 95/5) as eluent gave a solid (m.p. 161-163 °C) 1H NMR (CDCl3) δ 3.10 (d, 1 H), 3.52 (d, 1 H), 3.54 (d, 1 H), 3.75 (d, 1 H), 3.97 (d, 1 H), 4.23 (d, 1 H), 6.84-7.52 (m, 16 H).
Example 43
6-[2-(Benzo[l,3]dioxol-5-yl)ethyl]-5,6-dihydro-4-hydroxy-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 165 mg of 6-[2-(benzo[l,3]dioxol-5-yl)ethyl]-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one, 150 mg of benzyl-p-toluenethiosulfonate and 0.075 mL of triethylamine in 5 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using CH2Cl2/methanol (100/0 to 95/5) as eluent gave a solid (m.p. 45-50 °C) 1H NMR (CDCl3) δ 2.08-2.30 (m, 3 H), 2.62- 2.71 (m, 1 H), 2.98 (dd, 2 H), 3.53 (d, 1 H), 3.76 (d, 1 H), 5.89 (s, 2 H), 6.50-6.86 (m, 5 H), 7.06-7.26 (m, 4 H), 7.33-7.44 (m, 5 H).
Example 44
6-[2-(3,4-Dichlorophenyl)ethyl]-5,6-dihydro-4-hydroxy-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 365 mg of 6-[2-(3,4-dichlorophenyl)ethyl]-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one, 310 mg of benzyl-p-toluenethiosulfonate and 0.15 mL of triethylamine in 5 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using
CH2Cl2/methanol (100/0 to 95/5) as eluent gave a solid (m.p. 43-50 °C) 1H NMR (CDCl3) δ 2.07-2.16 (m, 1 H), 2.21-2.28 (m, 2 H), 2.71-2.77 (m, 1 H), 2.99 (dd, 2 H), 3.54 (d, 1 H), 3.78 (d, 1 H), 6.84-6.91 (m, 3 H), 7.10-7.45 (m, 11 H).
Example 45
6-[2-(4-Fluorophenyl)ethyl]-5,6-dihydro-4-hydroxy-6-phenyl-3- [(phenylmethyl)thio]-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 4 using 312 mg of 6 [2-(4-fluorophenyl)ethyl]-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one, 310 mg of benzyl-p-toluenethiosulfonate and 0.15 mL of triethylamine in 5 mL of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using
CH2Cl2/methanol (100/0 to 95/5) as eluent gave a solid (m.p. 86-90 °C) 1H NMR (CDCl3) δ 2.08-2.35 (m, 3 H), 2.70-2.77 (m, 1 H), 2.99 (dd, 2 H), 3.54 (d, 1 H), 3.77 (d, 1 H), 6.85-7.44 (m, 15 H). Example 46
5, 6-Dihydro-6-hexyl-4-hydroxy-6-phenyl-3- [ (phenylmethyl) thio]- 2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 0.91 mmol of 5,6-dihydro-6-hexyl-4-hydroxy-6-phenyl-2H-pyran-2-one (±), 5 mL of absolute EtOH, 1.1 mmol of benzyl-p-toluenethiosulfonate in 5 mL of absolute EtOH and 1.27 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed using CH2Cl2/MeOH (99.5/0.5) to afford a viscous gum. 1H NMR (CDCl3) δ 0.81 (t, 3 H), 1.0-1.4 (m, 8 H), 1.8-2.0 (m, 2 H), 2.97 (ABq, 2 H), 3.5 (d, 1 H), 3.7 (d, 1 H), 6.8-6.9 (m, 2 H), 7.0-7.4 (m, 9 H). Example 47
5,6-Dihydro-6-hexyl-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one (+)
The title compound was prepared as described in General Method 4 using 0.91 mmol of 5,6-dihydro-6-hexyl-4-hydroxy-6-phenyl-2H-pyran-2-one (±), 5 mL of absolute EtOH, 1.Q9 mmol of phenethyl-p-toluenethiosulfonate in 5 mL of absolute EtOH and 1.27 mmol of triethylamine in 5mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed using CH2Cl2/MeOH
(99.75/0.25-99/1) to afford a viscous gum. 1H NMR (CDCl3) δ 0.84 (t, 3 H), 1.0-1.4 (m, 8 H), 1.8-2.0 (m, 2 H), 2.2-2.3 (m, 1 H), 2.3-2.5 (m, 1 H), 2.6-2.8 (m, 2 H) 3.13 (ABq, 2 H), 6.9 (dd, 2 H), 7.1-7.5 (m, 8 H). Example 48
5,6-Dihydro-4-hydroxy-6-(4-methylpentyl)-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 1 mmol of 5,6-dihydro-4-hydroxy-6-(4-methylpentyl)-6-phenyl-2H-pyran-2-one (±), 5 mL of absolute EtOH, 1.2 mmol of benzyl-p-toluenethiosulfonate in 5 mL of absolute EtOH and 4 mmol of NaHCO3 in 5 mL of absolute EtOH. The reaction was heated to 50 °C for 1.5 hours then stirred at room temperature overnight. The product was flash
chromatographed using CH2Cl2/MeOH (100/0-99/1) to afford a viscous gum. 1H NMR (CDCl3) δ 0.78 (d, 6 H), 1.0-1.5 (m, 5 H), 1.8-2.0 (m, 2 H), 2.97 (ABq, 2 H), 3.5 (d, 1 H), 3.7 (d, 1 H), 6.8-6.9 (m, 2 H), 7.0-7.4 (m, 9 H).
Example 49
5,6-Dihydro-4-hydroxy-6-(4-methylpentyl)-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 1 mmol of 5,6-dihydro-4-hydroxy-6-(4-methylpentyl)-6-phenyl-2H-pyran-2- one (±), 5 mL of absolute EtOH, 1.2 mmol of phenethyl-p-toluenethiosulfonate in 5 mL of absolute EtOH and 1.4 mmol of triethylamine in 5mL of absolute EtOH. The reaction was stirred for 2 hours at 50 °C. The product was flash chromatographed using hexane/ethyl acetate (80/20) to afford a viscous gum. 1H NMR (CDCl3) δ 0.79 (d, 6 H), 1.0-1.5 (m, 5 H), 1.8-2.0 (m, 2 H), 2.2-2.3 (m, 1 H), 2.3-2.5 (m, 1 H), 2.6-2.8 (m, 2 H) 3.14 (ABq, 2 H), 6.9 (d, 2 H), 7.1-7.5 (m, 8 H).
Example 50
6-Cyclopentylmethyl-5,6-dihydro-4-hydroxy-6-phenyl-3-[(phenylmethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 1 mmol of 6-cyclopentyImethyl-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2 -one (±), 5 mL of absolute EtOH, 1.2 mmol of benzyl-p-toluenethiosulfonate in 5 mL of absolute EtOH and 4 mmol of NaHCO3 in 5 mL of absolute EtOH. The reaction was heated to 120 °C for 15 minutes. The product was flash chromatographed using hexane/ethyl acetate (75/25) and then CH2Cl-2/MeOH (99.5/0.5) to afford a viscous gum. 1H NMR (CDCl3) δ 0.8-1.0 (m, 1 H), 1.0-1.2 (m, 1 H), 1.3-1.6 (m, 5 H), 1.6-1.8 (m, 2 H), 1.97 (dd, 1 H), 2.07 (dd, 1 H), 2.97
(ABq, 2 H), 3.5 (d, 1 H), 3.7 (d, 1 H), 6.8-6.9 (m, 2 H), 7.0-7.4 (m, 9 H). Example 51
6-Cyclopentylmethyl-5,6-dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 1 mmol of 6-cyclopentyImethyl-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran -2-one (±), 5 mL of absolute EtOH, 1.2 mmol of phenethyl-p-toluenethiosulfonate in 5 mL of absolute EtOH and 1.4 mmol of triethylamine in 5mL of absolute EtOH. The reaction was stirred at room temperature for 2 days. The product was flash chromatographed using
hexane/ethyl acetate (75/25-60/40) to afford a viscous gum. 1H NMR (DMSO-d6) δ 0.8-1.0 (m, 1 H), 1.0-1.1 (l, 1 H), 1.2-1.8 (m, 7 H), 1.9-2.1 (m, 2 H), 2.3 (t, 2 H), 2.5-2.6 (m, 2 H) 3.25 (s, 2 H), 6.95 (d, 2 H), 7.1-7.4 (m, 8 H).
Example 52
3,4-Dihydro-4'-hydroxy-5'-[(phenylmethyl)thio]-spiro[naphthalene-l(2H),2'-[2H]pyran]-6'(3'H)-one (±)
The title compound was prepared as described in General Method 4 using 1.1 mmol of 3,4-dihydro-4'-hydroxy-spiro[naphthalene-l(2H),2'-[2H]pyran]-6'(3'H)-one (±), 5 mL of absolute EtOH, 1.3 mmol of benzyl-p-toluenethiosulfonate in 5 mL of absolute EtOH and 1.5 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred overnight at room temperature. The product was flash chromatographed using hexane/ethyl acetate (90/10-60/40) and then triturated from ether to afford a solid (m.p. 143-145 °C). 1H NMR (CDCl3) δ 1.5-1.8 (m, 2 H), 1.8-2.1 (m, 2 H), 2.6 (d, 1 H), 2.7-2.9 (m, 2 H), 3.0 (dd, 1 H), 3.9 (ABq, 2 H), 7.0-7.2 (m, 1 H), 1.2-7.4 (m, 7 H), 7.4-7.5 (m, 1 H).
Example 53
3,4-Dihydro-4'-hydroxy-5'-[(2-phenylethyl)thio]-spiro[naphthalene-l(2H),2'-[2H]pyran]-6'(3'E)-one (±)
The title compound was prepared as described in General Method 4 using 1.1 mmol of 3,4-dihydro-4'-hydroxy-spiro[naphthalene-l(2H),2'-[2H]pyran]-6'(3'H)-one (±), 5 mL of absolute EtOH, 1.3 mmol of phenethyl-p-toluenethiosulfonate in 5 mL of absolute EtOH and 1.5 mmol of triethylamine in 5mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed using
CH2Cl2/MeOH (100/0-98/2) to afford a solid which was
recrystallized from CH2Cl2/diethyl ether to afford a solid (m.p. 125-126.5 °C). 1H NMR (CDCl3) δ 1.6-1.9 (m, 1 H), 1.9-2.1 (m, 1 H), 2.1-2.3 (m, 2 H), 2.7-3.3 (m, 8 H), 7.1-7.4 (m, 7 H), 7.5-7.7 (m, 2 H).
Example 54
3-(3,6-Dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(2-phenylethyl)thio]-2H-pyran-2-yl)propanoic acid (±)
The title compound was prepared as described in General Method 4 using 0.95 mmol of 3-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)-propanoic acid (±), 5 mL of absolute EtOH, 1.1 mmol of phenethyl-p-toluenethiosulfonate in 5 mL of absolute EtOH and 2.3 mmol of triethylamine in 5mL of absolute EtOH. The reaction was refluxed for 2 hours. The product was flash chromatographed using CH2Cl2/MeOH/MeCO2H (95/5/0.05) to afford a solid which was recrystallized from ethyl acetate (m.p. 150.5-152 °C). 1H NMR (CDCl3) 5 2.1-2.9 (m, 8 H), 3.15 (ABq, 2 H), 6.9 (d, 2 H), 7.1-7.4 (m, 8 H). Example 55
4-(3,6-Dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(2-phenylethyl)thio]-2H-pyran-2-yl)butyric acid (±)
The title compound was prepared as described in General Method 4 using 1.8 mmol of 4-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)-butyric acid (±), 5 mL of absolute EtOH, 2.1 mmol of phenethyl-p-toluenethiosulfonate in 5 mL of absolute EtOH and 4.3 mmol of triethylamine in 5mL of absolute EtOH. The reaction was refluxed for 3 hours. The product was flash chromatographed using CH2Cl2/MeOH/MeCO2H (95/5/0.05) to afford a amorphous solid. 1H NMR (CDCl3) δ 1.4-1.6 (m, 1 H), 1.6-1.8 (m, 1 H), 1.9-2.1 (m, 2 H), 2.2-2.4 (m, 3 H), 2.4-2.5 (m, 1 H), 2 . 6-2 .8 (m, 2 H), 3 . 15 (ABq, 2 H), 6. 9 (d, 2 H), 7 . 1-7 .5 (m, 8 H) .
Example 56
5-(3,6-Dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(2-phenylethyl)thio]-2H-pyran-2-yl)pentanoic acid (±)
The title compound was prepared as described in General Method 4 using 1.8 mmol of 5-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)-pentanoic acid (±), 10 mL of absolute EtOH, 2.2 mmol of phenethyl-p-toluenethiosulfonate in 10 mL of absolute EtOH and 4.3 mmol of triethylamine in 10 mL of absolute EtOH. The reaction was refluxed for 3 hours. The product was flash chromatographed using CH2Cl2/MeOH/MeCO2H (99/1/0.05) to afford a solid (m.p. 113-119.5 °C). 1H NMR (CDCl3) δ 0.8-1.1 (m, 1 H), 1.1-1.3 (m, 1 H), 1.3-1.5 (m, 2 H), 1.8-2.0 (m, 2 H), 2.1 (t, 2 H), 2.2 (t, 2 H), 2.5-2.8 (m, 2 H), 3.2 (ABq, 2 H), 6.9 (d, 2 H), 7.1-7.4 (m, 8 H), 11.5 (bs, 1 H), 11.9 (bs, 1 H). Example 57
5,6-Dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-6-pyridin-4-yl-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 0.47 mmol of 5,6-dihydro-4-hydroxy-6-phenyl-6-pyridin-4-yl-2H-pyran-2-one (±), 0.56 mmol of phenethyl-p-toluenethiosulfonate in 5 mL of absolute EtOH, 2 mmol of
NaHCO3, and 0.65 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred overnight at room temperature. The solid product was triturated from ethyl acetate (m.p. 203-205 °C). 1H NMR (DMSO-d6) δ 2.1 (t, 2 H), 2.5 (t, 2 H), 3.7 (ABq, 2 H), 6.9 (d, 2 H), 7.1-7.6 (m, 10 H), 8.6 (d, 2 H). Example 58
5,6-Dihydro-4-hydroxy-6-[(methylphenylamino)methyl]-6-phenyl- 3-[(2-phenylethyl)thio]-2H-pyran-2-one (±)
The title compound was prepared as described in General Method 4 using 0.55 mmol of 5,6-dihydro-4-hydroxy-6- [(methylphenylamino)methyl]-6-phenyl-2H-pyran-2-one (±), 0.61 mmol of phenethyl-p-toluenethiosulfonate in 5 mL of absolute EtOH, 2.2 mmol of NaHCO3, and 0.61 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was stirred overnight at room temperature then 2 hours at 50 °C. The solid product was flash chromatographed using CH2Cl2/MeOH (99/1) to afford a solid (m.p. 48-57 ºC). 1H NMR (CDCl3) δ 2.2-2.3 (m, 1 H), 2.3-2.5 (m, 1 H), 2.6-2.8 (m, 2 H), 3.08 (s, 3 H), 3.15 (d, 1 H), 3.35 (d, 1 H), 3.7 (ABq, 2 H), 6.7-6.9 (m, 3 H), 7.1-7.6 (m, 12 H).
Example 59
4-(3,6-Dihydro-4-hydroxy-6-oxo-2-phenyl-5- [(phenylmethyl)thio]-2H-pyran-2-yl)butyramide (+)
To a 50 mL reaction flask was added 0.75 mmol of 4-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)propanoic acid (±), 1.5 mmol of 4-methylmorpholine, and 7.5 mL of CH2Cl2.
The reaction was cooled to 0°C and 1.5 mmol of methyl
chloroformate in 3.5 mL of CH2Cl2 was added. The reaction was stirrred at 0°C for 2 hours. Ammonia was bubbled into the vessel for 10-15 minutes and the reaction allowed to stir for 30 min at 0°C then 1.5 hours at room temperature. The
reaction was poured into ethyl acetate and 1N HCl, the aqueous layer extracted with 2x ethyl acetate, dried over MgSO4, and concentrated. The crude reaction mixture was flash
chromatographed using CH2Cl2/MeOH/MeCO2H (98/2/0.05) to afford 4-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)butyramide (±) as a solid (m.p. 51-54 °C). 1H NMR (DMSO-d6) δ 1.0-1.2 (m, 1 H), 1.3-1.6 (m, 1 H), 1.8-2.0 (m, 4 H), 2.9 (ABq, 2 H), 4.8 (s, 1 H), 6.6 (s, 1 H), 7.2 (s, 1 H), 7.2-7.5 (m, 5 H), 11.4 (bs, 1 H). The title compound was prepared as described in General Method 4 using 0.42 mmol of 4-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)-butyramide (±) 5 mL of absolute EtOH, 0.58 mmol of benzyl-p-toluenethiosulfonate in 5 mL of absolut EtOH, 1.67 mmol NaHCO3, and 0.42 mmol of triethylamine in 5mL of absolute EtOH. The reaction was stirred at room
temperature overnight. The product was flash chromatographed using CH2Cl2/MeOH (90/10) to afford the desired compound as a solid (m.p. 47.5-53 °C). 1H NMR (DMSO-d6) δ 1.0-1.3 (m, 1 H), 1.3-1.6 (m, 1 H), 1.7-2.1 (m, 4 H), 3.1 (s, 2 H), 3.5 (ABq, 2 H) 6.7 (s, 1 H) 7.0-7.5 (m, 11 H), 11.4 (s, 1 H).
Example 60
5-(3,6-Dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(2-phenylethyl)thio]-2H-pyran-2-yl)pentanoic acid amide (±)
To a 50 mL reaction flask was added 1.2 mmol of 5-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)pentanoic acid (±), 2.4 mmol of 4-methylmorpholine, and 10 mL of CH2Cl2. The reaction was cooled to 0°C and 2.4 mmol of methyl
chloroformate in 3 mL of CH2Cl2 was added. The reaction was stirrred at 0°C for 2 hours. Ammonia was bubbled into the vessel for 10-15 minutes and the reaction allowed to stir for 30 minutes at 0°C. The reaction was poured into ethyl acetate and 1N HCl, the aqueous layer extracted with ethyl acetate, dried over MgSO4, and concentrated. The crude solid was triturated using CH2Cl2 to afford 5-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)pentanoic acid amide (±) as a solid (m.p. 173-174 °C). 1H NMR (DMSO-d6) δ 0.8-1.0 (m, 1 H), 1.1-1.3 (m, 1 H), 1.3-1.5 (m, 2 H), 1.8-2.0 (m, 4 H), 2.9 (ABq, 2 H), 4.8 (s, 1 H), 6.6 (s, 1 H), 7.2 (s, 1 H), 7.2-7.5 (m, 5 H), 11.4 (s, 1 H).
The title compound was prepared as described in General Method 4 using 0.60 mmol of 5-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)pentanoic acid amide (±) 5 mL of absolute EtOH, 0.85 mmol of phenethyl-p-toluenethiosulfonate, 2.4 mmol NaHCO3, and 0.60 mmol of triethylamine in 5mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed using CH2Cl2/MeOH
(90/10) then triturated from ether to afford a solid (softened 100-105 °C, melted completely at 120 °C). 1H NMR (DMSO-d6) δ 0.9-1.1 (m, 1 H), 1.1-1.3 (m, 1 H), 1.3-1.5 (m, 2 H), 1.8-2.0 (m, 4 H), 2.2 (t, 2 H), 2.5-2.6 (m 2 H), 3.2 (s, 2 H), 6.6 (s, 1 H), 6.9 (d, 2 H), 7.1-7.6 (m, 9 H), 11.5 (bs, 1 H).
Example 61
N-Benzyl-4-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(phenylmethyl)thio]-2H-pyran-2-yl)butyramide (±)
To a 50 mL reaction flask was added 0.75 mmol of 4-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)propanoic acid (±), 1.5 mmol of 4-methylmorpholine, and 7.5 mL of CH2Cl2.
The reaction was cooled to 0 °C and 1.5 mmol of methyl
chloroformate in 3.5 mL of CH2Cl2 was added. The reaction was stirrred at 0 °C for 2 hours. Benzyl amine (1.6 mmol) in CH2Cl2 (5 mL) was added and the reaction allowed to stir for 30 min at 0 °C then 1.5 hours at room temperature. The reaction was poured into ethyl acetate and 1N HCl, the aqueous layer extracted with 2x ethyl acetate, dried over MgSO4, and concentrated. The crude reaction mixture was flash
chromatographed using CH2Cl2/MeOH (99/1).
The resulting carbamate (200mg) was hydrolized by
treatment with 0.1N HCl (20 mL) in p-dioxane (4 mL) for 1 hour at room temperature to afford N-benzyl-4-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)-butyramide (+/-).
The title compound was prepared as described in General Method 4 using 0.33 mmol of N-benzyl-4-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)butyramide (±), 5 mL of absolute EtOH, 0.47 mmol of benzyl-p-toluenethiosulfonate in 5 mL of absolute EtOH, 1.33 mmol NaHCO3, and 0.33 mmol of
triethylamine in 5mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed using CH2Cl2/MeOH (95/5) to afford the desired compound as a solid (m.p. 48-52 °C). 1H NMR (DMSO-d6) δ 1.1-1.3 (m, 1 H), 1.4-1.6 (m, 1 H), 1.8-1.9 (m, 2 H), 2.0-2.2 (m, 2 H), 3.1 (s, 2 H), 3.6 (ABq, 2 H), 4.2 (d, 2 H), 7.0 (m, 2 H), 7.1-7.5 (m, 13 H), 8.3 (t, 1 H), 11.4 (bs, 1 H).
Example 62
5-(3,6-Dihydro-4-hydroxy-6-oxo-2-phenyl-5-[(2-phenylethyl)thio]-2H-pyran-2-yl)pentanoic acid benzylamide (±
To a 50 mL reaction flask was added 0.83 mmol of 5-(3,6--ihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)pentanoic acid (±), 1.65 mmol of 4-methylmorpholine, and 10 mL of CH2Cl2. The reaction was cooled to 0°C and 1.65 mmol of methyl chloroformate in 5 mL of CH2Cl2 was added. The reaction was stirrred at 0°C for 2 hours. Benzyl amine (1.7 mmol) in CH2Cl2 (5 mL) was added and the reaction allowed to stir for 2 hours at room temperature. The reaction was poured into ethy acetate and IN HCl, the aqueous layer extracted with 2x ethyl acetate, dried over MgSO4, and concentrated. The crude reaction mixture was carried on without purification.
The resulting carbamate (200mg) was hydrolized by treatment with 0.1N HCl (20 mL) in p-dioxane (4 mL) for 8 hours at room temperature to afford 5-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)-pentanoic acid benzylamide (±). 1NMR (DMSO-d6) δ 0.8-1.0 (m, 1 H), 1.1-1.3 (m, 1 H), 1.3-1.5 (m, 2 H), 1.8-2.0 (m, 2 H), 2.0-2.2 (m, 2 H), 2.9 (ABq, 2 H), 4.2 (ABq, 2 H), 4.85 (s, 1 H), 7.1-7.5 (m, 10 H), 8.2 (bt, 1 H), 11.4 (s, 1 H).
The title compound was prepared as described in General Method 4 using 0.58 mmol of N-benzyl-5-(3,6-dihydro-4-hydroxy 6-oxo-2-phenyl-2H-pyran-2-yl)-pentanoic acid amide (±), 5 mL of absolute EtOH, 0.82 mmol of benzyl-p-toluenethiosulfonate, 2.34 mmol NaHCO3, and 0.82 mmol of triethylamine in 5mL of absolute EtOH. The reaction was stirred at room temperature overnight. The product was flash chromatographed using
CH2Cl2/MeOH (99/1) to afford the desired compound as a solid (m.p. 47-49 °C). 1H NMR (CDCl3) δ 1.0-1.2 (m, 1 H), 1.3-1.5 (m, 1 H), 1.5-1.7 (m, 2 H), 1.8-2.0 (m, 2 H), 2.0-2.2 (m, 2 H), 2.9 (ABq, 2 H), 3.5 (d, 1 H), 3.7 (d, 1 H), 4.4 (m, 2 H), 5.7 (bt, 1 H), 6.8-6.9 (m, 2 H), 7.0-7.5 (m, 13 H). Example 63
N-Benzyl-4-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-5- [(phenylmethyl)thio]-2H-pyran-2-yl)-N-methylbutyramide (±)
The title compound was prepared as described in General Method 4 using 0.66 mmol of N-benzyl-4-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl)-N-methylbutyramide (±), 0.92 mmol of benzyl-p-toluenethiosulfonate in 5 mL of absolute EtOH, 2.63 mmol of NaHCO3, and 0.92 mmol of triethylamine in 5 mL of absolute EtOH. The reaction was heated for 2 hours at 50 °C. The solid product was flash chromatographed using CH2Cl2/MeOH (99/1-98/2) to afford a solid (m.p. 47-49 °C). 1H NMR (CDCl3) δ 1.5-1.8 (m, 2 H), 1.9-2.1 (m, 2 H), 2.3 (ABq, 2 H), 2.84/2.91 (s/s 3 H), 2.98-3.02 (m, 2 H), 3.5 (dd, 1 H), 3.7 (dd, 1 H), 4.46/4.55 (s/s, 2 H), 6.8-6.9 (m, 2 H), 7.0-7.5 (m, 13 H).
General Method 5.
The desired compounds were prepared by adding the
appropriate acid chloride (1.05 equiv.) to a solution of the 5,6-dihydro-2H-pyran-2-one (1.0 equiv.), triethylamine (1.05 equiv.), and THF at 5 °C. The suspension was stirred overnight at room temperature and then diluted with ethyl acetate and water. The organic phase was washed with ice-cold 1 N HCl and brine, dried over MgSO4, and concentrated. The residue was dissolved in toluene, treated with catalytic DMAP, and heated at 80-85 °C for 4 to 8 hours. The solution was cooled to room temperature and diluted with water. The organic phase was washed with ice-cold 1 N HCl and brine, dried (MgSO4), and concentrated. The product was chromatographed on silica gel, eluting with 5:1 hexane:ethyl acetate, to give the 3-acylated intermediate. This material was dissolved in glacial acetic acid, treated with sodium cyanoborohydride (2 equiv), and stirred at room temperature for two hours. The reaction mixture was diluted with water, acidified with cone. HCl, and extracted with ethyl acetate. The extract was washed with brine, dried (MgSO4), and concentrated to afford the desired compound.
Example 64
5,6-Dihydro-4-hydroxy-6,6-diphenyl-3-(2-phenylethyl)-2H-pyran-2-one
The title compound was prepared as described in General Method 5 using 2.0 mmol of 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one, 2.1 mmol of phenylacetyl chloride, 2.1 mmol of triethylamine, and 10 mL of THF, followed by 10 mL of toluene and catalytic DMAP. Chromatography of the residue afforded 1.5 mmol of the intermediate 3-acyl compound. Reduction of this acyl derivative was accomplished with 3 mmol of sodium
cyanoborohydride. The product was triturated from ether (m.p. 158-159 °C) . 1H NMR (DMSO-d6) δ 2 . 31 (m, 4 H), 3 . 37 (m, 2 H), 6 . 93 (d, 1 H), 7 . 07-7 . 17 (m, 3 H), 7 . 24-7 .28 (m, 2 H), 7 . 35 (m, 8 H) .
Alternatively, the title compound could be prepared as follows. A suspension of 0.25 g (6.2 mmol) of sodium hydride in 5 mL of dry THF was cooled to 0°C under nitrogen and treated with a solution of 1.40 g (6.0 mmol) of ethyl 2-(2-phenylethyl)acetoacetate in THF (2 mL). The solution was stirred at 0°C for ten minutes, treated with 4.3 mL of 1.4 M n-butyllithium, and stirred for another fifteen minutes. A solution of 0.55 g (3.0 mmol) of benzophenone in THF (3 mL) was added all at once, and the reaction mixture was stirred a room temperature for two hours. Water (75 mL) was added, and the mixture was stirred overnight at room temperature. The solution was washed with ether. The aqueous layer was
acidified to pH 2 with 6 N HCl and extracted with ethyl acetate; the extract was washed with brine, dried over
magnesium sulfate, and concentrated. The residue was
triturated with ether : hexane 1:1, and the solids were filtered and dried to give the title compound.
Example 65 5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-3-(2-phenylethyl)-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 5 using 2.0 mmol of 5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one, 2.1 mmol of phenylacetyl chloride, 2.1 mmol of triethylamine, and 10 mL of THF, followed by 10 mL of toluene and catalytic DMAP.
Chromatography of the residue afforded 1.0 mmol of the
intermediate acyl compound. Reduction of this intermediate was effected with 2 mmol of sodium cyanoborohydride. The product was obtained as a solid (m.p. 125-126 °C). 1H NMR (DMSO-d6) δ 0.76 (m, 7 H), 1.12 (m, 1 H), 1.38 (m, 1 H), 1.87 (m, 2 H), 2.27-2.46 (m, 4 H), 2.97 (q, 2 H), 6.98-7.38 (m, 10 H).
Example 66
5,6-Dihydro-4-hydroxy-6,6-diphenyl-3-(3-phenylpropyl)-2H-pyran-2-one
The title compound was prepared as described in General Method 5 using 2.5 mmol of 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one, 2.7 mmol of phenylacetyl chloride, 2.8 mmol of triethylamine, and 20 mL of THF, followed by 20 mL of toluene and catalytic DMAP. Chromatography of the residue afforded 1.0 mmol of the intermediate 3-acyl compound. Reduction of this acyl derivative was accomplished with 3 mmol of sodium
cyanoborohydride. The product was triturated from ether to give the title compound (m.p. 61-63 °C). 1H NMR (DMSO-d6) δ 1.35 (m, 2 H), 2.05 (t, 2 H), 2.14 (t, 2 H), 3.42 (bs, 2 H), 6.92 (m, 2 H), 7.17-7.40 (m, 13 H).
Example 67
5,6-Dihydro-4-hydroxy-6-phenyl-3,6-bis(2-phenylethyl)-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 5 using 3.0 mmol of 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one, 3.2 mmol of hydrocinnamoyl chloride, 3.2 mmol of triethylamine, and 30 mL of THF, followed by 30 mL of toluene and catalytic DMAP.
Chromatography of the residue afforded 1.5 mmol of the intermediate 3-acyl compound. Reduction of this acyl
derivative was accomplished with 3 mmol of sodium
cyanoborohydride. The product was triturated from ether:hexan (1:5) to give the title compound (m.p. 68-70 °C). 1H NMR
(DMSO-d6) δ 2.20 (m, 2 H), 2.35 (m, 2 H), 2.42-2.59 (m, 4 H plus DMSO), 3.06 (q, 2 H), 7.00 (dd, 2 H), 7.07-7.43 (m, 13
H).
General Method 6.
The desired compounds were prepared by adding piperidine (1.05 equiv) to a cold (ice bath) solution of the 3-bromo-5,6-dihydro-4-hydroxy-2H-pyran-2-ones (1.0 mmol, prepared in
General Method 3), the requisite thiol (1.05 mmol), and dichloromethane (20 mL). The mixture was stirred at room temperature for 8 to 48 hours. Water was added, and the organic phase was separated, dried over MgSO4, and
concentrated.
Example 68
4-Hydroxy-3-(2-isopropylphenylthio)-5,6-dihydro-6,6-diphenyl- 2H-pyran-2-one
The title compound was prepared as described in General Method 6 from 1.0 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (prepared in example AAA), 1.05 mmol of 2-isopropylbenzenethiol, and 1.05 mmol of piperidine in 20 mL of dichloromethane. The product was triturated with ether to afford a solid (m.p. 216-217 °C). 1H NMR (DMSO-d6) δ 1.17 (d, J = 6.8 Hz, 6 H), 3.20 (m, 1 H), 3.77 (bs, 2 H), 5.64 (d, 1 H), 6.45 (t, 1 H), 6.92 (t, 1 H), 7.12 (d, 1 H), 7.32 - 7.48 (m, 10 H).
Example 69
5,6-Dihydro-4-hydroxy-6,6-diphenyl-3-phenylthio-2H-pyran-2-one
The title compound was prepared as described in General Method 6 from 0.96 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6,6- diphenyl-2H-pyran-2-one (prepared in example AAA), 1.0 mmol of benzenethiol, and 1.0 mmol of piperidine in 20 mL of
dichloromethane. The product was triturated with hexane:ether (1:1) to afford a solid (m.p. 78-80 °C). 1H NMR (DMSO-d6) δ 3.37 (bs, 2 H), 6.35 (m, 2 H), 6.93 (m, 3 H), 7.29-7.49 (m, 10 H).
Example 70
5,6-Dihydro-4-hydroxy-3-(3-methylphenylthio)-6,6-diphenyl-2H-pyran-2-one
The title compound was prepared as described in General Method 6 from 1.3 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (prepared in example AAA), 1.4 mmol of 3-methylbenzenethiol, and 1.4 mmol of piperidine in 25 mL of dichloromethane. The product was triturated with hexane:ether (1:1) to afford a solid which was dissolved in 2 N NaOH, washed with ether, acidified to pH 2, and extracted with ethyl acetate. The extract was washed with water, dried over MgSO4, and concentrated to give a solid (m.p. 58-60 °C). 1H NMR (DMSO-d6) δ 2.07 (s, 3 H), 3.77 (s, 2 H), 6.06 (m, 1 H), 6.45 (s, 1 H), 6.78 (m, 2 H), 7.25-7.47 (m, 10 H).
Example 71
5,6-Dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-3-phenylthio-2H-pyran-2-one (+/-)
The title compound was prepared as described in General Method 6 from 1.50 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (prepared in example BBB), 1.60 mmol of benzenethiol, and 1.60 mmol of piperidine in 30 mL of dichloromethane. The product was triturated with hexane: ether (1:1) to afford a solid. The crude product was chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform, to give the title compound (m.p. 58-60 °C). 1H NMR (DMSO-d6) δ 2.22-2.39 (m, 3 H), 2.62 (m, 1 H), 3.46 (q, 2 H), 6.48 (m, 2 H), 6.98 (m, 3 H), 7.15 (m, 3 H), 7.25 (m, 2 H), 7.46 (m, 5 H). Example 72
5,6-Dihydro-4-hydroxy-3-(2-isopropylphenylthio)-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-)
The title compound was prepared as described in General Method 6 from 1.50 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (prepared in example BBB), 1.60 mmol of 2-isopropylbenzenethiol, and 1.60 mmol of piperidine in 30 mL of dichloromethane. The product was triturated with hexane:ether (1:1) to afford a solid. The crude product was chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform, to give the title compound (m.p. 66-67 ºC). 1H NMR (DMSO-d6) δ 1.16 (t, 6 H), 2.21-2.35 (m, 3 H), 2.60 (m, 1 H), 3.21 (m, 1 H), 3.42 (q, 2 H), 5.88 (d, 1 H), 6.56 (t, 1 H), 6.94 (t, 1 H), 7.13 (m, 4 H), 7.25 (m, 2 H), 7.45 (m, 5 H).
Example 73
5,6-Dihydro-4-hγdroxy-3-(3-methylphenylthio)-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-)
The title compound was prepared as described in General Method 6 from 2.0 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (prepared in example BBB), 2.2 mmol of 3-methylbenzenethiol, and 2.2 mmol of piperidine in 30 mL of dichloromethane. The crude product was chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform, to give the title compound (m.p. 68-70 °C). 1H NMR (DMSO-d6) δ 2.06 (s, 3 H), 2.18-2.36 (m, 3 H), 2.60 (m, 1 H), 3.38 (2 H + H2O), 6.26 (d, 1 H), 6.46 (s, 1 H), 6.75 (m, 1 H), 6.83 (t, 1 H), 7.15 (m, 3 H), 7.24 (m, 2 H), 7.45 (m, 5 H).
Example 74
5-[3,6-Dihydro-4-hydroxy-5-(2-isopropylphenylthio)-6-oxo-2-phenyl-2H-pyran-2-yl]pentanoic acid (+/-)
The title compound was prepared as described in General Method 6 from 1.1 mmol of 5-[5-bromo-3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-2H-pyran-2-yl]pentanoic acid (prepared in example DDD), 1.3 mmol of 2-isopropylbenzenethiol, and 1.3 mmol of piperidine in 20 mL of dichloromethane. The crude product was chromatographed on silica gel, eluting first with 5% methanol in chloroform and then with 9:1:0.5 chloroform:methanol:acetic acid, to give the title compound, (m.p. 145-146 °C). 1H NMR (DMSO-ds) δ 1.07-1.19 (t plus m, 7 H), 1.25 (m, 1 H), 1.43 (m, 2 H), 1.91 (m, 2 H), 2.15 (t, 2 H), 3.19 (m, 1 H), 3.41 (2 H + H2O), 5.81 (d, 1 H), 6.54 (t, 1 H), 6.93 (t, 1 H), 7.12 (d, 1 H), 7.29-7.44 (m, 5 H).
Example 75
5,6-Dxhydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-3-(2-isopropyl-phenylthio)-2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 6 from 2.0 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (prepared in example CCC), 2.2 mmol of 2-isopropylbenzenethiol, and 2.2 mmol of piperidine in 30 mL of dichloromethane. The crude product was chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform, to give the title compound (m.p. 64-66 °C). 1H NMR (DMSO-d6) δ 0.80 (m, 6 H), 0.95 (m, 1 H), 1.17 (t, 7 H), 1.42 (m, 1 H), 1.93 (m, 2 H), 3.20 (m, 1 H), 3.45 (2 H + H2O), 5.84 (d, 1 H), 6.55 (t, 1 H), 6.93 (t, 1 H), 7.12 (d, 1 H), 7.40 (m, 5 H).
Example 76
5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-3-phenylthio- 2H-pyran-2-one, (+/-)
The title compound was prepared as described in General Method 6 from 1.5 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (prepared in example CCC), 1.6 mmol of benzenethiol, and 1.6 mmol of piperidine in 20 mL of dichloromethane. The crude product was
chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform, to give the title compound, (m.p. 154-155 °C). 1H NMR (DMSO-d6) δ 0.80 (m, 6 H), 0.97 (m, 1 H), 1.16 (m, 2 H), 1.42 (m, 1 H), 1.91 (m, 2 H), 3 .40 (2 H + H2O), 6 .45 (m, 2 H), 6. 93 (m, 3 H), 7 . 37 (m, 5 H) .
Example 77
Methyl 2-[[5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-2-oXo-6-phenyl-2H-pyran-3-yl]thio]benzoate
The title compound was prepared as described in General Method 6 from 1.9 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (prepared in example CCC), 2.2 mmol of methyl thiosalicylate and 2.1 mmol of piperidine in 30 mL of dichloromethane. The crude product wa chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform, to give the title compound (m.p. 115-116 °C). 1H NMR (DMSO-d6) δ 0.80 (m, 6 H), 1.0 (m, 1 H), 1.17 (m, 1 H), 1.43 (m, 1 H), 1.96 (m, 2 H), 3.4 (2 H + H2O), 3.81 (s, 3 H), 6.02 (bd, 1 H), 6.88 (t, 1 H), 7.05 (t, 1 H), 7.42 (m, 5 H), 7.80 (dd, 1 H).
Example 78
2-[[5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-2-oxo-6-phenyl-2H-pyran-3-yl]thio]benzoic acid (+/-)
A solution of 0.3 mmol of the compound prepared in
Example 77 in 15 mL of 1 N sodium hydroxide was stirred at room temperature for 3 hours. The solution was washed with ether and then acidified to pH 2.0 with 6 N hydrochloric acid. The solution was extracted with ethyl acetate, and the extract was washed with brine, dried over magnesium sulfate, and concentrated to give the title compound (m.p. 99-101 °C). 1H NMR (DMSO-d6) δ 0.80 (m, 6 H), 0.95 (m, 1 H), 1.15 (m, 1 H), 1.43 (m, 1 H), 1.91 (m, 2 H), 3.4 (2 H + H2O), 6.05 (d, 1 H), 6.85 (bt, 1 H), 7.03 (t, 1 H), 7.42 (m, 5 H), 7.79 (dd, 1 H). Example 79
5,6-Dihydro-3-(2-sec-butylphenylthio)-4-hydroxy-6,6-diphenyl- 2H-pyran-2-one (+/-)
The title compound was prepared as described in General Method 6 from 1.6 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (prepared in example AAA), 1.7 mmol of 2-sec-butylbenzenethiol, and 1.7 mmol of piperidine in 25 mL of dichloromethane. The product was chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform, to give the title compound (m.p. 161-162 °C). 1H NMR (DMSO-d6) δ 0.81 (t, 3 H), 1.15 (d, 3 H), 1.43-1.64 (m, 2 H), 2.98 (m, 1 H), 3.77 (s, 2 H), 5.65 (dd, 1 H), 6.47 (t, 1 H), 6.92 (t, 1 H), 7.07 (d, 1 H), 7.34-7.48 (m, 10 H), 12.4 (bs, 1 H).
Example 80
5,6-Dihydro-4-hydroxy-3-(2-methoxyphenylthio)-6,6-diphenyl-2H-pyran-2-one
The title compound was prepared as described in General Method 6 from 1.5 mmol of 3-bromo-5,6-dihydro-4-hydroχy-6,6-diphenyl-2H-pyran-2-one (prepared in example AAA), 1.6 mmol of 2-methoxybenzenethiol, and 1.6 mmol of piperidine in 25 mL of dichloromethane. The product was chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform, to give the title compound (m.p. 170-172 °C dec.). 1H NMR (DMSO-d6) δ 3.76 (bs, 5 H), 5.44 (dd, 1 H), 6.26 (t, 1 H), 6.85 (m, 1 H), 6.91 (t, 1 H), 7.34-7.50 (m, 10 H). Example 81
5,6-Dihydro-3-(2-sec-butylphenylthio)-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-)
The title compound was prepared as described in General Method 6 from 2.0 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (prepared in example BBB), 2.1 mmol of 2-sec-butylbenzenethiol, and 2.1 mmol of piperidine in 25 mL of dichloromethane. The product was chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform, to give the title compound (m.p. 67-68 °C). 1H NMR (DMSO-d6) δ 0.82 (q, 3 H), 1.09 (t, 3 H), 1.46-1.61 (m, 2 H), 2.26 (m, 2 H), 2.35 (m, 1 H), 2.62 (m, 1 H), 2.98 (m, 1 H), 3.47 (q, 2 H), 5.90 (t, 1 H), 6.56 (t, 1 H), 6.94 (t, 1 H), 7.07-7.18 (m, 4 H), 7.25 (m, 2 H), 7.45 (m, 5 H).
Example 82
5,6-Dihydro-4-hydroxy-3-(4-methyl-2-isopropylphenylthio)-6,6-diphenyl-2H-pyran-2-one
The title compound was prepared as described in General Method 6 from 2.0 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (prepared in example AAA), 2.1 mmol of 4-methyl-2-isopropylbenzenethiol, and 2.1 mmol of piperidine in 30 mL of dichloromethane. The product was chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform (m.p. 185-186°C). 1H NMR (DMS0-ds) δ 1.17 (d, J = 10 Hz, 6 H), 2.15 (s, 3 H), 3.17 (m, 1 H), 3.76 (bs, 2 H), 5.56 (d, 1 H), 6.29 (d, 1 H), 6.94 (s, 1 H), 7.32 - 7.47 (m, 10 H).
Example 83
5,6-Dihydro-4-hydroxy-3-(3-methoxyphenylthio)-6,6-diphenyl-2H-pyran-2-one
The title compound was prepared as described in General Method 6 from 1.8 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (prepared in example AAA), 2.0 mmol of 3-methoxybenzenethiol, and 2.0 mmol of piperidine in 25 mL of dichloromethane. The product was chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform (m.p. 61-62 °C). 1H NMR (DMSO-d6) δ 3.63 (s, 3 H), 3.76 (s, 2 H), 5.64 (bd, 1 H), 6,42 (s, 1 H), 6.54 (d, 1 H), 6.74 (t, 1 H), 7.32-7.47 (m, 10 H).
Example 84 5,6-Dihydro-4-hydroxy-3-(5-methyl-2-isopropylphenylthio)-6,6-diphenyl-2H-pyran-2-one
The title compound was prepared as described in General Method 6 from 2.0 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (prepared in example AAA), 2.1 mmol of 5-methyl-2-isopropylbenzenethiol, and 2.1 mmol of piperidine in 30 mL of dichloromethane. The product was chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform (m.p. 183-184 °C). 1H NMR (DMSO-d6) δ 1.15 (d, 6 H), 1.85 (s, 3 H), 3.22 (m, 1 H), 3.80 (bs, 2 H), 5.88 (bs, 1 H), 6.77 (d, 1 H), 7.03 (d, 1 H), 7.32-7.47 (m, 10 H).
Example 85
5,6-Dihydro-4-hydroxy-3-(5-methyl-2-isopropylphenylthio)-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-)
The title compound was prepared as described in General Method 6 from 2.0 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (prepared in example BBB), 2.1 mmol of 5-methyl-2-isopropylbenzenethiol, and 2.1 mmol of piperidine in 30 mL of dichloromethane. The product was chromatographed on silica gel, eluting first with
chloroform and then with 5% methanol in chloroform (m.p. 66-67 °C). 1H NMR (DMSO-d6) δ 1.16 (m, 6 H), 1.87 (s, 3 H), 2.26 (m, 3 H), 2.57 (m, 1 H), 3.23 (m, 1 H), 3.43 (q, 2 H), 6.01 (bs, 1 H), 6.78 (d, 1 H), 7.03-7.27 (m, 6 H), 7.37-7.47 (m, 5 H).
Example 86
5,6-Dihydro-3-(4-chloro-2-isopropylphenylthio)-4-hydroxy-6,6-diphenyl-2H-pyran-2-one
The title compound was prepared as described in General Method 6 from 2.0 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (prepared in example AAA), 2.1 mmol of 4-chloro-2-isopropylbenzenethiol, and 2.1 mmol of piperidine in 30 mL of dichloromethane. The product was chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform (m.p. 95-96 °C). 1H NMR (DMSO-d6) δ 1.16 (d, 6 H), 3.23 (m, 1 H), 3.73 (bs, 2 H), 5.60 (d, 1 H), 6.45 (d, 1 H), 7.14 (d, 1 H), 7.32-7.48 (m, 10 H). Example 87
5,6-Dihydro-4-hydroxy-3-(4-methyl-2-isopropylphenylthio)-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-)
The title compound was prepared as described in General Method 6 from 2.0 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (prepared in example BBB), 2.1 mmol of 4-methyl-2-isopropylbenzenethiol, and 2.1 mmol of piperidine in 30 mL of dichloromethane. The product was chromatographed on silica gel, eluting first with
chloroform and then with 5% methanol in chloroform (m.p.75-76 °C). 1H NMR (DMSO-d6) δ 1.15 (m, 6 H), 2.16 (s, 3 H), 2.19- 2.36 (m, 3 H), 2.62 (m, 1 H), 3.21 (m, 1 H), 3.44 (q, 2 H), 5.82 (d, 1 H), 6.40 (dd, 1 H), 6.95 (d, 1 H), 7.10-7.18 (m, 3 H), 7.25 (m, 2 H), 7.44 (m, 5 H). Example 88
Methyl 2-[[5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-phenyl-2H-pyran-3-yl]thio]benzoate (+/-)
The title compound was prepared as described in General Method 6 from 1.9 mmol of 3-bromo-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (prepared in example BBB), 2.2 mmol of methyl thiosalicylate and 2.1 mmol of piperidine in 30 mL of dichloromethane. The crude product was chromatographed on silica gel, eluting first with chloroform and then with 5% methanol in chloroform, to give the title compound (m.p. 91-92 °C). 1H NMR (DMSO-d6) δ 2.25 (m, 2 H), 2.38 (m, 1 H), 2.62 (m, 1 H), 3.44 (q, 2 H), 3.82 (s, 3 H), 6.06 (bd, 1 H), 6.90 (t, 1 H), 7.05-7.52 (m, 11 H), 7.81 (dd, 1 H). General Method 7
The desired compounds were prepared by adding the 5,6 -dihydropyro-2H-pyran-2-one, absolute ethanol, the p- toluenethiosulfonate reagent (prepared in general method 2), sodium bicarbonate, and Et3N to a reaction vessel. The mixture was then subsequently heated to 40 °C for 4 to 48 h. The mixture was then diluted with H2O, acidified with cone. HCl, and the product extracted with diethyl ether, CH2Cl2, or ethyl acetate. The organic layers were combined and dried with Na2SO4.
Example 89
5,6-Dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-3-[(2-trifluoromethyIphenyl)methylthio]-2H-pyran-2-one (+/-)
The title compound was prepared as described in General Method 1 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.850 mmol), (2-trifluoromethyl)benzyl-p-toluenethiosulfonate (0.350 g, 1.02 mmol), Et3N (0.280 mL, 2.00 mmol), NaHCO3 (0.68 mmol), (0.50 g), absolute ethanol (3.0 mL). The mixture was heated to 40°C for 16 h then diluted with diethyl ether (100 mL), and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 2% methanol in CH2Cl2) to provide a solid (0.316 g, m.p. 59 - 62 °C). 1H NMR (400 MHz, DMSO-d6) δ 7.603 - 7.581 (m, 1 H), 7.432 - 7.026 (m, 13 H), 3.780 (d, 1 H, J = 14 Hz), 3.69 (d, 1 H, J = 14 Hz), 3.310 (d, 1 H, J = 17.5 Hz), 3.220 (d, 1 H, J = 17.5 Hz), 2.5677 - 2.505 (m, 1 H), 2.253 - 2.157 (m, 3 H).
Example 90
5,6-Dihydro-4-hydroxy-3-[(2,5-dxmethylphenyl)methγltbio]-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.850 mmol), 2,5-dimethylbenzyl-p-toluenethiosulfonate (0.312 g, 1.02 mmol), Et3N (0.230 mL, 1.60 mmol), NaHCO3 (0.071 g, 0.85 mmol), absolute ethanol (3.0 mL). The mixture was heated to 40°C for 16 h then diluted with diethyl ether (100 mL), and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 2% methanol in CH2Cl2) to provide a solid (0.116 g, m.p. 54 - 56°C) which was dried in vacuo. 1H NMR (400 MHz, DMSO-d6) δ 11.498 (bs, 1 H), 7.405 - 7.380 (m, 4 H), 7.327 - 7.285 (m, 1 H), 7.258 - 7.221 (m, 2 H), 7.168 - 7.128 (m, 1 H), 7.090 (d, 2 H, J = 7.5 Hz), 6.970 (d, 1 H, J = 8 Hz), 6.890 (d, 1 H, J = 8 Hz), 6.821 (s, 1 H), 3.600 (d, 1 H , J = 11 Hz), 3.505 (d, 1 H, J = 11 Hz), 3.250 (d, 1 H, J = 17 Hz), 3.176 (d, 1 H, J = 17), 2.619 - 2.564 (m, 1 H), 2.235 - 2.168 (m, 9 H).
Example 91
5,6-Dihydro-4-hydroxy-3-(naphthalen-1-ylmethylthio)-6-phenyl-6- (2-phenylethyl)-2H-pyran-2-one (+/-).
The title compound was prepared as described in General
Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6- (2-phenylethyl)-2H-pyran-2-one (0.20 g, 0.68 mmol), (1-naphthalen-1-ylmethyl)-p-toluenethiosulfonate (0.27 g, 0.82 mmol), Et3N (0.18 mL, 1.3 mmol), NaHCO3 (0.68 mmol) absolute ethanol (3.0 mL). The mixture was heated to 40 °C for 16 h then diluted with diethyl ether (100 mL), and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 ) to provide a solid (0.158 g, m.p. 132 - 134 °C). 1H NMR (400 MHz, DMSO-d6) δ 11.533 (bs, 1 H), 8.177 (d, 1 H, J = 8 Hz), 7.886 (dd, 1 H, J = 2 Hz, J = 7 Hz), 7.761 (d, 1 H, J = 8 Hz), 7.501 - 7.05 ( m, 14 H), 4.120 (d, 1 H, J = 12 Hz), 3.995 (d, 1 H, J = 12 Hz), 3.274 (d, 1 H, J = 18 Hz), 3.194 ( d, 1 H, J = 18 Hz), 2.636 - 2.581 (m, 1 H), 2.288 - 2.169 (m, 3 H).
Example 92
3-(Biphenyl-2-yImethylthxo)-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.85 mmol), (biphen-2-ylmethyl)-p-toluenethiosulfonate (0.360 g, 1.02 mmol), Et3N (0.14 mL, 1.0 mmol), NaHCO3 (0.85 mmol) absolute ethanol (5.0 mL). The mixture was heated to 40 °C for 16 h then diluted with diethyl ether (100 mL), and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 1% methanol in CH2Cl2) to provide a solid (0.317 g, m.p. 58 - 60 °C). 1H NMR (400 MHz, DMSO-d6) δ 11.569 (bs, 1 H), 7.429 -7.066 (m, 19 H), 3.528 (d, 1 H, J = 12 Hz), 3.477 (d, 1 H, J = 12 Hz), 3.280 (dd, 1 H, J = 17 Hz), 3.183 (d, 1 H, J = 17 Hz), 2.607 - 2.502 (m, 1 H), 2.246 - 2.144 (m, 3 H).
Example 93
3-(2-ChlorophenyImethylthio)-5,6-dihydro-4-hydroxy-6-pbenyl-6- (2-phenylethyl)-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6- (2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.85 mmol), (2-cholorbenzyl)-p-toluenethiosulfonate (0.320 g, 1.02 mmol), Et3N (0.14 mL, 1.0 mmol), absolute ethanol (5.0 mL). The mixture was heated to 40 °C for 16 h then diluted with diethyl ether (100 mL), and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100 % CH2Cl2 to 2 % methanol in CH2Cl2) to provide a solid (0.317 g, m.p. 53 - 55 °C). 1H NMR (400 MHz, DMSO-d6) δ 11.551 (bs, 1 H), 7.435 - 7.005 (m, 13 H), 6.800 (dd, 1 H, J = 1.5 Hz, J = 7.5 Hz), 3.750 (d, 1 H, J = 13 Hz), 3.620 (d, 1 H, J = 13 Hz), 3.251 (d, 1 H, J = 17 Hz), 3.171 (d, 1 H, J = 17 Hz) 2.595 - 2.542 (m, 1 H), 2.233 - 2.125 (m, 3 H).
Example 94
3-(2-Chlorophenylmethylthio)-5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6-(3-methylbutyl)-2H-pyran-2-one (0.250 g, 0.85 mmol), (2-chlorobenzyl)-p-toluenethiosulfonate (0.390 g, 1.24 mmol), Et3N (0.17 mL, 1.24 mmol), absolute ethanol (5.0 mL), NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h then diluted with diethyl ether (100 mL), and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 2 % methanol in CH2Cl2) to provide a thick oil (0.36 g) which was dried in vacuo. 1H NMR (400 MHz, DMSO-d6) δ 7.388 - 7.267 (m, 6 H), 7.181 (td, 1 H, J = 1.5 Hz, J = 7.5 Hz), 7.052 (t, 1 H, J = 7.5 Hz), 6.800 (dd, 1 H, J = 1.5 Hz, J - 7.5 Hz), 3.718 (d, 1 H, J = 13 Hz), 3.596 (d, 1 H, J = 13 Hz), 3.112 (s, 2 H), 1.921 - 1.797 (m, 2 H), 1.402 - 1.320 (m, 1 H), 1.156 - 1.065 (m, 1 H), 0.844 - 0.739 (m, 7 H).
Example 95
3 - ( Biphen-2 -ylmethylthio ) -5 , 6-dihydro-4-hydroxy-6- ( 3 -methylbutyl) -6-phenyl-2H-pyran-2-one (+/-) .
The title compound was prepared as described in General Method 7 using the following: 5 , 6-dihydro-4-hydroxy-6-phenyl-6- (3-methylbutyl) -2H-pyran-2-one (0.250 g, 0.96 mmol), (2-methylbiphenyl)-p-toluenethiosulfonate (0.439 g, 1.24 mmol),
Et3N (0.17 mL, 1.24 mmol), absolute ethanol (3.0 mL), NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h then diluted with diethyl ether (100 mL), and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 2% methanol in CH2Cl2) to provide a solid (0.33 g, m.p. 49-51 °C). 1H NMR (400 MHz, DMSO-d6) δ 7.425 - 7.153 (m, 13 H), 7.74 (dd, 1 H, J = 1 Hz, J = 7 Hz), 3.480 (dd, 2 H, J = 12 Hz, J = 17 Hz), 3.149 (dd, 2 H, J = 17 Hz, J = 22 Hz), 1.921 - 1.821 (m, 2 H), 1.402 - 1.336 (m, 1 H), 1.161 - 1.071 (m, 1 H), 0.847 - 0.707 (m, 7 H).
Example 96
5 ,6-Dihydro-3-(2,5-dimethyIphenylmethylthio)-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (0.250 g, 0.96 mmol), (2,5-dimethylbenzyl)-p-toluenethiosulfonate (0.380 g, 1.24 mmol), Et3N (0.17 mL, 1.24 mmol), absolute ethanol (3.0 mL), NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h then diluted with diethyl ether (100 mL), and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 2% methanol in CH2Cl2) to provide a thick oil (0.286 g). 1H NMR (400 MHz, DMSO-d6) δ 11.433 (bs, 1 H), 7.380 - 7.251 (m, 5 H), 6.973 (d, 1 H, J = 7.5 Hz), 6.905 (d, 1 H, J = 7.5 Hz), 6.187 (s, 1 H), 3.584 (d, 1 H, J = 11.5 Hz), 3.481 (d, 1 H, J = 11.5 Hz), 3.133 (s, 2 H), 2.209 (s, 3 H), 2.184 (s, 3 H), 1.933 - 1.858 (m, 2 H), 1.421 - 1.355 (m, 1 H), 1.177 - 1.086 (m, 1 H), 0.870 - 0.751 (m, 7 H).
Example 97
5,6-Dihydro-4-hydroxy-3-(3-methoxyphenylmethylthio)-6-phenyl-6- (2-phenylethyl)-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl- (2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.85 mmol), (3-methoxybenzyl)-p-toluenethiosulfonate (0.340 g, 1.11 mmol), Et3N (0.25 mL, 1.81 mmol), absolute ethanol (3.0 mL), NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h then diluted with diethyl ether (100 mL), and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 2% methanol in CH2Cl2) to provide a thick oil (0.286 g). 1H NMR (400 MHz, DMSO-d6) δ 77.411 - 7.376 (m, 4 H), 7.361 - 7.280 (m, 1 H), 7.235 (t, 2 H, J = 7 Hz), 7.146 (t, 1 H, J = 7 Hz), 7.078 - 7.019 (m, 3 H), 6.769 (d, 1 H, J = 2 H), 6.762 - 6.698 (m, 1 H), 6.555 (d, 1 H, J = 7 Hz), 3.694 (s, 3 H), 3.670 (d, 1 H, J = 13 Hz), 3.585 (d, 1 H, J = 13 Hz), 3.220 (d, 1 H, J = 17 Hz), 3.158 (d, 1 H, J = 17), 2.590 - 2.525 (m, 1 H), 2.219 - 2.141 (m, 3 H).
Example 98
3-(Biphenyl-2-ylmethylthio)-5,6-dihydro-4-hydroxy-6,6-diphenyl- 2H-pyran-2-one.
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (0.250 g, 0.94 mmol), (2-methylbiphenyl)-p-toluenethiosulfonate (0.389 g, 1.1 mmol), Et,N (0.26 mL, 1.9 mmol), absolute ethanol (5.0 mL), NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h, then diluted with diethyl ether (100 mL) and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 2% methanol in CH2Cl2) to provide a thick oil (0.286 g). 1H NMR (400 MHz, DMSO-d6) δ 11.770 (bs, 1 H), 7.434 - 7.148 (m, 18 H), 6.969 (d, 1 H, J = 7 Hz), 3.595 (s, 2 H), 3.407 (s, 2 H). Example 99
3-(3-Chlorophenylmethylthio)-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-(2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.85 mmol), [(3-chlorophen-1-yl)methyl]-p-toluenethiosulfonate (0.340 g, 1.11 mmol), Et3N (0.25 mL, 1.81 mmol), absolute ethanol (3.0 mL), NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h, then diluted with diethyl ether (100 mL) and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 2% methanol in CH2Cl2) to provide a thick oil (0.155 g). 1H NMR (400 MHz, DMSO-d6) δ 7.420 - 7.060 (m, 13 H), 6.848 (d, 1 H, J = 7 Hz), 3.688 (d, 1 H, J = 13 Hz), 3.597 (d, 1 H, J = 13 Hz), 3.219 (d, 1 H, J = 17 Hz), 3.153 (d, 1 H, J = 17 Hz), 2.592 - 2.526 (m, 1 H), 2.241 - 2.120 (m, 3 H).
Example 100
5,6-Dihydro-4-hydroxy-6-(2-phenylethyl)-6-phenyl-3-[((3-trifluoromethyl)phenyl)methylthio]-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-(2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.85 mmol), [(3-trifluoromethylphen-1-yl)methyl]-p-toluenethiosulfonate (0.380 g, 1.11 mmol), Et3N (0.25 mL, 1.81 mmol), absolute ethanol (3.0 mL), NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h, then diluted with diethyl ether (100 mL) and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100 % CH2Cl2 to 2 % methanol in CH2Cl2) to provide a thick oil (0.273 g). 1H NMR (400 MHz, DMSO-d6) δ 11.60 (bs, 1 H), 7.523 - 7.481 (m, 2 H), 7.392 - 7.124 (m, 9 H), 7.064 (d, 2 H, J = 8 Hz), 3.794 (d, 1 H, J = 13 Hz), 3.703 (d, 1 H, J = 13 Hz), 3.162 (s, 2 H), 2.583 - 2.525 (m, 1 H), 2.233 - 2.124 (m, 3 H).
Example 101
5,6-Dihydro-4-hydroxy-3-(3-methyIphenylmethylthio)-6-phenyl-6- (2-phenylethyl)-2H-pyran-2-one (+/-).
The title compound was prepared as described in General
Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl- (2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.85 mmol), [(3-methylphen-1-yl)methyl]-p-toluenethiosulfonate (0.298 g, 1.02 mmol), Et3N (0.25 mL, 1.81 mmol), absolute ethanol (5.0 mL), NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h, then diluted with diethyl ether (100 mL) and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 2% methanol in CH2Cl2) to provide a thick oil (0.242 g). 1H NMR (400 MHz, DMSO-d6) δ 11.427 (bs, 1 H), 7.423 - 7.374 (m, 4 H), 7.330 - 7.288 (m, 1 H), 7.238 (t, 2 H, J = 7 Hz), 7.145 (t, 1 H, J = 8 Hz), 7.086 - 7.007 (m, 2 H), 6.952 (d, 2 H, J = 6 Hz), 6.790 (d, 1 H, J = 7 Hz), 3.630 (d, 1 H, J = 12.5 Hz), 3.544 (d, 1 H, J = 12.5 Hz), 3.227 (d, 1 H, J = 17.5 Hz), 3.153 (d, 1 H, J = 17.5 Hz), 2.567 (bt, 1 H, J = 12 Hz), 2.244 - 2.132 (m, 3 H).
Example 102
3-[4-Hydroxy-2-oxo-6-(2-phenylethyl)-6-phenyl-5,6-dihydro-2H-pyran-3-ylthiomethyl]benzonitrile (+/-).
The title compound was prepared as described in General
Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl- (2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.85 mmol), [(3-cyanophen-1-yl)methyl]-p-toluenethiosulfonate (0.309 g, 1.02 mmol), Et3N (0.25 mL, 1.81 mmol), absolute ethanol (5.0 mL),
NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h, then diluted with diethyl ether (100 mL), and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100 % CH2Cl2 to 2 % methanol in CH2Cl2) to provide a solid (0.242 g, m.p. 58 - 60 °C). 1H NMR (400 MHz, DMSO-d6) δ 11.572 (bs, 1 H), 7.585 (d, 1 H, J = 7 Hz), 7.499 (s, 1 H), 7.426 - 7.078 (m, 10 H), 7.066 (d, 2 H, J =7 Hz), 3.736 (d, 1 H, J = 13.5 Hz), 3.637 (d, 1 H, J = 13.5 Hz), 3.185 (AB, 2 H, JAB = 17.5 Hz), 2.570 - 2.511 (m, 1 H), 2.207 - 1.074 (m, 3 H).
Example 103
3-(2-ChlorophenyImethylthio)-5,6-dihydro-4-hydroxy-6,6-diphenyl- 2H-pyran-2-one.
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H- pyran-2-one (0.250 g, 0.94 mmol), [(2-chlorophen-1-yl)methyl]-p-toluenethiosulfonate (0.304 g, 1.10 mmol), Et3N (0.26 mL, 1.9 mmol), absolute ethanol (5.0 mL), NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h then diluted with diethyl ether (100 mL), and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 2% methanol in CH2Cl2) to provide a solid (0.123 g, m.p. 153 - 155 °C). 1H NMR (400 MHz , DMS0-ds) δ 7.415 - 7.271 (m, 11 H), 7.187 (td, 1 H, J = 1.3 Hz, J = 7 Hz), 7.047 (td, 1 H, J = 1.3 Hz, J = 7 Hz), 6.658 (dd, 1 H, J = 1.5 Hz , J = 7 Hz), 3.610 (s, 2 H), 3.582 (s, 2 H).
Example 104
5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-3-[(trifluoromethylphenyl)methylthio]-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6-(3-methylbutyl)-2H-pyran-2-one (0.250 g, 0.94 mmol), (3-trifluoromethylbenzyl)-p-toluenethiosulfonate (0.43 g, 1.24 mmol), Et3N (0.17 mL, 1.24 mmol), absolute ethanol (5.0 mL), NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h, then diluted with diethyl ether (100 mL) and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 1.5% methanol in CH2Cl2) to provide a thick oil (0.364 g). 1H NMR (400 MHz, DMSO-d6) δ 7.523 - 7.503 (m, 2 H), 7.318 - 7.232 (m, 6 H), 7.188 (d, 1 H, J = 7.5 Hz), 3.781 (d, 1 H, J = 13 Hz), 3.689 (d, 1 H, J = 13 Hz), 3.076 (AB, 2 H, JAB = 14 Hz), 1.869 - 1.783 (m, 2 H), 1.380 - 1.314 (m, 1 H), 1.141 - 1.040 (m, 1 H), 0.828 - 0.727 (m, 7 H). Example 105
5,6-Dihydro-4-hydroxy-3-(methoxyphenyImethylthio)-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6- (3-methylbutyl)-2H-pyran-2-one (0.250 g, 0.94 mmol), (3-methoxybenzyl)-p-toluenethiosulfonate (0.385 g, 1.24 mmol), Et3N (0.17 mL, 1.24 mmol), absolute ethanol (3.0 mL), NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h, then diluted with diethyl ether (100 mL)and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 1.5% methanol in CH2Cl2) to provide a thick oil (0.364 g). 1H NMR (400 MHz, DMSO-d6) δ 7.365 - 7.243 (m, 5 H), 7.071 (t, 1 H, J = 8 Hz), 7.754 - 6.715 (m, 2 H), 6.562 (d, 1 H, J = 7.5 Hz), 3.699 (s, 3 H), 3.651 (d, 1 H, J = 12 Hz), 3.567 (d, 1 H, J = 12 Hz), 3.098 (s, 2 H), 1.869 - 1.819 (m, 2 H), 1.387 - 1.321 (m, 1 H), 1.125 - 1.066 (m, 1 H), 0.809 - 0.702 (m, 7 H).
Example 106
5,6-Dihydro-4-hydroxy-3-(3-methyIphenyImethylthio)-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (+/-).
The title compound was prepared as described in General
Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6- (3-methylbutyl)-2H-pyran-2-one (0.250 g, 0.94 mmol), [(3-methylphen-1-yl)methyl]-p-toluenethiosulfonate (0.36 g, 1.24 mmol), Et3N (0.17 mL, 1.24 mmol), absolute ethanol (3.0 mL),
NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h, then diluted with diethyl ether (100 mL) and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 1.5% methanol in CH2Cl2) to provide a thick oil (0.290 g). 1H NMR (400 MHz, DMSO- d6) δ 7.384 - 7.262 (m, 5 H), 7.054 (t, 1 H, J = 7.5 Hz), 6.979 (d, 1 H, J = 7.5 Hz), 6.937 (s, 1 H), 6.782 (d, 1 H, J = 7.5 Hz), 3.609 (d, 1 H, J = 12.5 Hz), 3.524 (d, 1 H, J = 12.5 Hz), 3.108 (s, 2 H), 2.226 (s, 3 H), 1.902 - 1.803 (m, 2 H), 1.398 - 1.332 (m, 1 H), 1.149 - 1.059 (m, 1 H), 0.849 - 0.709 (m, 7 H). Example 107
3-(Benzo[1,3]dioxo1-5-yImethylthio)-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 7 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.85 mmol), benzo[1,3]dioxol-5-yImethyl-p-toluenethiosulfonate (0.36g, 1.02 mmol), Et3N (0.25 mL, 1.81mmol), absolute ethanol (3.0 mL), NaHCO3 (0.5 g). The mixture was heated to 40 °C for 16 h then diluted with diethyl ether (100 mL), and washed with H2O. The solvent was then removed in vacuo and the residue submitted to column chromatography (SiO2, 100% CH2Cl2 to 1.5% methanol in CH2Cl2) to provide a solid (0.290 g, m.p. 53 - 55 °C). 1H NMR (400 MHz, DMSO-d6) δ 11.404 (bs, 1 H), 7.449 - 7.249 (m, 5 H), 7.239 - 7.216 (m, 2 H), 7.168 - 7.124 (m, 1 H), 7.077 (d, 2 H, J = 7 Hz), 6.683 (d, 1 H, J = 1.5 Hz), 6.607 (d, 1 H, J = 8 Hz), 6.390 (dd, 1 H, J = 1.5 Hz, J = 8 Hz), 5.942 (d, 2 H, J = 2 Hz), 3.600 (d, 1 H, J = 13 Hz), 3.509 (d, 1 H, J = 13 Hz), 3.195 (AB, 2 H, JAB = 17 Hz), 2.595 - 2.511 (m, 1 H), 2.244 - 2.094 (m, 3 H).
General Method 8
The desired compounds were prepared by adding the 5,6- dihydro-2H-pyran-2-one and dry dichloromethane to a reaction vessel followed by the addition of the acid chloride and Et3N. The mixture was allowed to stir for 15 min. and then diluted with diethyl ether. The mixture was then washed with sat'd NaHCO3 (2x) and the organic layer dried with MgSO4. The solvent was then removed in vacuo, the residue redissolved in CH3CN an then treated with Et3N and acetone cyanohydrin. The mixture was allowed to stir for 18 h and then diluted with diethyl ether. The mixture was then washed with 1.0 N HCl, dried with Na2SO4, and the solvent removed in vacuo. The residue was then dissolved in glacial acetic acid and treated with NaBH3CN. The reaction was allowed to proceed for 30 min then treated with brine. The mixture was then extracted with ethyl acetate, the organic layers combined, dried with MgSO4, and the solvent removed in vacuo.
Example 108
5,6-Dihydro-4-hydroxy-6,6-diphenyl-3-phenylmethyl-2H-pyran-2-one.
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (0.250 g, 0.940 mmol), Et3N (0.13 mL, 0.94 mmol), benzoyl chloride (0.109 mL, 0.94 mmol), CH2Cl2 (2.0 mL), acetonitrile (5.0 mL), acetone cyanohydrin (0.01 mL, 0.09 mmol), Et3N (0.27 mL, 1.9 mmol), glacial acetic acid (10.0 mL), sodium cyanoborohydride (0.133 g, 2.11 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 4/1 hexane/ ethyl acetate to 3/2 hexane / ethyl acetate) to provide a solid (0.105 g, 63 - 65 °C). 1H NMR (400 MHz, DMSO-d6) δ 11.136 (s, 1 H), 7.501 - 7.280 (m, 11 H), 6.997 - 6.932 (m, 2 H), 6.566 (d, 2 H, J = 7 Hz), 3.530 (s, 2 H), 3.432 (s, 2 H).
Example 109
5,6-Dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-3-phenylmethyl-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.850 mmol), Et3N (0.26 mL, 1.94 mmol), benzoyl chloride (0.109 mL, 0.94 mmol), CH2Cl2 (2.0 mL), acetonitrile (5.0 mL), acetone cyanohydrin (0.04 mL, 0.43 mmol), Et3N (0.26 mL, 1.9 mmol), glacial acetic acid (10.0 mL), sodium cyanoborohydride (0.151 g, 2.4 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2 to 2% MeOH in CH2Cl2) to provide a thick oil (0.384 g). 1H NMR (400 MHz, DMSO-d6) δ 10.922 (bs, 1 H), 7.395 - 7.315 (m, 5 H), 7.297 - 7.126 (m, 3 H), 7.084 - 7.028 (m, 5 H), 6.775 - 6.611 (m, 2 H), 3.423 (s, 2 H), 3.248 (d, 1 H, J = 17 Hz), 3.175 (d, 1 H, J = 17 Hz), 2.619 - 2.551 (m, 1 H), 2.292 - 2.227 (m, 3 H). Example 110
5,6-Dihydro-4-hydroxy-3-[(2-methylphenyl)methyl]-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6- (2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.850 mmol), Et3N (0.12 mL, 0.85 mmol), 2-methylbenzoyl chloride (0.11 mL, 0.85 mmol), CH2Cl2 (5.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.04 mL, 0.43 mmol), Et3N (0.24 mL, 1.7 mmol), glacial acetic acid (10.0 mL), sodium cyanoborohydride (0.151 g, 2.4 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2 to 2% MeOH in CH2Cl2) to provide a solid (0.195 g, m.p. 109 - 111 °C). 1H NMR (400 MHz, DMSO-d6) δ 10.886 (bs, 1 H), 7.457 - 7.359 (m, 5 H), 7.242 (t,
2 H, J = 7 Hz), 7.169 - 7.130 (m, 1 H), 7.097 (d, 2 H, J = 7.5 Hz), 7.001 (d, 1 H, J = 7.5 Hz), 6.937 (t, 1 H, J = 7.5 Hz),
6.695 (t, 1 H, J = 7 Hz), 6.215 (d, 1 H, J = 7.5 Hz), 3.292 (d, 1 H, J = 17 Hz), 3.169 (d, 1 H, J = 17 Hz), 2.643 - 2.584 (m, 1 H), 2.50-2.475 (2 H + solvent) 2.296 - 2.182 (m, 3 H), 2.125 (s,
3 H).
Example 111
5,6-Dihydro-4-hydroxy-3-[(3-methylphenyl)methyl]-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6- (2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.850 mmol), Et3N (0.12 mL, 0.85 mmol), 3-methylbenzoyl chloride (0.12 mL, 0.89 mmol), CH2Cl2 (3.0 mL), acetonitrile (5.0 mL), acetone cyanohydrin (0.037 mL, 0.40 mmol), Et3N (0.24 mL, 1.8 mmol), glacial acetic acid (5.0 mL), sodium cyanoborohydride (0.16 g, 2.6 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100 % CH2Cl2 to 2 % MeOH in CH2Cl2) to provide a solid (0.250 g, m.p. 53 - 55 °C). 1H NMR (400 MHz, DMSO-d6) δ 10.884 (bs, 1 H), 7.418 - 7.310 (m, 5 H), 7.231 (t,
2 H, J = 7.5 Hz), 7.148 - 7.122 (m, 1 H), 7.071 (d, 2 H, J = 7 Hz), 6.929 (t, 1 H, J = 7.5 Hz), 6.843 (d, 1 H, J = 7.5 Hz), 6.587 (d, 1 H, J = 7.5 Hz), 6.545 (s, 1 H), 3.398 (AB, 2 H, JAB = 15.5 Hz), 3.248 (d, 1 H, J = 17 Hz), 3.125 (d, 1 H, J = 17 Hz), 2.607 - 2.511 (m, 1 H), 2.338 - 2.159 (m, 3 H), 2.094 (s,
3 H). Example 112
5,6-Dihydro-4-hydroxy-3-[(3-methylphenyl)methyl]-6,6-diphenyl-2H-pyran-2-one.
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (0.300 g, 1.13 mmol), Et3N (0.16 mL, 1.15 mmol), 3-methylbenzoyl chloride (0.15 mL, 1.13 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.58 mmol), Et3N (0.32 mL, 2.3 mmol), glacial acetic acid (4.0 mL), sodium cyanoborohydride (0.28 g, 4.5 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2 to 1% MeOH in CH2Cl2) to provide a solid (0.223 g, m.p. 57 - 59 °C). 1H NMR (400 MHz, DMSO-d6) δ 11.112 (bs, 1 H), 7.414 - 7.270 (m, 10 H), 6.875 - 6.812 (m, 2 H), 6.429 - 6.392 (m, 2 H), 3.527 (s, 2 H), 3.409 (s, 2 H), 2.060 (s, 3 H).
Example 113
5,6-Dihydro-4-hydroxy-3-[(2-methylphenyl)methyl]-6,6-diphenyl-2H-pyran-2-one.
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (0.300 g, 1.13 mmol), Et3N (0.16 mL, 1.15 mmol), 2-methylbenzoyl chloride (0.15 mL, 1.13 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.58 mmol), Et3N (0.32 mL, 2.3 mmol), glacial acetic acid (4.0 mL), sodium cyanoborohydride (0.28 g, 4.5 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2 to 1% MeOH in CH2Cl2) to provide a solid (0.135 g, m.p. 169 - 171 °C). 1H NMR (400 MHz, DMSO-d6) δ 11.102 (bs, 1 H), 7.444 - 7.260 (m, 10 H), 6.981 (d, 1 H, J = 7.5 Hz), 6.900 (t, 1 H, J = 7.5 Hz), 6.577 (t, 1 H, J = 7 Hz), 5.897 (d, 1 H, J = 7.5 Hz), 3.557 (s, 2 H), 3.341 (s, 2 H), 2.115 (s, 3 H).
Example 114
5,6-Dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-3-[(2-trifluoromethyIphenyl)methyl]-2H-pyran-2-one.
The title compound was prepared as described in General
Method 8 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6- (2-phenylethyl)-2H-pyran-2-one (0.300 g, 1.02 mmol), Et3N (0.15 mL, 1.1 mmol), 2-trifluoromethylbenzoyl chloride (0.21 mL, 1.02 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.04 mL, 0.47 mmol), Et3N (0.29 mL, 2,1 mmol), glacial acetic acid (3.0 mL), sodium cyanoborohydride (0.20 g, 3.1 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2 to 1% MeOH in CH2Cl2) to provide an oil (0.102 g). 1H NMR (400 MHz, DMSO-d6) δ 11.21 (bs, 1 H), 7.584 (d, 1 H, J = 8 Hz), 7.457 - 7.030 (m, 12 H), 6.179 (d, 1 H, J = 7.5 Hz), 3.594 (s, 2 H), 3.362 (d, 1 H, J = 17 Hz), 3.249 (d, 1 H, J = 17 Hz), 2.686 - 2.603 (m, 1 H), 2.374 - 2.182 (m, 3 H). Example 115
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)methyl]-6,6-diphenyl-2H-pyran-2-one.
The title compound was prepared as described in General
Method 8 using the following: 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (0.300 g, 1.15 mmol), Et3N (0.17 mL, 1.2 mmol), 2-isopropylbenzoyl chloride (1.02 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid (5.0 mL), sodium cyanoborohydride (0.50 g, 8.5 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2 to 1% MeOH in CH2Cl2) to provide a solid (0.128 g, 224 - 226 °C). 1H NMR (400 MHz, DMSO-d6) δ 11.180 (bs, 1 H), 7.445 - 7.235 (m, 10 H), 7.109 (d, 1 H, J = 7.5 Hz), 6.970 (t, 1 H, J = 7.5 Hz), 6.515 (t, 1 H, J = 7.5 Hz), 5.841 (d, 1 H, J = 7.5 Hz), 3.560 (s, 2 H), 3.463 (s, 2 H), 1.174 - 1.094 (m, 7 H). Example 116
5, 6-Dihydro-4-hydroxy-6- (3-methylbutyl) -3-[ (3-methylphenyl)methyl]-6-phenyl-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6- (3-methylbutyl)-2H-pyran-2-one (0.300 g, 1.15 mmol), Et3N (0.17 mL, 1.2 mmol), 3 -methy lbenzoyl chloride (0.15 mL, 1.15 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid (4.0 mL), sodium cyanoborohydride (0.51 g, 8.1 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2 to 0.5% MeOH in CH2Cl2) to provide a solid (0.252 g, 53 - 55 °C). 1H NMR (400 MHz, DMSO-d6) δ 7.376 - 7.244 (m, 5 H), 6.915 (t, 1 H, J = 7.5 Hz), 6.831 (d, 1 H, J = 7.5 Hz), 6.549 (d, 1 H, J = 7.5 Hz), 6.509 (s, 1 H), 3.369 (AB, 2 H, JAB = 14.4 Hz), 3.112 (AB, 2 H, JAB = 17.5 Hz), 2.088 (s, 3 H), 1.962 (m, 2 H), 1.416 - 1.333 (m, 1 H), 1.152 - 1.061 (m, 1 H), 0.898 - 0.726 (m, 7 H).
Example 117
5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-3-phenylmethyl-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (0.300 g, 1.15 mmol), Et3N (0.17 mL, 1.2 mmol), benzoyl chloride (0.13 mL, 1.15 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid (4.0 mL), sodium cyanoborohydride (0.51 g, 8.1 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2 to 1% MeOH in CH2Cl2) to provide a solid (0.215 g, 46 - 48 °C). 1H NMR (400 MHz, DMSO-d6) δ 10.864 (bs, 1 H), 7.375 - 7.248 (m, 7 H) , 7.026 - 7.000 (m, 2 H), 6.737 - 6.713 (m, 1 H), 3.393 - 3.332 (2 H, obscurred by solvent), 3.110 (AB, 2 H, JAB = 17 Hz), 1.933 - 1.870 (m, 2 H), 1.402 - 1.353 (m, 1 H), 1.132 - 1.084 (m, 1 H), 0.891 - 0.710 (m, 7 H).
Example 118
5, 6-Dihydro-4-hydroxy-6- (3-methylbutyl) -3-[ (2-methylphenyl)methyl]-6-phenyl-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-( methylbutyl)-6-phenyl-2H-pyran-2-one (0.300 g, 1.15 mmol), Et3N (0.17 mL, 1.2 mmol), 2 -methy lbenzoyl chloride (0.15 mL, 1.15 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid (4.0 mL), sodium cyanoborohydride. (0.51 g, 8.1 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2 to 1% MeOH in CH2Cl2) to provide a solid (0.215 g, 46 - 48 °C). 1H NMR (400 MHz, DMSO-d6) δ 10.829 (bs, 1 H), 7.395 - 7.303 (m, 5 H), 6.994 (d, 1 H, J = 7 HZ), 6.927 (t, 1 H, J = 7 Hz), 6.674 (t, 1 H, J = 7 Hz), 6.149 (d, 1 H, J = 7 Hz), 3.305 (AB, 2 H, JAB = 17 Hz), 3.158 (AB, 2 H, JAB = 17.5 Hz), 2.115 (s, 3 H), 1.988 - 1.854 (m, 2 H), 1.439 - 1.356 (m, 1 H), 1.177 - 1.087 (m, 1 H), 0.943 - 0.852 (m, 1 H), 0.792 - 0.767 (m, 6 H).
Example 119
5,6-Dihydro-4-hydroxy-3-[(3-methoxyphenyl)methyl]-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6-phenyl- (2-phenylethyl)-2H-pyran-2-one (0.300 g, 1.02 mmol), Et3N (0.15 mL, 1.1 mmol), 2-methoxybenzoyl chloride (0.17 g, 1.02 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid (5.0 mL), sodium cyanoborohydride (0.47 g, . 7.5 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2 to 1% MeOH in CH2Cl2) to provide a solid (0.227 g, 62 - 64 °C). 1H NMR (400 MHz, DMSO-d6) δ 10.823 (bs, 1 H), 7.436 - 7.362 (m, 5 H), 7.265 (t, 2 H, 7.176 - 7.098 (m, 3 H), 7.022 (td, 1 H, J = 1 Hz, J = 8 Hz), 6.815 (d, 1 H, J = 7.5 Hz), 6.400 (td, 1 H, J = 1 Hz, J = 7.5 Hz), 5.952 (dd, 1 H, J = 1 Hz, J = 7 Hz), 3.716 (s, 3 H), 3.391 - 3.169 (m, 4 H), 2.650 - 2.582 (m, 1 H), 2.354 - 2.182 (m, 3 H).
Example 120
5,6-Dihydro-4-hydroxy-3-[(naphthalen-1-yl)methyl]-6,6-diphenyl-2H-pyran-2-one.
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (0.300 g, 1.13 mmol), Et3N (0.160 mL, 1.15 mmol), 1-naphthoyl chloride (1.13 mmol), CH2Cl2 (6.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid (6.0 mL), sodium cyanoborohydride (0.50 g, 7.9 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2 to 1.5% MeOH in CH2Cl2) to provide a solid (0.120 g, 203 - 205 °C(dec.)). 1H NMR (400 MHz, DMSO-d6) δ 11.223 (bs, 1 H), 8.057 (d, 1 H, J = 7 Hz), 7.855 - 7.821 (m, 1 H), 7.603 (d, 1 H, J = 8 Hz), 7.514 - 7.302 (m, 12 H), 6.866 (dd, 1 H, J = 6.5 Hz, J = 8 Hz), 5.975 (d, 1 H, J = 7 Hz), 3.874 (s, 2 H), 3.621 (s, 2 H).
Example 121
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)methyl]-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (0.300 g, 1.15 mmol), Et3N
(0.17 mL, 1.2 mmol), 2-isopropylbenzoyl chloride (1.15 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid
(5.0 mL), sodium cyanoborohydride (0.50 g, 8.1 mmol).
Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2) to provide a solid
(0.118 g, 124 - 126 °C). 1H NMR (400 MHz, DMSO-d6) δ 10.855 (bs,
1 H), 7.395 - 7.306 (m, 5 H), 7.115 (dd, 1 H, J = 1 Hz, J = 7.5 Hz), 6.991 (t, 1 H, J = 7 Hz), 6.622 (td, 1 H, J = 1 Hz, J = 7
Hz), 6.123 (d, 1 H, J = 7 Hz), 3.422 (s, 2 H), 3.210 - 3.102 (m, 3 H), 1.975 - 1.871 (m, 2 H), 1.437 - 1.371 (m, 1 H), 1.142 -
1.084 (m, 7 H), 0.938 - 0.807 (m, 1 H), 0.791 - 0.766 (m, 6 H).
Example 122
5,6-Dihydro-4-hydroxy-3-[(2-isopropylphenyl)methyl])-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (+/-).
The title compound was prepared as described in General
Method 8 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6- (2-phenylethyl)-2H-pyran-2-one (0.300 g, 1.02 mmol), Et3N (0.17 mL, 1.2 mmol), 2-isopropylbenzoyl chloride (1.02 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid (4.0 mL), sodium cyanoborohydride (0.45 g, 7.1 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2) to provide a solid (0.130 g, 73 - 74 °C). 1H NMR (400 MHz, DMSO-d6) δ 7.424 - 7.328 (m, 6 H), 7.259 - 7.222 (m, 2 H), 7.197 - 7.082 (m, 3 H), 6.996 (t, 1 H, J = 7 Hz), 6.638 (td, 1 H, J = 1.5 Hz, J = 8 Hz), 6.195 (d, 1 H, J = 7 Hz), 3.440 (s, 2 H), 3.268 - 3.133 (m, 2 H), 2.630 - 2.528 (m, 1 H), 2.332 - 2.147 (m, 3 H), 2.332 - 2.147 (m, 7 H).
Example 123
3-[(2-Chlorophenyl)methyl]-5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one (0.300 g, 1.15 mmol), Et3N
(0.17 mL, 1.2 mmol), 2-chlorobenzoyl chloride (0.15 mL, 1.15 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid (4.0 mL), sodium cyanoborohydride (0.720 g, 11.5 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2) to provide a solid (0.165 g, 51 - 53 °C). 1H NMR (400 MHz, DMSO-d6) δ 11.062 (bs, 1 H), 7.425 - 7.275 (m, 6 H), 7.072 (td, 1 H, J = 1.5 Hz, J = 7.5 Hz), 6.774 ( td, 1 H, J = 1.2 Hz , J = 7.5 Hz), 6.059 (dd, 1 H, J = 1.2 Hz, J = 7.5 Hz), 3.428 (AB, 2 H, JAB = 16.5 Hz), 3.191 (AB, 2 H, JAB = 17 Hz), 1.964 - 1.884 (m, 2 H), 1.450
- 1.384 (m, 1 H), 1.163 - 1.118 (m, 1 H), 0.951 (m, 1 H), 0.802
- 0.776 (m, 6 H).
Example 124
3-[(2-Chlorophenyl)methyl]-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H- pyran-2-one (+/-).
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (0.300 g, 1.13 mmol), Et3N (0.17 mL, 1.2. mmol), 2-chlorobenzoyl chloride (0.14 mL, 1.15 mmol), CH2Cl2
(4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL,
0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid (4.0 mL), sodium cyanoborohydride (0.50 g, 7.9 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2 to 0.5% MeOH in CH2Cl2) to provide a solid (0.130 g, 185 - 187 °C). 1H NMR (400 MHz, DMSO-d6) δ 11.351 (bs, 1 H), 7.464 - 7.282 (m, 11 H), 7.054 (t, 1 H, J = 7 Hz), 6.679 (td, 1 H, J = 1 Hz, J = 7.5 Hz), 5.797 (d, 1 H, J = 7 Hz), 3.586 (s, 2 H), 3.472 (s, 2 H).
Example 125
6-CyclopentyImethyl-5,6-dihydro-4-hydroxy-6-phenyl-3-phenylmethyl -2H-pyran-2-one (+/-).
The title compound was prepared as described in General Method 8 using the following: 6-cyclopentylmethyl-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one (0.300 g, 1.10 mmol), Et3N (0.17 mL, 1.2 mmol), benzoyl chloride (0.13 mL, 1.10 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid (4.0 mL), sodium cyanoborohydride (0.50 g, 7.9 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2) to provide a solid (0.188 g, 53 - 55 °C). 1H NMR (400 MHz, DMSO-d6) δ 10.849 (bs, 1 H), 7.371 - 7.284 (m, 5 H), 7.040 - 7.004 (m, 3 H), 6.747 - 6.724 (m, 2 H), 3.395 (s, 2 H), 3.117 (AB, 2 H, JAB = 17.5 Hz), 2.059 - 1.950 (m, 2 H), 1.652 - 1.578 (m, 2 H), 1.561 - 1.289 (m, 5 H), 1.021 - 0.844 (m, 2 H).
Example 126
5,6-Dihydro-4-hydroxy-6-pentyl-6-phenyl-3-phenyImethyl-2H-pyran- 2-one (+/-).
The title compound was prepared as described in General Method 8 using the following: 5,6-dihydro-4-hydroxy-6-n-pentyl-6-phenyl-2H-pyran-2-one (0.300 g, 1.15 mmol), Et3N (0.17 mL, 1.2 mmol), benzoyl chloride (0.13 mL, 1.15 mmol), CH2Cl2 (4.0 mL), acetonitrile (4.0 mL), acetone cyanohydrin (0.05 mL, 0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid (4.0 mL.), sodium cyanoborohydride (0.50 g, 7.9 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 100% CH2Cl2) to provide an oil (0.215 g). 1H NMR (400 MHz, DMSO- d6) δ 10.850 (bs, 1 H), 7.367 - 7.287 (m, 5 H), 7.018 - 7.002 (m, 3 H), 6.724 - 6.700 (m, 2 H), 3.380 (AB, 2 H, JAB = 14 Hz), 3.096 (AB, 2 H, JAB = 17 Hz), 1.950 - 1.820 (m, 2 H), 1.230 - 1.100 (m, 5 H), 1.080 - 0.920 (m, 1 H), 0.775 (t, 3 H, J = 7 Hz). Example 127
3-[(3-Chloromethylphenyl)methyl]-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one.
The title compound was prepared as described in General
Method 8 using the following: 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (0.300 g, 1.13 mmol), Et3N (0.17 mL, 1.2 mmol), 3-(chloromethyl)benzoyl chloride (0.13 mL, 1.13 mmol), CH2Cl2 (5.0 mL), acetonitrile (5.0 mL), acetone cyanohydrin (0.05 mL, 0.5 mmol), Et3N (0.35 mL, 2.5 mmol), glacial acetic acid (6.0 mL), sodium cyanoborohydride (0.50 g, 7.9 mmol). Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 4/1 hexane/ethyl acetate to 3/2 hexane/ethyl acetate) to provide a solid (0.118 g, 135 - 137 °C). 1H NMR (400 MHz, DMSO-d6) δ 11.211 (s, 1 H), 7.418 - 7.280 (m, 10 H), 7.088 (d, 1 H, 7.5 Hz), 6.975 (t, 1 H, J = 7.5 Hz), 6.689 (s, 1 H), 6.513 (d, 1 H, J = 7.5 Hz), 4.498 (s, 2 H), 3.540 (s, 2 H), 3.447 (s, 2 H).
Example 128
5,6-Dihydro-3-(benzoylcarbonyl)-4-hydroxy-6,6-diphenyl-2H-pyran
2-one.
The desired compounds were prepared by adding 5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one (0.500 g, 1.88 mmol) and dry dichloromethane (10.0 mL) to a reaction vessel followed by the addition of the benzoyl chloride (0.22 mL, 1.88 mmol) and Et3N (0.28 mL, 2.0 mmol). The mixture was allowed to stir for 15 min. and then diluted with diethyl ether. The mixture was then washed with sat'd NaHCO3 (2x) and the organic layer dried with MgSO4. The solvent was then removed in vacuo, the residue redissolved in CH3CN and then treated with Et3N (0.56 mL, 4.0 mmol) and acetone cyanohydrin. The mixture was allowed to stir for 18 h and then diluted with diethyl ether. The mixture was then washed with 1.0 N HCl, dried with NaSO4, and the solvent removed in vacuo. Purification was achieved by submitting the final residue to column chromatograpy (SiO2, 3/2 hexane/ethyl acetate), to provide a solid (0.357 g, 66 - 68 ºC). 1H NMR (400 MHz, CDCl3) δ 7.495 - 7.208 (m, 15 H), 3.558 (s, 2 H).
Example 129
5,6-Dihydro-4-hydroxy-6,6-dipentyl-3-phenyImethylthio-2H-pyran- 2-one.
The title compound was prepared as described in General Method 4 to provide an oil. 1H NMR (400 MHz, CDCl3) δ 7.3-7.14 (m, 5 H), 3.8 (s, 2 H), 2.54 (s, 2 H), 1.5-1.35 (m, 4 H), 1.26- 1.11 (m, 12 H), 0.87-0.80 (t, 6 H). Example 130.
5,6-Dihydro-4-hydroxy-6-pheny1-3-[(2-isopropyl-5-methylphenyl)thio]-2(1H)-pyridinone (±).
The title compound was prepared as described in General MethoI III using 95.6 mg of 5,6-dihydro-4-hydroxy-6-phenyl-2 (1H)-pyridinone, 180 mg of toluene-4-thiosulfonic acid S-(2¬isopropyl-5-methylphenyl) ester (prepared as per Ranasinghe and Fuchs, Synthetic Communications 18: 227 (1988)) and 0.08 ml of triethylamine in 5 ml of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using CH2Cl2/isopropanol (99/1 to 95/5) as eluent gave a solid (m.p. 184-186 ºC). 1H NMR (CDCl3) δ 1.28 (d, 3H), 1.29 (d, 3H), 2.23 (s, 3H), 2.98 (d, 2H), 3.52 (qn, 1H), 4.85 (t, 1H), 5.63 (s, 1H), 6.78 (s, 1H), 6.96 (m, 1H), 7.14 (d, 1H), 7.35-7.44 (m, 5H), 7.55 (s, 1H).
Example 131
4-Hydroxy-3-[(1-isopropyl-4,4-dxmethyl-4,5-dihydro-1H-imidazol- 2-yl)thio]-6-phenyl-5,6-dihydro-2H-pyran-2-one.
The desired compounds were prepared by adding 4-hydroxy-6,6-diphenyl-5,6-dihydro-2H-pyran-2-one (0.250 g, 0.85 mmol) and dry t-butanol (4.5 mL) to a reaction vessel followed by the addition of n-bromosuccinimide (0.151 g, 0.850 mmol). The mixture was allowed to stir for 1 h in the dark and the solvent then removed in vacuo. The residue was then dissolved in CH2Cl2 and the mixture washed with H2O. The organic layer was then dried with Na2SO4 and the solvent removed in vacuo. The resulting residue was then redissolved in CH2Cl2 (6.0 mL) and treated with 1-isopropylimidazolidine-2-thione (0.184 g, 1.28 mmol, prepared by the method described by A.F. McKay et al., J. Am. Chem. Soc, 78: 1618 (1956))) followed by piperidine (0.084 mL, 0.85 mmol). The mixture was allowed to stir for 14 h in the dark then diluted with additional CH2Cl2 and the mixture washed with H2O. The organic layer was then dried with Na2SO4 and the solvent removed in vacuo. the resulting solid was then submitted to column chromatography (siO2, 1 / 1 CH2Cl2 / ethyl acetate to 14 / 4 / 1 CH2Cl2 / ethyl acetate / methanol) to provide a solid which was redissolved in CH2Cl2, filtered through a fiberglass filter, and the solvent removed in vacuo to provide the title compound (0.234 g, m.p. 160 - 162°C (dec.)). 1H NMR (400 MHz, DMSO-d6) δ 7.732 (s, 1 H), 7.420 - 7.336 (m, 4 H), 7.277 - 7.212 (m, 3 H), 7.137 (t, 1 H, J = 7 Hz), 7. 080 - 7.060 (m, 2 H), 3.970 - 3.904 (m, 1 H), 3.842 (t, 2 H, J = 10 Hz), 3.602 - 3.517 (m, 2 H), 2.925 (AB, 2 H, JAB = 16 Hz), 2.617 - 2.540 (m, 1 H), 2.315 - 2.240 (m, 1 H), 2.160 - 2.025 (m, 2 H), 1.206 - 1.180 (m, 6 H).
Example 132
4-Hydroxy-3-[(1-isopropyl-1,4,5,6-tetrahydro-pyrimidine-2-yl)thio]-6-phenyl-5,6-dihydro-2H-pyran-2-one.
The title compound was prepared as described in example 41 using the following: 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one (0.250 g, 0.850 mmol), t-butanol
(3.5 mL), n-bromosuccinimide (0.151 g, 0.85 mmol), CH2Cl2 (6.0 mL), 1-isopropyltetrahydropyrimidine-2-thione (0.270 g, 1.70 mmol, prepared by the method described by A.F. McKay et al., J. Am. Chem . Soc , 78: 1618 (1956)), piperidine (0.084. mL, 0.85 mmol). Purification was achieved by submitting the final residue to column chromatograpy (siO2, 1/1 CH2Cl2/ethyl acetate to 2/14/1 ethyl acetate/CH2Cl2/methanol) to provide a solid which was redissolved in CH2Cl2, filtered through a fiberglass filter, and the solvent removed in vacuo to provide the title compound
(0.356 g, m.p. 103 - 105°C). 1H NMR (400 MHz, DMSO-d6) δ 7.440 -
7.371 (m, 4 H), 7.296 (t, 1 H, J = 7 Hz), 7.233 (t, 2 H, J = 7
Hz), 7.139 (t, 1 H, J = 7 Hz), 7.077 (d, 2 H, J = 7 Hz), 6.515
(bs, 1 H), 4.365 - 4.300 (m, 1 H), 3.335 - 3.308 (m, 2 H), 3.024 - 2.924 (m, 4 H), 2.624 - 2.548 (m, 1 H), 2.341 - 2.265 (m, 1 H), 2.156 - 2.061 (m, 2 H), 1.763 - 1.737 (m, 2 H), 1.201 - 1.180 (m, 6 H).
Example 133
6- (2-Benzo [ 1, 3 ] dioxol-5-y1-ethyl) -5 , 6-dihydro-4-hydroxy-6-phenyl-3-[ (2-isopropyl-5-methyl-phenylthio]-2H-pyran-2-one (+/-), The title compound was prepared as described in General Method iii using 400 mg of 6-(2-benzo[l,3]dioxol-5-yl-ethyl)- 5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one, 415 mg of toluene-4-thiosulfonic acid S-(2-isopropyl-5-methylphenyl) ester and 0.17 ml of triethylamine in 20 ml of absolute ethanol. The solution was stirred overnight at room temperature. Purification by flash chromatography using hexanes/isopropanol (90/10 to 50/50) as eluent gave a solid (mp=83-85 ºC) 1H NMR (CDCl3) d 1.21 (d, 3H), 1.25 (d, 3H), 1.93 (s, 3H), 2.20-2.40 (m, 3H), 2.60-2.75 (m, 1H), 3.30 (dd, 2H), 3.42 (q, 1H), 5.89 (s, 2H), 6.11 (s, 1H), 6.52 (d, 1H), 6.56 (s, 1H), 6.69 (d, 1H), 6.87 (d, 1H), 7.07 (d, 1H), 7.30-7.50 (m, 5H), 7.64 (br.s, 1H).
4.3 Determination of HIV Protease Inhibition
4.3.1 Starting Materials
DTT Buffer: 1.0 mM dithiothreitol (DTT) was prepared fresh daily in 0.1% polyethylene glycol (mw 8000) 80 mM NaOAc, 160 mM NaCl, 1.0 mM EDTA, and brought to pH 4.7 with HCl.
HXV-1 Protease: The enzyme is obtained from Bachem Bioscience Inc. The undiluted enzyme is thawed from -80 °C and diluted 50- fold with DTT buffer. The solution is always kept at 0 °C on ice water and used in the experiment within 20 minutes after thawing.
Enzyme substrate: Substrate III from Bachem Bioscience Inc. is the undecapeptide H-His-Lys-Ala-Arg-Val-Leu-p-Nitrophenylalanine-Glu-Ala-Norleucine-Ser-NH2 (>97% purity). A 200 μM stock solution in DTT buffer is prepared and stored on ice. Substrate solution is prepared fresh daily.
Test compound: 10 mM inhibitor (I) in dimethyl sulfoxide (DMSO) is diluted to 200 μM with DTT buffer. From the 200 μM stock solution is made a 10 μM stock solution with 2% DMSO in DTT buffer. The two inhibitor solutions are used to make final [I] = 100, 50, 20, 10, 5, 2, 1, 0.5 and 0 μM with 2% DMSO in DTT buffer in each reaction well (total inhibitor volume of 50 μl). 4.3.2 Assay
To each reaction well is added 20 μl of substrate (final concentration of 40 μM), 50 μl of inhibitor (at a concentration such that final dilution will produce the test concentration) and 20 μl of DTT buffer. The reaction plate (96 wells) is incubated at 37 °C for at least 5 minutes.
10 μl of the diluted protease is added to the reaction well while the reaction plate is shaking. Once shaken for 10 seconds, the plate is returned to the heating block at 37 °C. (final reaction volume 100 μl.)
The reaction is incubated for 5 minutes at 37 °C. The reaction is stopped by placing the reaction plate on the shaker and adding 20 μl of 10% trifluoroacetic acid (TFA) and shaking for 10 seconds. The amount of proteolysis is then determined by separation of noncleaved substrate and two cleaved products with reverse-phase HPLC, while measuring absorbance at 220 nm to determine the relative peak areas of the three components. The relative peak areas are used to calculate % conversion to product as a function of inhibitor concentration. The data are plotted as % Control (the ratio of % conversion in the. presence and absence of inhibitor × 100) versus inhibitor concentration and fitted with the equation Y=100/1+(X/OC50)A, where IC50 is the inhibitor concentration at 50% inhibition and A is the slope of the inhibition curve.
The results are listed in Table I.
Figure imgf000124_0001
Figure imgf000125_0001
Anti-HIV-1 Activity
Using the general methods of Pauwels et al . , (J. Virol . Methods, 16, 171-185, 1987) and Mann et al. (AIDS Research and Human Retroviruses, 253-255, 1989 (anti-viral assays of actue HIV-1 infection were performed in the H9 cell line. Cultures were batch infected in 1 ml of RPM1 1640 media/10% fetal calf serum containing 105 infectious doses of HIV1iiib for an effective multiplicity of infection of 0.01. After 2 hours of viral absorption, cells were washed once and palted in 96- wellmicrotiter plates at a density of 104 cells per well. Test compounds were added to produce the desired concentration of drug and 0.1% DMSO in a final volume of 200 μl. Uninfected parallel cultures were maintained for XTT cytotoxicity assay at 7 days post infection. Cultures were tested for viral replication by reverse transcriptase assay at 4 and 7 days post infection.
Figure imgf000126_0001
Combinations of protease inhibitor with other AIDS treatments, such as (but not limited to) the HIV reverse transcriptase inhibitors AZT or ddC, may produce synergistic results. J. C. Craig et al., Antiviral Chem. Chemother. , 4/3: 161-166 (1993); E. V. Connell et al., Antimicrob. Agents Chemother. , 38: 348-352 (1994); D. M. Lambert et al., Antiviral Res . , 21: 327-342 (1993); A. M. Caliendo et al., Clin. Infect . Dis . , 18/4: 516-524 (1994).
The compounds of the invention display antibacterial activity when tested by the microtitration dilution method as described in Heifetz, et al., Antimicr. Agents . & Chemoth . 6:124 (1974) which is incorporated herein by reference.
By use of the above referenced method, the following minimum inhibitory concentration values (MICs in μg/mL) were obtained for representative compounds of the invention vs. clinically relevant gram positive pathogens which have become highly resistant to conventional therapy in recent years.
Figure imgf000127_0001
It should be apparent to those skilled in the art that other compositions not specifically disclosed in the instant specification are, nevertheless, contemplated thereby. Such other compositions are considered to be within the scope and spirit of the present invention. Hence, the invention should not be limited by the description of the specific embodiments disclosed herein but only by the following claims.

Claims

WHAT IS CLAIMED IS:
1. A compound or a pharmaceutically acceptable salt thereof of formula
Figure imgf000128_0001
wherein
X is OR6, NHR5, CH2OR5, CO2R6, or SR5 wherein R6 is R6 or COR6 wherein R6 is independently H, a straight chain alkyl group containing 1 to 6 carbon atoms, a branched or cyclic alkyl group containing 3 to 7 carbon atoms, an alkylcycloalkyl group of 5 - 9 carbon atoms, benzyl, phenyl, or a heterocycle;
Z is O or S;
Y is O, S, C(R6)2, NF, or NR6;
R1 and R1' are each independently [CH2]n1-[W1]n2-[Ar]n2- [CH2]n3-[W2]n4-R7;
R2 is independently selected from the group of
structures from which R1 is selected with the proviso that if W1 is a heteroatom n1 is an integer of from 1 to 4;
R3 is independently selected from the group of
structures from which R1 is selected with the proviso that if W1 is a heteroatom n1 is an integer of from 1 to 4;
R2 and R3 may be taken together to form an unsubstituted or substituted 3-, 4-, 5-, 6-, or 7-membered ring, wherein the substituents are one or more of the R7 groups listed below;
R4 is [CH2]n1-[W3]n2-[CH2]n3-[W4]n4-[Ar]n2-[CH2]n3-[W2]n4-R7; n1, n2, n3, n4, and n5 are independently integers of from 0 to 4, 0 to 1, 0 to 4, 0 to 1, and 0 to 2, respectively;
W1, W2 and W4 are independently O, OCONR7, S(O)n5, CO, C(=NR7)NR7, CR7=CR7, C≡C, NR7, CS, C=N-R7, C=NOR7, NR7SO2, SO2NR7, C=C(R7)2, CR7N(R7)2, CR7OR7, C(R7)2, NCO2R7, NR7CO2, CO2, NCON(R7)2, NR7CONR7, NCOR7, NR7CO, or CONR7;
W3 is independently selected from the group of
structures from which W1 is selected, with the further limitation that if n1 in R4 is zero, that W3 is selected from the group of structures consisting of -CO, -CR7=CR7, -C≡C, -CS, -C=N-R7,
-C=NOR7, -CR7N(R7)2, -C=C(R7)2, -CR7OR7, -C(R7)2, -CO2, and -CONR7;
R7 is independently H, Ar, a straight or branched alkyl or alkenyl group containing from 1 to 6 carbon atoms, or two R7 groups can be taken together to form a ring of 3 - 7 atoms, or a substituted derivative thereof wherein the substituents are one or more of CO2R6, COR6, CON(R6)2, NR6CON(R6)2, NR6COR6, OR6, S(O)n5R6, N(R6)2,
Cl, Br, F, CF3, Ar, OAr, or S(O)n5Ar;
Ar is independently phenyl, naphthyl, a 5- or 6- membered heterocycle containing 1 to 4 heteroatoms, a cycloalkyl containing 3 to 6 atoms, a fused ring system containing 8-10 atoms, or a substituted derivative thereof wherein the substituents are of F, Cl, Br, CN, NO2, (CH2)n6R6, (CH2)n6C(Me)=CH2, (CH2)n6N(R6)2, (CH2)n6NR6CON(R6)2, (CH2) n6NR6COR6, (CH2)n6OR6, (CH2)n6OCOR6, (CH2)n6OCON(R6)2, (CH2)n6CO2R6, (CH2)n6CON(R6)2, (CH2)n6COR6, CF3, (CH2)n6S(O)n5R6, OCH2O, or 0(CH2)2O; and n6 is independently an integer of from 0 to 3.
2. A compound of the formula of claim 1 wherein
X is OH, NH2, or SH;
Z is O;
Y is C(R6)2, S, NF or NR6; and
R1 and R1' are H.
3. A compound of the formula of claim 1 wherein
X is OH or NH2;
Z is O;
Y is O;
R2 and R3 are not H; and
W3 is selected from a group consisting of CO, CR7=CR7, C≡C, CS, C=N-R7, C=NOR7, C=C(R7)2, CR7OR7, C(R7)2, -CO2, and CONR.
4. A compound of the formula of claim 3 wherein
Figure imgf000130_0002
5. A compound of the formula of claim 3 wherein
Figure imgf000130_0001
6. A compound of the formula of claim 3 wherein
W3 is selected from the group consisting of CR7=CR7, -C≡C-, and C(R7)2.
7. A compound of the formula of claim 6 selected from the group consisting of
5,6-Dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-3-[[3-(phenylmethoxy)phenyl]methyl]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-3-[5-methyl-1-(phenylmethyl)hexyl]-6-phenyl-2H-pyran-2-one;
3-[1-(Cyclohexylthio)-5-methylhexyl]-5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one;
3-[2-Cyclohexyl-1-[(3-methylbutyl)amino]ethyl]-5,6-dihydro-4-hydroxy-6-(3-methylbutyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(2-isopropyl-5-methyIphenyl)methyl]-6-(2-phenylethyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(3-hydroxymethyl-2-isopropyl-5-methylphenyl)methyl]-6,6-diphenyl-2H-pyran-2-one;
5 , 6 - D i hy dr o - 4 -hydr o xy - 3 - [ [ 4 -(hydroxymethyl)phenyl]methyl]-6-pentyl-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[(3-hydroxyphenyl)methyl]-6-(2-phenylethyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-pentyl-6-phenyl-3-[[4-(pyridin-3-ylmethoxy)phenyl]methyl]-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-[[2-isopropyl-3-[2-(morpholin-4-yl)ethoxy]phenyl]methyl]-6-(2-phenylethyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-3-(3-methyl-1-phenyl-but-2-enyl)-6,6-diphenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(3-methylbutyl)-3-(3-methy1-1-propyl-but-2-enyl)-6-phenyl-2H-pyran-2-one;
5 , 6 - D i h y d r o - 4 - h y d r o x y - 3 - [ [ 2 -(hydroxymethyl)phenyl]methyl]-6-(2-phenylethyl)-6-phenyl-2H-pyran-2-one;
5,6-Dihydro-4-hydroxy-6-(2-phenylethyl)-6-phenyl-3-(2-phenyl-[1,3]dithiolan-2-yl)-2H-pyran-2-one;
4-Hydroxy-3-[methoxy(phenyl)methyl]-6-phenyl-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one; 3-[Cyclopentyl(cyclopentyloxy)methyl]-4-hydroxy-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-2-one;
3-(1-Cyclopentyloxy-3-methylbutyl)-4-hydroxy-6-(3-methylbutyl)-6-phenyl-5,6-dihydro-2H-pyran-2-one and 6-Cyclopentyl-3-[cyclopentyl(isopropoxy)methyl]-4-hydroxy-6-(3-methylbutyl)-5,6-dihydro-2H-pyran-2-one.
8. A compound of the formula of claim 3 wherein
R4 is -Ar [CH2]n3 [W2]n4 R7 with the limitation that Ar is not a C3-C5 spirocycle.
9. A compound of the formula of claim 8 selected from the group consisting of
6-Butyl-3-(3,5-dimethylphenyl)-5,6-dihydro-4-hydroxy-6-phenyl-2H-pyran-2-one;
3-[4-[(Phenylmethoxy)methyl]-1-tert-butyl-1H-imidazol-2-yl]-5,6-dihydro-4-hydroxy-6-(2-phenylethyl)-6-phenyl-2H-pyran-2-one and
3-(1-tert-Butyl-4-methyl-1H-pyrrol-2-yl)-5,6-dihydro-4-hydroxy-6,6-diphenyl-2H-pyran-2-one.
10. A compound of the formula of claim 1 wherein
X is OR6, NHR5 or SR5;
Z is O;
Y is O;
R5 is COR6 or R6; and
R6 is a straight chain alkyl group containing 1 to 6 carbon atoms, a branched or cyclic alkyl group containing 3 to 7 carbon atoms, benzyl, or phenyl.
11. A compound of the formula of claim 10 selected from the group consisting of
N-[3-[Cyclopropyl[4-(acetyloxy)-5,6-dihydro-2-oxo-6-phenyl-(2-phenylethyl)-2H-pyran-3-yl]methyl]phenyl]-benzenesulfonamide;
Propanoic acid 5-[cyclopropyl[3-[(phenylsulfonyl)amino]phenyl]methyl]-3,6- dihydro-6-oxo-2,2-diphenyl-2H-pyran-4-yl ester;
2,2-Dimethylbutanoic acid 3,5-dihydro-6-oxo-2-(2-phenylethyl)-5-(1-phenylpropyl)-2-propyl-2H-pyran-4-yl ester and
Benzenacetic acid 5-[cyclopropyl[3- [(ethylsulfonyl)amino]phenyl]methyl]-3,6-dihydro-6-oxo-2-(2-phenylethyl)-2-propyl-2H-pyran-4-yl ester.
12. A pharmaceutical composition for the treatment of infection or disease caused by a bacterium, which comprises an amount of the compound of claim 1 sufficient to provide an antibacterially effective dosage of the compound in the range of about 1 to about 50 mg/kg-day and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition for the treatment of infection or disease caused by a retrovirus, which comprises an amount of the compound of claim 1 sufficient to provide an antivirally effective dosage of the compound in the range of about 1 to about 50 mg/kg-day and a pharmaceutically effective carrier.
14. A pharmaceutical composition for the treatment of infection or disease caused by a retrovirus, which comprises an amount of the compound of claim 2 sufficient to provide an antivirally effective dosage of the compound in the range of about 1 to about 50 mg/kg-day and a pharmaceutically effective carrier.
15. A pharmaceutical composition for the treatment of infection or disease caused by a retrovirus, which comprises an amount of the compound of claim 4 sufficient to provide an antivirally effective dosage of the compound in the range of about 1 to about 50 mg/kg-day and a pharmaceutically effective carrier.
16. A method of treatment of infection or disease caused by a retrovirus, which comprises administering to a subject in need of such treatment a composition of claim 1.
17. A method of treatment of infection or disease caused by a retrovirus, which comprises administering to a subject in need of such treatment a composition of claim 1 in combination with an HIV reverse transcriptase inhibitor.
18. A method of treatment of infection or disease caused by a retrovirus, which comprises administering to a subject in need of such treatment a composition of claim 1 in combination with AZT.
19. A method of treatment of infection or disease caused by a retrovirus, which comprises administering to a subject in need of such treatment a composition of claim 1 in combination with ddC.
20. A method of treatment of infection or disease caused by a retrovirus, which comprises administering to a subject in need of such treatment a composition of claim 2.
21. A method of treatment of infection or disease caused by a retrovirus, which comprises administering to a subject in need of such treatment a composition of claim 2 in combination with a HIV reverse transcriptase inhibitor.
22. A method of treatment of infection or disease caused by a retrovirus, which comprises administering to a subject in need of such treatment a composition of claim 3.
23. A method of treatment of infection or disease caused by a retrovirus, which comprises administering to a subject in need of such treatment a composition of claim 4.
24. A method of treatment of infection or disease caused by a retrovirus, which comprises administering to a subject in need of such treatment a composition of claim 4 in combination with a HIV reverse transcriptase inhibitor.
25. A method of treatment of infection or disease caused by a retrovirus, which comprises administering to a subject in need of such treatment a composition of claim 7.
PCT/US1994/012269 1993-11-19 1994-10-26 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents WO1995014012A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
RU96113098/04A RU2140917C1 (en) 1993-11-19 1994-10-26 Derivatives of 5,6-dihydropyrone and pharmaceutical composition based on thereof
NZ275961A NZ275961A (en) 1993-11-19 1994-10-26 5,6-dihydropyrone derivatives and pharmaceutical compositions as anti-viral agents in the treatment of HIV infection
JP51445895A JP3684426B2 (en) 1993-11-19 1994-10-26 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
AU81256/94A AU689158B2 (en) 1993-11-19 1994-10-26 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
EP95900429A EP0729464A1 (en) 1993-11-19 1994-10-26 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
FI962022A FI962022A (en) 1993-11-19 1996-05-13 5,6-dihydropyrone derivatives as protease inhibitors and antivirals
NO19962017A NO316172B1 (en) 1993-11-19 1996-05-15 5,6-dihydropyrone derivatives and pharmaceutical composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15544393A 1993-11-19 1993-11-19
US08/155,443 1993-11-19
US08/319,820 1994-10-12
US08/319,820 US5840751A (en) 1993-11-19 1994-10-12 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents

Publications (1)

Publication Number Publication Date
WO1995014012A1 true WO1995014012A1 (en) 1995-05-26

Family

ID=26852338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/012269 WO1995014012A1 (en) 1993-11-19 1994-10-26 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents

Country Status (18)

Country Link
EP (1) EP0729464A1 (en)
JP (1) JP3684426B2 (en)
AT (1) ATE263761T1 (en)
AU (1) AU689158B2 (en)
CA (1) CA2176043A1 (en)
DE (1) DE69433705T2 (en)
DK (1) DK1142887T3 (en)
ES (1) ES2219457T3 (en)
FI (1) FI962022A (en)
HR (1) HRP940935B1 (en)
HU (1) HUT77668A (en)
IL (1) IL111674A0 (en)
NO (1) NO316172B1 (en)
NZ (1) NZ275961A (en)
PT (1) PT1142887E (en)
RU (1) RU2140917C1 (en)
SI (1) SI1142887T1 (en)
WO (1) WO1995014012A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019997A2 (en) * 1996-11-01 1998-05-14 Warner-Lambert Company Dihydropyrones with improved antiviral activity
WO1999012919A1 (en) * 1997-09-11 1999-03-18 Pharmacia & Upjohn Company Process to produce 4-hydroxy-2-oxo-pyrane derivates useful as protease inhibitors
WO2000015634A2 (en) * 1998-09-11 2000-03-23 Warner-Lambert Company Hiv protease inhibitors
WO2001098288A1 (en) * 2000-06-19 2001-12-27 Bayer Cropscience Ag Phenyl-substituted 5,6-dihydropyrone derivatives for use as pesticides and herbicides
WO2002068403A1 (en) 2001-02-22 2002-09-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Continuous method for producing dihydropyrones
WO2002068404A1 (en) * 2001-02-22 2002-09-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for producing optically active dihydropyrones
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
US6686503B2 (en) 1999-04-14 2004-02-03 Ortho-Mcneil Pharmaceutical, Inc. Methods for the synthesis of highly substituted 2,4-dioxopiperidine libraries
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
US7115658B2 (en) 2002-05-10 2006-10-03 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase
US7141681B2 (en) 2001-02-22 2006-11-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Continuous process for preparing dihydropyrones
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US7151105B2 (en) 2004-08-18 2006-12-19 Agouron Pharmaceuticals, Inc. Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US7157470B2 (en) 2002-05-06 2007-01-02 Bristol-Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
WO2007096058A1 (en) 2006-02-21 2007-08-30 Bayer Cropscience Ag Cycloalkylphenyl substituted cyclic ketoenols
WO2010102758A2 (en) 2009-03-11 2010-09-16 Bayer Cropscience Ag Halogenalkylmethylenoxy-phenyl-substituted ketoenols
WO2011098433A1 (en) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft Cyclic keto-enols for therapy
US8247351B2 (en) 2005-12-13 2012-08-21 Bayer Cropscience Ag Insecticidal compositions having improved effect
WO2013110612A1 (en) 2012-01-26 2013-08-01 Bayer Intellectual Property Gmbh Phenyl-substituted ketoenols for controlling fish parasites
WO2017095319A1 (en) 2015-12-02 2017-06-08 Ultupharma Ab Compounds and methods of treating bacterial infections
US9758502B2 (en) 2012-11-28 2017-09-12 Sumitomo Chemical Company, Limited Dihydropyrone compounds and herbicides comprising the same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006880A2 (en) * 1995-08-11 1997-02-27 Zenon Environmental Inc. Vertical skein of hollow fiber membranes and method of maintaining clean fiber surfaces
WO2007144423A1 (en) * 2006-06-16 2007-12-21 Pharma Mar, S.A. Antitumoral dihydropyran-2-one compounds
RU2461555C1 (en) * 2011-07-07 2012-09-20 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Method of producing 5-aryl-3-phenyl-2-oxaspiro[5,6]dodec-3-en-1-ones, exhibiting analgesic activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3818046A (en) * 1972-12-18 1974-06-18 Dow Chemical Co Sulfur-containing hydroxy pyrones and alkali metal salts thereof
WO1994011361A1 (en) * 1992-11-13 1994-05-26 The Upjohn Company Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3818046A (en) * 1972-12-18 1974-06-18 Dow Chemical Co Sulfur-containing hydroxy pyrones and alkali metal salts thereof
WO1994011361A1 (en) * 1992-11-13 1994-05-26 The Upjohn Company Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019997A2 (en) * 1996-11-01 1998-05-14 Warner-Lambert Company Dihydropyrones with improved antiviral activity
WO1998019997A3 (en) * 1996-11-01 1998-08-27 Warner Lambert Co Dihydropyrones with improved antiviral activity
WO1999012919A1 (en) * 1997-09-11 1999-03-18 Pharmacia & Upjohn Company Process to produce 4-hydroxy-2-oxo-pyrane derivates useful as protease inhibitors
CZ298847B6 (en) * 1997-09-11 2008-02-27 Pharmacia & Upjohn Company Process for preparing protease inhibitor
US6077963A (en) * 1997-09-11 2000-06-20 Pharmacia & Upjohn Company Process to produce a protease inhibitor
CN1298714C (en) * 1997-09-11 2007-02-07 法玛西雅厄普约翰美国公司 Process to produce 4-hydroxy-2-oxo-pyrone derivates useful as protease inhibitors
US6265604B1 (en) 1997-09-11 2001-07-24 Pharmacia & Upjohn Company (R)-3-hydroxy-3-(2-phenylethyl)-hexanoic acid derivatives
US6528510B1 (en) * 1998-09-11 2003-03-04 Warner-Lambert Company HIV protease inhibitors
US6852711B2 (en) * 1998-09-11 2005-02-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
WO2000015634A2 (en) * 1998-09-11 2000-03-23 Warner-Lambert Company Hiv protease inhibitors
WO2000015634A3 (en) * 1998-09-11 2000-11-16 Warner Lambert Co Hiv protease inhibitors
AU773567B2 (en) * 1998-09-11 2004-05-27 Warner-Lambert Company HIV protease inhibitors
US6686503B2 (en) 1999-04-14 2004-02-03 Ortho-Mcneil Pharmaceutical, Inc. Methods for the synthesis of highly substituted 2,4-dioxopiperidine libraries
WO2001098288A1 (en) * 2000-06-19 2001-12-27 Bayer Cropscience Ag Phenyl-substituted 5,6-dihydropyrone derivatives for use as pesticides and herbicides
KR100798733B1 (en) * 2000-06-19 2008-01-29 바이엘 크롭사이언스 아게 Phenyl-substituted 5,6-dihydropyrone derivatives for use as pesticides and herbicides
US6951872B2 (en) 2000-11-06 2005-10-04 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
US7141681B2 (en) 2001-02-22 2006-11-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Continuous process for preparing dihydropyrones
WO2002068403A1 (en) 2001-02-22 2002-09-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Continuous method for producing dihydropyrones
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
WO2002068404A1 (en) * 2001-02-22 2002-09-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for producing optically active dihydropyrones
US7524863B2 (en) 2002-05-06 2009-04-28 Bristol-Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7157470B2 (en) 2002-05-06 2007-01-02 Bristol-Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7115658B2 (en) 2002-05-10 2006-10-03 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase
US7473790B2 (en) 2003-02-21 2009-01-06 Pfizer Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US7151105B2 (en) 2004-08-18 2006-12-19 Agouron Pharmaceuticals, Inc. Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US7622605B2 (en) 2004-08-18 2009-11-24 Pfizer Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US8247351B2 (en) 2005-12-13 2012-08-21 Bayer Cropscience Ag Insecticidal compositions having improved effect
EP2184275A1 (en) 2006-02-21 2010-05-12 Bayer CropScience AG Cycloalkyl-phenyl-substituted cyclic ketoenoles
EP2186791A1 (en) 2006-02-21 2010-05-19 Bayer CropScience AG Cycloalkyl-phenyl-substituted cyclic ketoenoles
EP2186805A1 (en) 2006-02-21 2010-05-19 Bayer CropScience AG Cycloalkyl-phenyl-substituted cyclic ketoenoles
WO2007096058A1 (en) 2006-02-21 2007-08-30 Bayer Cropscience Ag Cycloalkylphenyl substituted cyclic ketoenols
US9045390B2 (en) 2009-03-11 2015-06-02 Bayer Cropscience Ag Haloalkylmethyleneoxyphenyl-substituted ketoenols
US8518985B2 (en) 2009-03-11 2013-08-27 Bayer Cropscience Ag Haloalkylmethyleneoxyphenyl-substituted ketoenols
WO2010102758A2 (en) 2009-03-11 2010-09-16 Bayer Cropscience Ag Halogenalkylmethylenoxy-phenyl-substituted ketoenols
EP3153503A1 (en) 2009-03-11 2017-04-12 Bayer Intellectual Property GmbH Intermediates for halogenoalkylmethylenoxy-phenyl-substituted ketoenols
WO2011098433A1 (en) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft Cyclic keto-enols for therapy
WO2013110612A1 (en) 2012-01-26 2013-08-01 Bayer Intellectual Property Gmbh Phenyl-substituted ketoenols for controlling fish parasites
US9758502B2 (en) 2012-11-28 2017-09-12 Sumitomo Chemical Company, Limited Dihydropyrone compounds and herbicides comprising the same
WO2017095319A1 (en) 2015-12-02 2017-06-08 Ultupharma Ab Compounds and methods of treating bacterial infections
EP3383857A4 (en) * 2015-12-02 2019-05-22 Ultupharma AB Compounds and methods of treating bacterial infections
US10471043B2 (en) 2015-12-02 2019-11-12 Ultupharma Ab Compounds and methods of treating bacterial infections
US10933048B2 (en) 2015-12-02 2021-03-02 Ultupharma Ab Compounds and methods of treating bacterial infections

Also Published As

Publication number Publication date
ES2219457T3 (en) 2004-12-01
AU689158B2 (en) 1998-03-26
NZ275961A (en) 2001-11-30
HRP940935B1 (en) 2004-08-31
DK1142887T3 (en) 2004-06-21
JP3684426B2 (en) 2005-08-17
PT1142887E (en) 2004-08-31
HUT77668A (en) 1998-07-28
NO316172B1 (en) 2003-12-22
EP0729464A1 (en) 1996-09-04
NO962017D0 (en) 1996-05-15
DE69433705T2 (en) 2005-03-10
ATE263761T1 (en) 2004-04-15
JPH09505294A (en) 1997-05-27
SI1142887T1 (en) 2004-08-31
HU9601348D0 (en) 1996-07-29
RU2140917C1 (en) 1999-11-10
NO962017L (en) 1996-07-08
HRP940935A2 (en) 1997-04-30
CA2176043A1 (en) 1995-05-26
FI962022A0 (en) 1996-05-13
DE69433705D1 (en) 2004-05-13
AU8125694A (en) 1995-06-06
IL111674A0 (en) 1995-01-24
FI962022A (en) 1996-07-12

Similar Documents

Publication Publication Date Title
AU689158B2 (en) 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
AU680064B2 (en) 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
EP1142887B1 (en) 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US6005103A (en) Pyrone derivatives as protease inhibitors and antiviral agents
US5510375A (en) Coumarin derivatives as protease inhibitors and antiviral agents
KR100447557B1 (en) 5,6-dihydropyron derivatives as protease inhibitors and antiviral agents
KR100441361B1 (en) 5,6-dihydropyron derivatives as protease inhibitors and antiviral agents
AU682417B2 (en) Pyrone derivatives as protease inhibitors and antiviral agents
AU687465B2 (en) Pyrone derivatives as protease inhibitors and antiviral agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BG BY CA CZ EE FI GE HU JP KG KR KZ LT LV MD NO NZ PL RO RU SI SK TJ UA UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 275961

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995900429

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2176043

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 962022

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1090

Country of ref document: MD

WWE Wipo information: entry into national phase

Ref document number: 1019960702652

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1995900429

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995900429

Country of ref document: EP